10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 2, 2018

OR

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from               to          

Commission File Number: 1-5742

RITE AID CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	23-1614034 (I.R.S. Employer Identification No.)
30 Hunter Lane, Camp Hill, Pennsylvania	17011
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (717) 761-2633.

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report):

Not Applicable

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files).  Yes x  No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “Large Accelerated Filer,” “Accelerated Filer,” “Smaller Reporting Company” and “Emerging Growth Company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer x Accelerated Filer o Non-Accelerated Filer o
(Do not check if a
smaller reporting company) Smaller reporting company o
Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange act).  Yes o  No x

The registrant had 1,066,805,893 shares of its $1.00 par value common stock outstanding as of June 27, 2018.

RITE AID CORPORATION

TABLE OF CONTENTS

	Cautionary Statement Regarding Forward-Looking Statements	2
	PART I FINANCIAL INFORMATION
ITEM 1.	Financial Statements (unaudited):
	Condensed Consolidated Balance Sheets as of June 2, 2018 and March 3, 2018	5
	Condensed Consolidated Statements of Operations for the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017	6
	Condensed Consolidated Statements of Comprehensive Loss for the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017	7
	Condensed Consolidated Statements of Cash Flows for the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017	8
	Notes to Condensed Consolidated Financial Statements	20
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	32
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	45
ITEM 4.	Controls and Procedures	46
	PART II OTHER INFORMATION
ITEM 1.	Legal Proceedings	46
ITEM 1A.	Risk Factors	46
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	46
ITEM 3.	Defaults Upon Senior Securities	47
ITEM 4.	Mine Safety Disclosures	47
ITEM 5.	Other Information	47
ITEM 6.	Exhibits	47

1

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This report, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “should,” “could,” “may,” “plan,” “project,” “predict,” “will” and similar expressions and include references to assumptions and relate to our future prospects, developments and business strategies.

Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

·our high level of indebtedness;

·our ability to make interest and principal payments on our debt and satisfy the other covenants contained in our credit facility and other debt agreements;

·the continued impact of private and public third party payors reduction in prescription drug reimbursement rates and their ongoing efforts to limit access to payor networks, including through mail order;

·our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs, and our ability to achieve drug pricing efficiencies;

·the impact of the loss of one or more major third party payor contracts;

·risks related to the expected timing and likelihood of completion of the pending Merger (as defined in Part I Item 1 below) with Albertsons Companies, Inc. (“Albertsons”), including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, including that the required approval of the Merger by our stockholders was not obtained;

·the inability to complete the sale of distribution centers to WBA (as defined in Part I, Item 1 below), receive the related proceeds and recognize the corresponding expected gain due to the failure to satisfy the minimal remaining conditions applicable only to the distribution centers being transferred at such distribution center closing and other risks related to obtaining the requisite consents to the remaining distribution center closing of the Sale;

·risks related to our ability to successfully integrate with Albertsons’ business, which may result in the combined company not operating as effectively and efficiently as expected and the risk that the combined company may be unable to achieve cost savings or revenue synergies or it may take longer than expected to achieve those synergies;

·the risk of the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement (as defined in Part I, Item 1 below) with Albertsons, including circumstances requiring us to pay Albertsons a termination fee pursuant to the Merger Agreement;

·the risk that the proposed Merger and its announcement could have an adverse effect on our ability to retain customers and retain and hire key personnel and maintain relationships with our suppliers and customers and on our operating results and businesses generally;

·the impact on our business, operating results and relationships with customers, suppliers, third party payors, and employees, resulting from our efforts over the past two years to consummate a significant transaction with Walgreens Boots Alliance, Inc. (“WBA”);

·the risk that we will not be able to meet our obligations under our Transition Services Agreement (“TSA”) with WBA, which could expose us to significant financial penalties;

·the risk that we cannot reduce our selling, general and administrative expenses enough to offset lost revenue from the TSA agreement as the amount of stores serviced under the agreement decreases;

·the risk that there may be a significant decline in our stock price or that there may be changes to our strategy in the event that the Merger and/ or the remaining distribution center closing of the Sale do not close, which may include delaying or reducing capital or other expenditures, selling assets or other operations, closing underperforming stores, attempting to restructure or refinance our debt, seeking additional capital or incurring other costs associated with restructuring our business;

·our ability to refinance our indebtedness on terms favorable to us;

·our ability to improve the operating performance of our stores in accordance with our long term strategy;

2

·our ability to grow prescription count and realize front-end sales growth;

·our ability to hire and retain qualified personnel;

·decisions to close additional stores and distribution centers or undertake additional refinancing activities, which could result in charges to our operating statement;

·our ability to manage expenses and working capital;

·continued consolidation of the drugstore and the pharmacy benefit management (“PBM”) industries;

·the risk that changes in federal or state laws or regulations, including the Health Care Education Affordability Reconciliation Act, the repeal of all or part of the Patient Protection and the Affordable Care Act (or “Patient Care Act”) and any regulations enacted thereunder may occur;

·the risk that provider and state contract changes may occur;

·risks related to compromises of our information or payment systems or unauthorized access to confidential or personal information of our associates or customers;

·our ability to maintain our current pharmacy services business and obtain new pharmacy services business, including maintaining renewals of expiring contracts, avoiding contract termination rights that may permit certain of our clients to terminate their contracts prior to their expiration and early price renegotiations prior to contract expirations;

·the continued impact of gross margin pressure in the PBM industry due to increased market competition and client demand for lower prices while providing enhanced service offerings;

·our ability to maintain our current Medicare Part D business and obtain new Medicare Part D business, as a result of the annual Medicare Part D competitive bidding process;

·the expiration or termination of our Medicare or Medicaid managed care contracts by federal or state governments;

·risks related to other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange or interest rates or credit ratings, changes in tax laws, regulations, rates and policies or competitive development including aggressive promotional activity from our competitors;

·the risk that we could experience deterioration in our current Star rating with the Centers of Medicare and Medicaid Services (“CMS”) or incur CMS penalties and/or sanctions;

·the nature, cost and outcome of pending and future litigation and other legal proceedings or governmental investigations, including any such proceedings related to the Merger or Sale and instituted against us and others;

·the potential reputational risk to our business during the period in which WBA is operating the Acquired Stores (as defined below) under the Rite Aid banner;

·the risk that the Tax Cuts and Jobs Act that was enacted on December 22, 2017 may have a negative impact on our financial results;

·the inability to fully realize the benefits of our tax attributes;

·other risks and uncertainties described from time to time in our filings with the Securities and Exchange Commission (the “SEC”).

We undertake no obligation to update or revise the forward-looking statements included in this report, whether as a result of new information, future events or otherwise, after the date of this report. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of

3

Operations” included herein and in our Annual Report on Form 10-K for the fiscal year ended March 3, 2018 (the “Fiscal 2018 10-K”), as well as in the “Risk Factors” section of the Fiscal 2018 10-K, which we filed with the SEC on April 26, 2018 and is available on the SEC’s website at www.sec.gov.

4

PART I. FINANCIAL INFORMATION

ITEM 1.  Financial Statements

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(unaudited)

	June 2, 2018			March 3, 2018
ASSETS
Current assets:
Cash and cash equivalents	$	147,092		$	447,334
Accounts receivable, net	1,908,955			1,869,100
Inventories, net of LIFO reserve of $591,056 and $581,090	1,809,595			1,799,539
Prepaid expenses and other current assets	151,059			181,181
Current assets held for sale	179,442			438,137
Total current assets	4,196,143			4,735,291
Property, plant and equipment, net	1,401,924			1,431,246
Goodwill	1,421,120			1,421,120
Other intangibles, net	568,920			590,443
Deferred tax assets	522,674			594,019
Other assets	218,672			217,208
Total assets	$	8,329,453		$	8,989,327
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	19,025		$	20,761
Accounts payable	1,767,777			1,651,363
Accrued salaries, wages and other current liabilities	1,030,292			1,231,736
Current liabilities held for sale	—			560,205
Total current liabilities	2,817,094			3,464,065
Long-term debt, less current maturities	3,134,704			3,340,099
Lease financing obligations, less current maturities	28,874			30,775
Other noncurrent liabilities	536,470			553,378
Total liabilities	6,517,142			7,388,317
Commitments and contingencies	—			—
Stockholders’ equity:
Common stock, par value $1 per share; 1,500,000 shares authorized; shares issued and outstanding 1,067,197 and 1,067,318	1,067,197			1,067,318
Additional paid-in capital	4,855,901			4,850,712
Accumulated deficit	(4,076,602		)	(4,282,471		)
Accumulated other comprehensive loss	(34,185		)	(34,549		)
Total stockholders’ equity	1,812,311			1,601,010
Total liabilities and stockholders’ equity	$	8,329,453		$	8,989,327

See accompanying notes to condensed consolidated financial statements.

5

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(unaudited)

	Thirteen Week Period Ended
	June  2, 2018			June 3, 2017
Revenues	$	5,388,490		$	5,436,523
Costs and expenses:
Cost of revenues	4,219,741			4,274,580
Selling, general and administrative expenses	1,152,627			1,160,940
Lease termination and impairment charges	9,859			4,038
Interest expense	62,792			51,000
Loss on debt retirements, net	554			—
Gain on sale of assets, net	(5,859		)	(5,877		)
	5,439,714			5,484,681
Loss from continuing operations before income taxes	(51,224		)	(48,158		)
Income tax benefit	(9,497		)	(12,121		)
Net loss from continuing operations	(41,727		)	(36,037		)
Net income (loss) from discontinued operations, net of tax	256,143			(39,312		)
Net income (loss)	$	214,416		$	(75,349	)
Computation of (loss) income attributable to common stockholders:
Loss from continuing operations attributable to common stockholders—basic and diluted	$	(41,727	)	$	(36,037	)
Income (loss) from discontinued operations attributable to common stockholders—basic and diluted	256,143			(39,312		)
Income (loss) attributable to common stockholders—basic and diluted	$	214,416		$	(75,349	)
Basic and diluted income (loss) per share:
Continuing operations	$	(0.04	)	$	(0.03	)
Discontinued operations	$	0.24		$	(0.04	)
Net basic and diluted income (loss) per share	$	0.20		$	(0.07	)

See accompanying notes to condensed consolidated financial statements.

6

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(unaudited)

	Thirteen Week Period Ended
	June 2, 2018		June 3, 2017
Net income (loss)	$	214,416	$	(75,349	)
Other comprehensive income:
Defined benefit pension plans:
Amortization of prior service cost, net transition obligation and net actuarial losses included in net periodic pension cost, net of $144 and $342 tax expense	364		514
Total other comprehensive income	364		514
Comprehensive income (loss)	$	214,780	$	(74,835	)

See accompanying notes to condensed consolidated financial statements.

7

RITE AID CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(unaudited)

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
Operating activities:
Net income (loss)	$	214,416		$	(75,349	)
Net income (loss) from discontinued operations, net of tax	256,143			(39,312		)
Net loss from continuing operations	$	(41,727	)	$	(36,037	)
Adjustments to reconcile to net cash (used in) provided by operating activities of continuing operations:
Depreciation and amortization	94,529			101,029
Lease termination and impairment charges	9,859			4,038
LIFO charge	9,966			10,173
Gain on sale of assets, net	(5,859		)	(5,877		)
Stock-based compensation expense	5,031			9,038
Loss on debt retirements, net	554			—
Changes in deferred taxes	(12,355		)	(38,160		)
Changes in operating assets and liabilities:
Accounts receivable	(194,159		)	(34,611		)
Inventories	31,101			28,068
Accounts payable	207,960			(34,313		)
Other assets and liabilities, net	(121,214		)	44,421
Net cash (used in) provided by operating activities of continuing operations	(16,314		)	47,769
Investing activities:
Payments for property, plant and equipment	(47,971		)	(38,325		)
Intangible assets acquired	(13,655		)	(5,521		)
Proceeds from insured loss	—			8,639
Proceeds from dispositions of assets and investments	9,916			2,137
Proceeds from sale-leaseback transactions	2,587			—
Net cash used in investing activities of continuing operations	(49,123		)	(33,070		)
Financing activities:
Net proceeds from (payments to) revolver	190,000			(90,000		)
Principal payments on long-term debt	(431,106		)	(3,503		)
Change in zero balance cash accounts	1,083			28,768
Net proceeds from issuance of common stock	910			147
Payments for taxes related to net share settlement of equity awards	—			(147		)
Financing fees paid for early redemption	(13		)	—
Net cash used in financing activities of continuing operations	(239,126		)	(64,735		)
Cash flows from discontinued operations:
Operating activities of discontinued operations	(74,050		)	44,965
Investing activities of discontinued operations	603,402			(25,126		)
Financing activities of discontinued operations	(525,031		)	(764		)
Net cash provided by discontinued operations	4,321			19,075
Decrease in cash and cash equivalents	(300,242		)	(30,961		)
Cash and cash equivalents, beginning of period	447,334			245,410
Cash and cash equivalents, end of period	$	147,092		$	214,449

See accompanying notes to condensed consolidated financial statements.

8

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. The accompanying financial information reflects all adjustments which are of a recurring nature and, in the opinion of management, are necessary for a fair presentation of the results for the interim periods. The results of operations for the thirteen week period ended June 2, 2018 are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Rite Aid Corporation (“Rite Aid”) and Subsidiaries (together with Rite Aid, the “Company”) Fiscal 2018 10-K.

The discussion and presentation of the operating and financial results of our business segments have been impacted by the following event.

Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement (the “Amended and Restated Asset Purchase Agreement”), dated as of September 18, 2017, by and among Rite Aid, WBA and Walgreen Co., an Illinois corporation and wholly owned direct subsidiary of WBA (“Buyer”), Buyer agreed to purchase from Rite Aid 1,932 stores (the “Acquired Stores”), three distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of approximately $4.375 billion, on a cash free, debt free basis (the “Asset Sale” or the “Sale”). As of March 27, 2018, the Company has sold all 1,932 Acquired Stores and related assets to WBA in exchange for proceeds of $4,156.7 million, which were used to repay outstanding debt. Based on its magnitude and because the Company is exiting certain markets, the Sale represents a significant strategic shift that has a material effect on the Company’s operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Asset Sale as required by Accounting Standards Codification 210-05—Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the assets and liabilities to be sold, including the 1,932 Acquired Stores, three (3) distribution centers, related inventory and other specified assets and liabilities related thereto (collectively the “Assets to be Sold” or “Disposal Group”) to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended June 2, 2018 and March 3, 2018, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. Additionally, corporate support activities related to the Disposal Group were not reclassified to discontinued operations. Please see additional information as provided in Note 3 Asset Sale to WBA.

Recently adopted accounting pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU No. 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU No. 2016-08, “Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net),” which amends the principal-versus-agent implementation guidance and in April 2016, the FASB issued ASU No. 2016-10, “Identifying Performance Obligations and Licensing,” which amends the guidance in those areas in the new revenue recognition standard. These ASUs, collectively the “new revenue standard”, are effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018.

The Company adopted the new revenue standard as of March 4, 2018 using the modified retrospective method and applying the new standard to all contracts with customers.  Therefore, the comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods.  In connection with the adoption of the new revenue standard, the Company identified one difference in its Retail Pharmacy segment related to the timing of revenue recognition for third party prescription revenues, which was historically recognized at the time the prescription was filled.  Upon adoption of ASU No. 2014-09, this revenue is recognized at the time the customer takes possession of the merchandise. In connection with its March 4, 2018

9

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

adoption of the new revenue standard on a modified retrospective basis, the Company recorded a reduction to accounts receivable of $57,897, a reduction to deferred tax assets of $1,772, an increase to inventory of $51,121, and a corresponding increase to accumulated deficit of $8,548 within its Retail Pharmacy segment.

In addition, the Company identified revenues under one specific rebate administration program under which the Company’s Pharmacy Services segment was determined to be the principal and historically recognized revenues and cost of revenues on a gross basis of approximately $123,500 during fiscal 2018. Upon adoption of the new revenue standard, the Company is required to record revenue from this program on a net basis.   The Company expects the impact of the adoption of the new revenue standard to be immaterial to its revenues, net income, and cash flows on an ongoing basis.

The following is a discussion of the Company’s revenue recognition policies by segment under the new revenue recognition accounting standard:

Revenue Recognition

Retail Pharmacy Segment

For front end sales, the Retail Pharmacy segment recognizes revenues upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation at the point of sale for front end transactions. The Retail Pharmacy segment front end revenue is measured based on the amount of fixed consideration that we expect to receive, net of an allowance for estimated future returns. Return activity is immaterial to revenues and results of operations in all periods presented.

For pharmacy sales, the Retail Pharmacy segment recognizes revenue upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation, upon pickup by the customer, which is when the customer takes title to the product.  Each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims.  The Company’s revenue is measured based on the amount of fixed consideration that we expect to receive, reduced by refunds owed to the third party payor for pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not highly subjective or volatile.  The effect of adjustments between estimated and actual amounts have not been material to the Company’s results of operations or financial position. Prescriptions are generally not returnable.

The Retail Pharmacy segment offers a chain-wide loyalty card program titled wellness +. Individual customers are able to become members of the wellness + program.  Members participating in the wellness + loyalty card program earn points on a calendar year basis for eligible front end merchandise purchases and qualifying prescription purchases which may be redeemed to pay for future purchases. One point is awarded for each dollar spent towards front end merchandise and 25 points are awarded for each qualifying prescription.

Members reach specific wellness + tiers based on the points accumulated during the calendar year, which entitles such customers to certain future discounts and other benefits upon reaching that tier. For example, any customer that reaches 1,000 points in a calendar year achieves the “Gold” tier, enabling him or her to receive a 20% discount on qualifying purchases of front end merchandise for the remaining portion of the calendar year and also the next calendar year. There is also a similar “Silver” level with a lower threshold and benefit level.

Points earned pursuant to the wellness+ program represent a performance obligations and the Company allocates revenue between the merchandise purchased and the wellness + points based on the relative stand-alone selling price of each performance obligation. The relative value of the wellness + points is initially deferred as a contract liability (included in other current and noncurrent liabilities). As customers redeem the points to receive discounted front end merchandise or when the points expire, the Retail Pharmacy segment recognizes an allocable portion of the deferred contract liability into revenue. The Retail Pharmacy segment had accrued contract liabilities of $73,191 as of June 2, 2018, of which $49,793 is included in other current liabilities and $23,398 is included in noncurrent liabilities. The Retail Pharmacy segment had accrued contract liabilities of $63,851 as of March 3, 2018, of which $50,036 is included in other current liabilities and $13,815 is included in noncurrent liabilities.

The wellness + program also allows a customer to earn Bonus Cash based on qualifying purchases. Wellness + Rewards members have the opportunity to redeem his or her accumulated Bonus Cash on a future purchase with a 60 day expiration window. All Bonus Cash is redeemed using a FIFO methodology (i e., first Bonus Cash earned are the first to be redeemed).

For a majority of the Bonus Cash issuances, funding is provided by our vendors through contractual arrangements. This funding is treated as a contract liability and remains a contract liability until i) a wellness + Rewards members redeem their Bonus Cash, or ii) wellness + Rewards members allow the Bonus Cash to expire. Upon redemption or expiration, the Retail Pharmacy segment recognizes an allocable portion of the accrued contract liability into revenue. For Bonus Cash issuances that are not vendor

10

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

funded, the contract liability is recorded at the time of issuance through a reduction to revenues, and not recognized until the Bonus Cash is redeemed or expires.

Pharmacy Services Segment

The Pharmacy Services segment sells prescription drugs indirectly through its retail pharmacy network and directly through its mail service dispensing pharmacy. The Pharmacy Services segment recognizes revenue from prescription drugs sold by (i) its mail service dispensing pharmacy and (ii) under retail pharmacy network contracts where it is the principal at the contract prices negotiated with its clients, primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans, Medicare plans, and other sponsors of health benefit plans, and individuals throughout the United States. Revenues include: (i) the portion of the price the client pays directly to the Pharmacy Services segment, net of any volume-related or other discounts paid back to the client (see “Drug Discounts” below), (ii) the price paid to the Pharmacy Services segment by client plan members for mail order prescriptions (“Mail Co-Payments”) (iii) client plan member copayments made directly to the retail pharmacy network, and (iv) administrative fees. Revenue is recognized when the Pharmacy Services segment meets its performance obligations relative to each transaction type, The following revenue recognition policies have been established for the Pharmacy Services segment:

·Revenues generated from prescription drugs sold by third party pharmacies in the Pharmacy Services segment’s retail pharmacy network and associated administrative fees are recognized at the Pharmacy Services segment’s point-of-sale, which is when the claim is adjudicated by the Pharmacy Services segment’s online claims processing system.  At this point the Company has performed all of its performance obligations.

·Revenues generated from prescription drugs sold by the Pharmacy Services segment’s mail service dispensing pharmacy are recognized when the prescription is shipped. At the time of shipment, the Pharmacy Services segment has performed all of its performance obligations under its client contracts, as control of and title to the product has passed to the clients plan member.  The Pharmacy Services segment does not experience a significant level of returns or reshipments.

·Revenues generated from administrative fees based on membership or claims volume are recognized monthly based on the terms within the individual contracts, either a monthly member based fee, or a claims volume based fee.

In the majority of its contracts, the Pharmacy Services segment is the principal because its client contracts give clients the right to obtain access to its pharmacy contracts under which the Pharmacy Services segment directs its pharmacy network to provide the services (drug dispensing, consultation, etc.) and goods (prescription drugs) to the clients’ members at its  negotiated pricing. The Pharmacy Services segment’s obligations under its client contracts are separate and distinct from its obligations to the third party pharmacies included in its retail pharmacy network contracts. Pursuant to these contracts, the Pharmacy Services segment is contractually required to pay the third party pharmacies in its retail pharmacy network for products sold after payment is received from its clients. The Pharmacy Services segment has control over these transactions until the prescription is transferred to the member and, thus, that it is acting as a principal. As such, the Pharmacy Services segment records the total prescription price contracted with clients in revenues.

Amounts paid to pharmacies and amounts charged to clients are exclusive of the applicable co-payment under Pharmacy Services segment contracts. Retail pharmacy co-payments, which we instruct retail pharmacies to collect from members, are included in our revenues and our cost of revenues.

For contracts under which the Pharmacy Services segment acts as an agent or does not control the prescription drugs prior to transfer to the client, no revenue is recognized.

Drug Discounts—The Pharmacy Services segment deducts from its revenues that are generated from prescription drugs sold by third party pharmacies any rebates, inclusive of discounts and fees, earned by its clients based on utilization levels and other factors as negotiated with the prescription drug manufacturers or suppliers. Rebates are paid to clients in accordance with the terms of client contracts.

Medicare Part D—The Pharmacy Services segment, through its EIC subsidiary, participates in the federal government’s Medicare Part D program as a Prescription Drug Plan (“PDP”). Please refer to Note 8, Medicare Part D.

11

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Disaggregation of Revenue

The following table disaggregates the Company’s revenue by major source in each segment for the thirteen week period ended June 2, 2018:

In millions	For the thirteen week period ended June 2, 2018
Retail Pharmacy segment:
Pharmacy sales	$	2,565,286
Front end sales	1,296,147
Other revenue	36,332
Total Retail Pharmacy segment	$	3,897,765
Pharmacy Services segment	1,542,762
Intersegment elimination	(52,037		)
Total revenue	$	5,388,490

Impact of New Revenue Recognition Standard on Financial Statement Line Items

The Company adopted the new revenue standard using the modified retrospective method. The cumulative effect of applying the new standard to all contracts was recorded as an adjustment to accumulated deficit as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue standard, the following adjustments were made to accounts on the condensed consolidated balance sheet as of March 4, 2018:

	Impact of Change in Accounting Policy
	As Reported						Adjusted
In millions	March 3, 2018			Adjustments			March 4, 2018
Condensed Consolidated Balance Sheet:
Accounts receivable, net	$	1,869,100		$	(57,897	)	$	1,811,203
Inventories, net	1,799,539			51,121			1,850,660
Deferred tax assets	594,019			(1,772		)	592,247
Total assets	8,989,327			(8,548		)	8,980,779
Accumulated deficit	(4,282,471		)	(8,548		)	(4,291,019		)
Total shareholders’ equity	1,601,010			(8,548		)	1,592,462

Recently Issued Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU No. 2016-02, Leases, (Topic 842), which is intended to improve financial reporting around leasing transactions. The ASU affects all companies and other organizations that engage in lease transactions (both lessee and lessor) that lease assets such as real estate and manufacturing equipment. This ASU will require organizations that lease assets—referred to as “leases”—to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. ASU No. 2016-02 is effective for fiscal years and interim periods within those years beginning January 1, 2019 (fiscal 2020). On January 5, 2018 the FASB issued an exposure draft amending certain aspects of the new leasing standard. The proposed amendments include a provision to allow entities to elect not to restate comparative periods in the period of adoption when transitioning to the new standard and instead allow a modified retrospective approach. The Company believes that the new standard will have a material impact on its financial position. The Company is currently evaluating the impact this standard implementation will have on its results of operations and cash flows.

2. Merger Agreement

On February 18, 2018, Rite Aid entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Albertsons, Ranch Acquisition II LLC, a Delaware limited liability company and a wholly-owned direct subsidiary of Albertsons (“Merger Sub II”) and Ranch Acquisition Corp., a Delaware corporation and a wholly-owned direct subsidiary of Merger Sub II (“Merger Sub” and, together with Merger Sub II, the “Merger Subs”). Pursuant to the Merger Agreement, (i) Merger Sub will merge with and into Rite Aid (the “Merger”), with Rite Aid surviving the Merger as a wholly-owned direct subsidiary of Merger Sub II (the “Surviving Corporation”), and (ii) immediately following the Merger, the Surviving Corporation will merge with and into Merger Sub II (the “Subsequent Merger” and, together with the Merger, the “Mergers”) with Merger Sub II surviving the Subsequent Merger as a wholly-owned direct subsidiary of Albertsons (the “Surviving Company”).

12

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

At the effective time of the Merger (the “Effective Time”), each share of Rite Aid’s common stock, par value $1.00 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Rite Aid common stock owned by Albertsons, Merger Sub or Rite Aid (including treasury stock held by Rite Aid), which will be cancelled) will be converted into the right to receive and become exchangeable for 0.1000 (the “Base Exchange Ratio”) of a fully paid and nonassessable share of Albertsons common stock, par value $0.01 per share (“Albertsons Common Stock”) (the “Base Consideration”), without interest, plus, at the election of the holder of Rite Aid common stock, either (i) an amount in cash equal to $0.1832 per share (the “Additional Cash Consideration” and, together with the Base Consideration, the “Cash Election Consideration”), without interest, or (ii) 0.0079 (the “Additional Stock Election Exchange Ratio” and, together with the Base Exchange Ratio, the “Stock Election Exchange Ratio”) of a fully paid and nonassessable share of Albertsons Common Stock (the “Additional Stock Consideration” and, together with the Base Consideration, the “Stock Election Consideration”).

Consummation of the Merger is subject to various closing conditions, including but not limited to (i) approval of the Merger Agreement by holders of a majority of the outstanding shares of our common stock entitled to vote on the Merger, (ii) the expiration or earlier termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) (which condition was satisfied on March 28, 2018), (iii) the absence of any law or order prohibiting the Merger, (iv) the absence of a material adverse effect on the Company and Albertsons, in each case, as defined in the Merger Agreement, (v) approval for listing, on the NYSE, of the shares of Albertsons Common Stock to be issued in the Merger and to be reserved for issuance in connection with the Merger (which approval was obtained on June 21, 2018), (vi) Albertsons’s registration statement on Form S 4 shall have become effective under the Securities Act (which Form S-4 was declared effective on June 25, 2018), and shall not be the subject of any stop order or proceedings seeking a stop order, (vii) approval of the Ohio Department of Insurance for the change of control of EIC, and (viii) Albertsons shall have delivered the Company a Lock Up Agreement, No Action Agreement and Standstill Agreement, in each case, in the form agreed to by the parties to the Merger Agreement.  The special meeting of Rite Aid’s stockholders to, among other things, consider and vote on a proposal to approve the Merger Agreement has been scheduled for August 9, 2018.

On February 18, 2018, in connection with the Merger Agreement, the Company entered into a standstill agreement (the “Standstill Agreement”) with Albertsons and Cerberus Capital Management, L.P. (“Cerberus”), pursuant to which Cerberus has agreed not to: (i) purchase shares of Albertsons Common Stock or other securities issued by Albertsons, except Cerberus may acquire beneficial ownership of Albertsons Common Stock provided that such beneficial ownership does not result in ownership of 30% or more of the issued and outstanding shares of Albertsons Common Stock in the aggregate following such transaction, (ii) make any public statement or public disclosure regarding any intent, purpose, plan or proposal by Cerberus or any of its controlled affiliates to the composition of the Albertsons board of directors, any merger, consolidation or acquisition of Albertsons or its subsidiaries, (iii) engage in any solicitation of proxies or otherwise solicit the stockholders of Albertsons or (iv) enter into any agreements to make any investment with any person that engages or offers or proposes to engage in any of (i) through (iii) during the standstill period. The standstill period commences at the Effective Time and terminates upon the earliest to occur of (a) thirty days following the date that Cerberus does not have any of its designees on the Albertsons board of directors, (b) the date on which Cerberus no longer has the right to appoint (and has not appointed) at least one director to the Albertsons board of directors and (c) the date on which Albertsons materially breaches or takes any action challenging the validity or enforceability of the provisions of the Merger Agreement that grant Cerberus certain rights to appoint directors to the Albertsons board of directors. In addition, pursuant to the Standstill Agreement, from February 18, 2018 until the Effective Time, Cerberus has agreed not to acquire or agree to acquire beneficial ownership of any shares of Albertsons Common Stock, Rite Aid common stock or other securities or debt issued by Albertsons or Rite Aid that would result in beneficial ownership of 30% or more of the issued and outstanding shares of Albertsons Common Stock at the Effective Time (assuming for the purposes of such calculation that the Effective Time occurred immediately after such acquisition).

3. Asset Sale to WBA

On September 18, 2017, the Company entered into the Amended and Restated Asset Purchase Agreement with WBA and Buyer, which amended and restated in its entirety the previously disclosed Asset Purchase Agreement (the “Original APA”), dated as of June 28, 2017, by and among the Company, WBA and Buyer. Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement, Buyer agreed to purchase from the Company 1,932 Acquired Stores, three (3) distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of approximately $4,375,000, on a cash-free, debt-free basis in the Sale.

The Company announced on September 19, 2017 that the waiting period under the HSR Act, expired with respect to the Sale. As of March 27, 2018, the Company has completed the store transfer process, and all 1,932 stores and related assets have been transferred to WBA and the Company has received cash proceeds of $4,156,686. The transfer of the three (3) distribution centers and related assets is expected to begin after September 1, 2018. The majority of the closing conditions have been satisfied, and the transfer of the three distribution centers and related assets remains subject to minimal customary closing conditions applicable only to the distribution centers being transferred at such distribution center closings, as specified in the Amended and Restated Asset Purchase Agreement.  The Company has recorded a pre-tax gain on the Sale of the stores of $2,489,389.

13

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The parties to the Amended and Restated Asset Purchase Agreement have each made customary representations and warranties. The Company has agreed to various covenants and agreements, including, among others, the Company’s agreement to conduct its business at the distribution centers being sold to WBA in the ordinary course during the period between the execution of the Amended and Restated Asset Purchase Agreement and the distribution center closing. The Company has also agreed to provide transition services to Buyer for up to three (3) years after the initial closing of the Sale. Under the terms of the TSA, the Company provides various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general and administrative activities. In connection with these services, the Company purchases the related inventory and incurs cash payments for the selling, general and administrative activities, which, the Company bills on a cash neutral basis to WBA in accordance with terms as outlined in the TSA. Total billings for these items during the thirteen week period ended June 2, 2018 were $2,041,075, of which $447,305 is included in Accounts receivable, net. The Company charged WBA TSA fees of $23,735 during the thirteen week period ended June 2, 2018 which are reflected as a reduction to selling, general and administrative expenses. Albertsons is obligated to assume the Company’s remaining obligations under the TSA.

Under the terms of the Amended and Restated Asset Purchase Agreement, the Company has the option to purchase pharmaceutical drugs through an affiliate of WBA under terms, including cost, that are substantially equivalent to Walgreen’s for a period of ten (10) years, subject to certain terms and conditions.

Based on its magnitude and because the Company is exiting certain markets, the Sale represents a significant strategic shift that has a material effect on the Company’s operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Sale as required by Accounting Standards Codification 210-05—Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the Disposal Group to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended June 2, 2018 and March 3, 2018, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. The Company also revised its discussion and presentation of operating and financial results to be reflective of its continuing operations as required by ASC 205-20.

The carrying amount of the Assets to be Sold, which were included in the Retail Pharmacy segment, have been reclassified from their historical balance sheet presentation to current assets and liabilities held for sale as follows:

	June 2, 2018		March 3, 2018
Inventories	$	111,001	$	264,286
Property and equipment	68,441		158,433
Goodwill(a)	—		4,629
Intangible assets	—		10,789
Current assets held for sale	$	179,442	$	438,137
Current maturities of long-term lease financing obligations	$	—	$	270
Accrued salaries, wages and other current liabilities	—		6,146
Long-term debt, less current maturities(b)	—		549,549
Lease financing obligations, less current maturities	—		838
Other noncurrent liabilities	—		3,402
Current liabilities held for sale	$	—	$	560,205

(a)The Company had $76,124 of goodwill in its Retail Pharmacy segment resulting from the acquisition of Health Dialog and RediClinic, which is accounted for as Retail Pharmacy segment enterprise goodwill. The Company has allocated a portion of its Retail Pharmacy segment enterprise goodwill to the discontinued operation.

(b)In connection with the Sale, the Company had estimated that the Sale would generate excess cash proceeds of approximately $4,027,400 which would be used to repay outstanding indebtedness. During the thirteen week period ended June 2, 2018, the Company has a use of cash for financing purposes of $525,031 in its discontinued operations and, based on refinements to its calculations, reduced its estimate of excess cash proceeds by approximately $24,500 and reclassified that amount to assets held and used. Consequently, the Company has classified $0 and $549,549 of estimated cash proceeds to be used for debt repayment to liabilities held for sale as of June 2, 2018 and March 3, 2018, respectively. As of June 2, 2018 and March 3, 2018, the Company repaid outstanding indebtedness of $525,031 and $3,135,000 with Sale proceeds.

14

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The operating results of the discontinued operations that are reflected on the consolidated statements of operations within net income (loss) from discontinued operations are as follows:

	June 2, 2018 (13 weeks)			June 3, 2017 (13 weeks)
Revenues	$	23,400		$	2,377,857
Costs and expenses:
Cost of revenues(a)	17,081			1,780,765
Selling, general and administrative expenses(a)	13,875			600,640
Lease termination and impairment charges	—			48
Loss on debt retirements, net	4,570			—
Interest expense(b)	4,615			58,937
Gain on stores sold to Walgreens Boots Alliance	(360,557		)	—
(Gain) loss on sale of assets, net	—			(156		)
	(320,416		)	2,440,234
Income (loss) from discontinued operations before income taxes	343,816			(62,377		)
Income tax expense (benefit)	87,673			(23,065		)
Net income (loss) from discontinued operations, net of tax	$	256,143		$	(39,312	)

(a)Cost of revenues and selling, general and administrative expenses for the discontinued operations excludes corporate overhead. These charges are reflected in continuing operations.

(b)In accordance with ASC 205-20, the operating results for the thirteen week periods ended June 2, 2018 and June 3, 2017, respectively, for the discontinued operations include interest expense relating to the outstanding indebtedness repaid with the estimated excess proceeds from the Sale.

The operating results reflected above do not fully represent the Disposal Group’s historical operating results, as the results reported within net income from discontinued operations only include expenses that are directly attributable to the Disposal Group.

4. Income (Loss) Per Share

Basic income (loss) per share is computed by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company subject to anti-dilution limitations.

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
Basic and diluted income (loss) per share:
Numerator:
Net loss from continuing operations	$	(41,727	)	$	(36,037	)
Net income (loss) from discontinued operations	256,143			(39,312		)
Income (loss) attributable to common stockholders— basic and diluted	$	214,416		$	(75,349	)
Denominator:
Basic weighted average shares	1,054,381			1,046,826
Outstanding options and restricted shares, net	—			—
Diluted weighted-average shares	1,054,381			1,046,826
Basic and diluted income (loss) per share:
Continuing operations	$	(0.04	)	$	(0.03	)
Discontinued operations	0.24			(0.04		)
Net basic and diluted income (loss) per share	$	0.20		$	(0.07	)

15

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Due to their antidilutive effect, 25,768 and 33,747 potential common shares related to stock options have been excluded from the computation of diluted income (loss) per share for the thirteen week period ended June 2, 2018 and June 3, 2017, respectively. Also, excluded from the computation of diluted income (loss) per share as of June 2, 2018 and June 3, 2017 are restricted shares of 11,339 and 5,623, respectively, which are included in shares outstanding.

5. Lease Termination and Impairment Charges

Lease termination and impairment charges consist of amounts as follows:

	Thirteen Week Period Ended
	June 2, 2018		June 3, 2017
Impairment charges	$	283	$	659
Lease termination charges	9,576		3,379
	$	9,859	$	4,038

Impairment Charges

These amounts include the write-down of long-lived assets at locations that were assessed for impairment because of management’s intention to relocate or close the location or because of changes in circumstances that indicated the carrying value of an asset may not be recoverable.

Lease Termination Charges

As part of the Company’s ongoing business activities, the Company assesses stores and distribution centers for potential closure or relocation. Decisions to close or relocate stores or distribution centers in future periods would result in lease termination charges, lease exit costs and inventory liquidation charges, as well as impairment of assets at these locations. The following table reflects the closed store and distribution center charges that relate to new closures, changes in assumptions and interest accretion:

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
Balance—beginning of period	$	133,290		$	165,138
Provision for present value of noncancellable lease payments of closed stores	8,130			913
Changes in assumptions about future sublease income,  terminations and changes in interest rates	(1,038		)	(549		)
Interest accretion	2,685			3,095
Cash payments, net of sublease income	(11,885		)	(12,931		)
Balance—end of period	$	131,182		$	155,666

6. Fair Value Measurements

The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:

·Level 1—Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

·Level 2—Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.

16

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

·Level 3—Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.

Non-Financial Assets Measured on a Non-Recurring Basis

Long-lived non-financial assets are measured at fair value on a nonrecurring basis for purposes of calculating impairment using Level 2 and Level 3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level 2 inputs is determined by evaluating the current economic conditions in the geographic area for similar use assets. The fair value of long-lived assets using Level 3 inputs is determined by estimating the amount and timing of net future cash flows (which are unobservable inputs) and discounting them using a risk-adjusted rate of interest (which is Level 1). The Company estimates future cash flows based on its experience and knowledge of the market in which the store is located. Significant increases or decreases in actual cash flows may result in valuation changes. During the thirteen week period ended June 2, 2018, long-lived assets from continuing operations with a carrying value of $1,575, primarily store assets, were written down to their fair value of $1,292, resulting in an impairment charge of $283. During the thirteen week period ended June 3, 2017, long-lived assets from continuing operations with a carrying value of $964, primarily store assets, were written down to their fair value of $305, resulting in an impairment charge of $659.   If our actual future cash flows differ from our projections materially, certain stores that are either not impaired or partially impaired in the current period may be further impaired in future periods.

The following table presents fair values for those assets measured at fair value on a non-recurring basis at June 2, 2018 and June 3, 2017:

Fair Value Measurement Using

	Level 1		Level 2		Level 3		Total as of June 2, 2018
Long-lived assets held for use	$	—	$	—	$	—	$	—
Long-lived assets held for sale	$	—	$	1,292	$	—	$	1,292
Total	$	—	$	1,292	$	—	$	1,292

	Level 1		Level 2		Level 3		Total as of June 3, 2017
Long-lived assets held for use	$	—	$	—	$	201	$	201
Long-lived assets held for sale	$	—	$	104	$	—	$	104
Total	$	—	$	104	$	201	$	305

The above assets reflected in the caption Long-lived assets held for sale are separate and apart from the Assets to be Sold and do to their immateriality have not been reclassified to assets held for sale.

As of June 2, 2018 and June 3, 2017, the Company did not have any financial assets measured on a recurring basis.

Other Financial Instruments

Financial instruments other than long-term indebtedness include cash and cash equivalents, accounts receivable and accounts payable. These instruments are recorded at book value, which we believe approximate their fair values due to their short term nature.  In addition, as of June 2, 2018 and March 3, 2018 the Company has $7,257 and $7,282, respectively, of investments, carried at amortized cost as these investments are being held to maturity, which are included as a component of other assets.  The Company believes the carrying value of these investments approximates their fair value.

The fair value for LIBOR-based borrowings under the Company’s senior secured credit facility and first and second lien term loans are estimated based on the quoted market price of the financial instrument which is considered Level 1 of the fair value hierarchy. The fair values of substantially all of the Company’s other long-term indebtedness are estimated based on quoted market prices of the financial instruments which are considered Level 1 of the fair value hierarchy. The carrying amount and estimated fair value of the Company’s total long-term indebtedness was $3,134,794 and $3,162,700, respectively, as of June 2, 2018. There were no outstanding derivative financial instruments as of June 2, 2018 and March 3, 2018.

17

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

7. Income Taxes

The new federal tax legislation commonly referred to as the Tax Cut and Jobs Act (the “Tax Act”) enacted on December 22, 2017 (the “Enactment Date”) introduced significant changes to U.S. income tax law. Effective for tax years beginning on or after January 1, 2018, the Tax Act reduced the U.S. federal corporate income tax rate from 35% to 21%.

The Company recorded an income tax benefit from continuing operations of $9,497 and $12,121 for the thirteen week periods ended June 2, 2018 and June 3, 2017. The effective tax rate for the thirteen week periods ended June 2, 2018 and June 3, 2017 was 18.5% and 25.2%, respectively. The effective tax rate for the thirteen week period ended June 2, 2018 includes an adjustment of (2.3)% to increase the valuation allowance related to certain state deferred taxes. The tax benefit for the thirteen week period ended June 3, 2017 is higher in comparison to 2018, as it is based on a federal statutory rate of 35%, offset by increases to the valuation allowance primarily related to state deferred taxes.

The Company recognizes tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.

The Company believes that it is reasonably possible that a decrease of up to $13,498 in unrecognized tax benefits related to state exposures may be necessary in the next twelve months however management does not expect the change to have a significant impact on the results of operations or the financial position of the Company.

The Company regularly evaluates valuation allowances established for deferred tax assets for which future realization is uncertain.  Management will continue to monitor all available evidence related to the net deferred tax assets that may change the most recent assessment, including events that have occurred or are anticipated to occur. The Company continues to maintain a valuation allowance against net deferred tax assets of $903,342 and $896,800, which relates primarily to state deferred tax assets at June 2, 2018 and March 3, 2018, respectively.

8. Medicare Part D

The Company offers Medicare Part D benefits through EIC, which has contracted with CMS to be a PDP and, pursuant to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, must be a risk-bearing entity regulated under state insurance laws or similar statutes.

EIC is a licensed domestic insurance company under the applicable laws and regulations. Pursuant to these laws and regulations, EIC must file quarterly and annual reports with the National Association of Insurance Commissioners (“NAIC”) and certain state regulators, must maintain certain minimum amounts of capital and surplus under formulas established by certain states and must, in certain circumstances, request and receive the approval of certain state regulators before making dividend payments or other capital distributions to the Company. The Company does not believe these limitations on dividends and distributions materially impact its financial position. EIC is subject to minimum capital and surplus requirements in certain states. The minimum amount of capital and surplus required to satisfy regulatory requirements in these states is $29,464 as of March 31, 2018. EIC was in excess of the minimum required amounts in these states as of June 2, 2018.

The Company has recorded estimates of various assets and liabilities arising from its participation in the Medicare Part D program based on information in its claims management and enrollment systems. Significant estimates arising from its participation in this program include: (i) estimates of low-income cost subsidies, reinsurance amounts, and coverage gap discount amounts ultimately payable to CMS based on a detailed claims reconciliation that will occur in the following year; (ii) an estimate of amounts receivable from CMS under a risk-sharing feature of the Medicare Part D program design, referred to as the risk corridor and (iii) estimates for claims that have been reported and are in the process of being paid or contested and for our estimate of claims that have been incurred but have not yet been reported.

18

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

As of June 2, 2018, accounts receivable, net included $442,690 due from CMS and accrued salaries, wages and other current liabilities included $163,134 of EIC liabilities under certain reinsurance contracts. As of March 3, 2018, accounts receivable, net included $350,563 due from CMS and accrued salaries, wages and other current liabilities included $183,318 of EIC liabilities under certain reinsurance contracts. During calendar 2017, EIC limited its exposure to loss and recovered a portion of benefits paid by utilizing quota-share reinsurance with a commercial reinsurance company. Beginning calendar 2018, EIC does not have a reinsurance agreement in place related to its individual and certain group Medicare Part D Plans.

9. Goodwill and Other Intangible Assets

There was no impairment charge for the thirteen week period ended June 2, 2018. At June 2, 2018 and March 3, 2018, accumulated impairment losses for the Pharmacy Services segment was $261,727.

The Company’s intangible assets are primarily finite-lived and amortized over their useful lives. Following is a summary of the Company’s finite-lived and indefinite-lived intangible assets as of June 2, 2018 and March 3, 2018.

	June 2, 2018								March 3, 2018
	Gross Carrying Amount		Accumulated Amortization			Net		Remaining Weighted Average Amortization Period	Gross Carrying Amount		Accumulated Amortization			Net		Remaining Weighted Average Amortization Period
Favorable leases and other(a)	$	379,809	$	(318,930	)	$	60,879	7 years	$	379,355	$	(316,798	)	$	62,557	7 years
Prescription files	906,181		(808,498		)	97,683		3 years	900,111		(801,706		)	98,405		3 years
Customer relationships(a)	465,000		(187,616		)	277,384		14 years	465,000		(172,635		)	292,365		15 years
CMS license	57,500		(6,747		)	50,753		22 years	57,500		(6,172		)	51,328		23 years
Claims adjudication and other developed software	58,985		(24,724		)	34,261		4 years	58,985		(22,617		)	36,368		5 years
Trademarks	20,100		(5,896		)	14,204		7 years	20,100		(5,394		)	14,706		8 years
Backlog	11,500		(11,244		)	256		1 year	11,500		(10,286		)	1,214		1 year
Total finite	$	1,899,075	$	(1,363,655	)	535,420			$	1,892,551	$	(1,335,608	)	$	556,943
Trademarks	33,500		—			33,500		Indefinite	33,500		—			33,500		Indefinite
Total	$	1,932,575	$	(1,363,655	)	$	568,920		$	1,926,051	$	(1,335,608	)	$	590,443

(a)            Amortized on an accelerated basis which is determined based on the remaining useful economic lives of the customer relationships that are expected to contribute directly or indirectly to future cash flows.

Also included in other non-current liabilities as of June 2, 2018 and March 3, 2018 are unfavorable lease intangibles with a net carrying amount of $17,857 and $18,888, respectively. These intangible liabilities are amortized over their remaining lease terms at time of acquisition.

Amortization expense for these intangible assets and liabilities was $35,400 and $40,962 for the thirteen week periods ended June 2, 2018 and June 3, 2017, respectively. The anticipated annual amortization expense for these intangible assets and liabilities is 2019—$124,583; 2020—$100,875; 2021—$76,995; 2022—$55,206 and 2023—$38,953.

10. Indebtedness and Credit Agreements

Following is a summary of indebtedness and lease financing obligations at June 2, 2018 and March 3, 2018:

	June 2, 2018			March 3, 2018
Secured Debt:
Senior secured revolving credit facility due January 2020 ($190,000 and $0 face value less unamortized debt issuance costs of $10,258 and $13,076)	$	179,742		$	(13,076	)
Other secured	90			90
	179,832			(12,986		)
Guaranteed Unsecured Debt:
9.25% senior notes due March 2020 ($0 and $902,000 face value plus unamortized premium of $0 and $1,400 and less unamortized debt issuance costs of $0 and $4,924 as of June 2, 2018 and March 3, 2018, respectively)	—			898,476
6.75% senior notes due June 2021 ($805,169 and $810,000 face value less unamortized debt issuance costs of $4,482 and $4,877)	800,687			805,123
6.125% senior notes due April 2023 ($1,753,490 and $1,800,000 face value less unamortized debt issuance costs of $20,106 and $21,708)	1,733,384			1,778,292
	2,534,071			3,481,891
Unguaranteed Unsecured Debt:
7.7% notes due February 2027 ($295,000 face value less unamortized debt issuance costs of $1,418 and $1,460)	293,582			293,540
6.875% fixed-rate senior notes due December 2028 ($128,000 face value less unamortized debt issuance costs of $691 and $707)	127,309			127,293
	420,891			420,833
Lease financing obligations	47,809			52,554
Total debt	3,182,603			3,942,292
Current maturities of long-term debt and lease financing obligations	(19,025		)	(21,031		)
Long-term debt and lease financing obligations, less current maturities	$	3,163,578		$	3,921,261

19

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Reconciliation of indebtedness included in continuing operations and discontinued operations:

	March 3, 2018
	Debt			Lease Financing Obligations			Total Debt and Lease Financing Obligations
Balance, March 3, 2018—per above table	$	3,889,738		$	52,554		$	3,942,292
Amounts reclassified as current liabilities held for sale in connection with the Sale(a)	(549,549		)	(1,108		)	(550,657		)
Total debt and lease financing obligations	3,340,189			51,446			3,391,635
Current maturities of long-term debt and lease financing obligations—continuing operations	(90		)	(20,671		)	(20,761		)
Long-term debt and lease financing obligations, less current maturities—continuing operations	$	3,340,099		$	30,775		$	3,370,874

(a)In connection with the Sale, the Company had estimated that the Sale would generate excess cash proceeds of approximately $4,027,400 which would be used to repay outstanding indebtedness. During the thirteen week period ended June 2, 2018, the Company has a use of cash for financing purposes of $525,031 in its discontinued operations and, based on refinements to its calculations, reduced its estimate of excess cash proceeds by approximately $24,500 and reclassified that amount to assets held and used. Consequently, the Company has classified $0 and $549,549 of estimated cash proceeds to be used for debt repayment to liabilities held for sale as of June 2, 2018 and March 3, 2018, respectively. Additionally, as part of the Sale, the Company will be relieved of approximately $0 and $1,108, respectively, of capital lease obligations as of June 2, 2018 and March 3, 2018. These amounts are also reflected as liabilities held for sale. Please see Note 3 for additional details.

Credit Facility

The Company’s Amended and Restated Senior Secured Credit Facility has a borrowing capacity of $2,700,000 and matures in January 2020. Borrowings under the revolver bear interest at a rate per annum between (i) LIBOR plus 1.50% and LIBOR plus 2.00% with respect to Eurodollar borrowings and (ii) the alternate base rate plus 0.50% and the alternate base rate plus 1.00% with respect to ABR borrowings, in each case, based upon the Average Revolver Availability (as defined in the Amended and Restated Senior Secured Credit Facility). The Company is required to pay fees between 0.250% and 0.375% per annum on the daily unused amount of the revolver, depending on the Average Revolver Availability (as defined in the Amended and Restated Senior Secured Credit Facility). Amounts drawn under the revolver become due and payable on January 13, 2020.

The Company’s ability to borrow under the revolver is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At June 2, 2018, the Company had $190,000 of borrowings outstanding under the revolver and had letters of credit outstanding against the revolver of $55,790 which resulted in additional borrowing capacity of $2,454,210.

The Amended and Restated Senior Secured Credit Facility restricts the Company and the Subsidiary Guarantors (as defined herein) from accumulating cash on hand, and under certain circumstances, requires the funds in the Company’s deposit accounts to be applied first to the repayment of outstanding revolving loans under the Amended and Restated Senior Secured Credit Facility and then to be held as collateral for the senior obligations.

The Amended and Restated Senior Secured Credit Facility allows the Company to have outstanding, at any time, up to $1,500,000 in secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock in addition to

20

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

borrowings under the Amended and Restated Senior Secured Credit Facility and existing indebtedness, provided that not in excess of $750,000 of such secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock shall mature or require scheduled payments of principal prior to 90 days after the latest of (a) the fifth anniversary of the effectiveness of the Amended and Restated Senior Secured Credit Facility and (b) the latest maturity date of any Term Loan or Other Revolving Loan (each as defined in the Amended and Restated Senior Secured Credit Facility) (excluding bridge facilities allowing extensions on customary terms to at least the date that is 90 days after such date and, with respect to any escrow notes issued by Rite Aid, excluding any special mandatory redemption of the type described in clause (iii) of the definition of “Escrow Notes” in the Amended and Restated Senior Secured Credit Facility). Subject to the limitations described in clauses (a) and (b) of the immediately preceding sentence, the Amended and Restated Senior Secured Credit Facility additionally allows the Company to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the Amended and Restated Senior Secured Credit Facility) is not in effect; provided, however, that certain of the Company’s other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The Amended and Restated Senior Secured Credit Facility also contains certain restrictions on the amount of secured first priority debt the Company is able to incur. The Amended and Restated Senior Secured Credit Facility also allows for the voluntary repurchase of any debt or other convertible debt, so long as the Amended and Restated Senior Secured Credit Facility is not in default and the Company maintains availability under its revolver of more than $365,000.

The Amended and Restated Senior Secured Credit Facility has a financial covenant that requires the Company to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (a) on any date on which availability under the revolver is less than $200,000 or (b) on the third consecutive business day on which availability under the revolver is less than $250,000 and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the revolver is equal to or greater than $250,000. As of June 2, 2018, the Company had availability under its revolver of $2,454,210, its fixed charge coverage ratio was greater than 1.00 to 1.00, and the Company was in compliance with the senior secured credit facility’s financial covenant. The Amended and Restated Senior Secured Credit Facility also contains covenants which place restrictions on the incurrence of debt, the payments of dividends, sale of assets, mergers and acquisitions and the granting of liens.

The Amended and Restated Senior Secured Credit Facility also provides for customary events of default.

With the exception of EIC, substantially all of Rite Aid Corporation’s 100 percent owned subsidiaries guarantee the obligations under the Amended and Restated Senior Secured Credit Facility and unsecured guaranteed notes. The Amended and Restated Senior Secured Credit Facility is secured, on a senior priority basis, by a lien on, among other things, accounts receivable, inventory and prescription files of the Subsidiary Guarantors. The subsidiary guarantees related to the Company’s Amended and Restated Senior Secured Credit Facility and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several, and there are no restrictions on the ability of the Company to obtain funds from its subsidiaries. The Company has no independent assets or operations. Additionally, prior to the Acquisition, the subsidiaries, including joint ventures, that did not guarantee the Amended and Restated Senior Secured Credit Facility and applicable notes, were minor. Accordingly, condensed consolidating financial information for the Company and subsidiaries is not presented for those periods. Subsequent to the Acquisition, other than EIC, the subsidiaries, including joint ventures, that do not guarantee the credit facility and applicable notes, are minor. As such, condensed consolidating financial information for the Company, its guaranteeing subsidiaries and non-guaranteeing subsidiaries is presented for those periods subsequent to the Acquisition. See Note 14 “Guarantor and Non-Guarantor Condensed Consolidating Financial Information” for additional disclosure.

Fiscal 2018 and 2019 Transactions

During January 2018, the Company used proceeds from the Asset Sale to repay and retire all of its outstanding second lien $470,000 tranche 1 term loan and $500,000 tranche 2 term loan principal (the “Second Lien Term Loan Prepayment”). During February 2018, the Company reduced the borrowing capacity on its Amended and Restated Senior Secured Credit Facility from $3,700,000 to $3,000,000. In connection with the transactions, the Company recorded a loss on debt retirement of $8,180, which included interest and unamortized debt issuance costs. The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On February 27, 2018, the Company announced that it had commenced an offer to purchase up to $900,000 of the outstanding 9.25% senior notes due 2020 (the “9.25% Notes”), the 6.75% senior notes due 2021 (the “6.75% Notes”) and the 6.125% Senior Notes due 2023 (the “6.125% Notes”), pursuant to the asset sale provisions of the indentures of such notes. On March 29, 2018, the Company accepted for payment, pursuant to its offer to purchase, $3,454 principal amount of the 9.25% Notes, representing 0.38% of the outstanding principal amount of the 9.25% Notes, $3,471 principal amount of the 6.75% Notes, representing 0.43% of the outstanding principal amount of the 6.75% Notes, and $41,751 principal amount of the 6.125% Notes, representing 2.32% of the outstanding principal amount of the 6.125% Notes.  In connection therewith, the Company recorded a loss on debt retirement of $49

21

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

which included unamortized debt issuance costs, partially offset by unamortized discount.  The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of discontinued operations. The debt repayment and related loss on debt retirement of $498 for the 6.125% Notes is included in the results of operations and cash flows of continuing operations.

On March 13, 2018, the Company issued a notice of redemption for all of the 9.25%. Notes that were outstanding on April 12, 2018, pursuant to the terms of the indenture of the 9.25% Notes. On April 12, 2018, the Company redeemed 100% of the remaining outstanding 9.25% Notes.  In connection therewith, the Company recorded a loss on debt retirement of $3,422 which included unamortized debt issuance costs, partially offset by unamortized discount.  The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On April 19, 2018, the Company announced that it had commenced an offer to purchase up to $700,000 of its outstanding 6.75% Notes and its 6.125% Notes pursuant to the terms of such indentures. On May 21, 2018, the Company redeemed $1,360 aggregate principal amount of the 6.75% Notes and $4,759 aggregate principal amount of the 6.125% Notes.  The debt repayment and related loss on debt retirement of $8 for the 6.75% Notes is included in the results of operations and cash flows of discontinued operations.  The debt repayment and related loss on debt retirement of $56 for the 6.125% Notes is included in the results of operations and cash flows of continuing operations.

On April 29, 2018, the Company further reduced the borrowing capacity on its Amended and Restated Senior Secured Credit Facility from $3,000,000 to $2,700,000. In connection therewith, the Company recorded a loss on debt retirement of $1,091, which included unamortized debt issuance costs. The loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On May 25, 2018, the Company issued a notice of redemption for all of the 6.75% Notes that were outstanding on June 25 2018, pursuant to the terms of the indenture of the 6.75% Notes. On June 25, 2018, the Company redeemed 100% of the remaining outstanding 6.75% Notes, which resulted in a loss on debt retirement of $18,075. The debt repayment and related loss on debt retirement will be included in the results of operations and cash flows of discontinued operations during the second quarter ending September 1, 2018.

Maturities

The aggregate annual principal payments of long-term debt for the remainder of fiscal 2019 and thereafter are as follows: 2019—$90; 2020—$190,000; 2021—$0; 2022—$805,169; 2023—$0 and $2,176,490 thereafter.

11. Retirement Plans

Net periodic pension expense recorded in the thirteen week periods ended June 2, 2018 and June 3, 2017, for the Company’s defined benefit plan includes the following components:

	Defined Benefit Pension Plan
	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
Service cost	$	312		$	346
Interest cost	1,578			1,603
Expected return on plan assets	(1,434		)	(1,147		)
Amortization of unrecognized prior service cost	—			—
Amortization of unrecognized net loss	507			856
Net periodic pension expense	$	963		$	1,658

During the thirteen week period ended June 2, 2018 the Company contributed $813 to the Defined Benefit Pension Plan. During the remainder of fiscal 2018, the Company expects to contribute $3,800 to the Defined Benefit Pension Plan.

12. Segment Reporting

The Company has two reportable segments, its retail drug stores (“Retail Pharmacy”), and its pharmacy services (“Pharmacy Services”) segments, collectively the “Parent Company”.

22

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

The Retail Pharmacy segment’s primary business is the sale of prescription drugs and related consultation to its customers. Additionally, the Retail Pharmacy segment sells a full selection of health and beauty aids and personal care products, seasonal merchandise and a large private brand product line. The Pharmacy Services segment offers a full range of pharmacy benefit management services including plan design and administration, on both a transparent pass-through model and traditional model, formulary management and claims processing. Additionally, the Pharmacy Services segment offers specialty and mail order services, infertility treatment, and drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program.

The Parent Company’s chief operating decision makers are its Parent Company Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, Chief Operating Officer—Retail Pharmacy, and the Chief Executive Officer—Pharmacy Services, (collectively the “CODM”). The CODM has ultimate responsibility for enterprise decisions. The CODM determines, in particular, resource allocation for, and monitors performance of, the consolidated enterprise, the Retail Pharmacy segment and the Pharmacy Services segment. The Retail Pharmacy and Pharmacy Services segment managers have responsibility for operating decisions, allocating resources and assessing performance within their respective segments. The CODM relies on internal management reporting that analyzes enterprise results on certain key performance indicators, namely, revenues, gross profit, and Adjusted EBITDA.

The following is balance sheet information for the Company’s reportable segments:

	Retail Pharmacy		Pharmacy Services		Eliminations(2)			Consolidated
June 2, 2018:
Total Assets	$	5,434,447	$	2,950,099	$	(55,093	)	$	8,329,453
Goodwill	43,493		1,377,627		—			1,421,120
Additions to property and equipment and intangible assets	58,067		3,559		—			61,626
March 3, 2018:
Total Assets	$	6,089,343	$	2,954,953	$	(54,969	)	$	8,989,327
Goodwill	43,492		1,377,628		—			1,421,120
Additions to property and equipment and intangible assets	199,437		15,327		—			214,764

(2)As of June 2, 2018 and March 3, 2018, intersegment eliminations include netting of the Pharmacy Services segment long-term deferred tax liability of $40,319 and $38,713, respectively, against the Retail Pharmacy segment long-term deferred tax asset for consolidation purposes in accordance with ASC 740, and intersegment accounts receivable of $14,774 and $16,256, respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products.

The following table is a reconciliation of the Company’s business segments to the consolidated financial statements for the thirteen week periods ended June 2, 2018 and June 3, 2017:

	Retail Pharmacy		Pharmacy Services		Intersegment Eliminations(1)			Consolidated
June 2, 2018:
Revenues	$	3,897,765	$	1,542,762	$	(52,037	)	$	5,388,490
Gross Profit	1,069,457		99,292		—			1,168,749
Adjusted EBITDA(2)	113,469		33,863		—			147,332
June 3, 2017:
Revenues	$	3,972,351	$	1,513,241	$	(49,069	)	$	5,436,523
Gross Profit	1,056,971		104,972		—			1,161,943
Adjusted EBITDA(2)	87,365		48,599		—			135,964

(1)Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis.

(2)See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” in MD&A for additional details. The following is a reconciliation of net (loss) income to Adjusted EBITDA for the thirteen week periods ended June 2, 2018 and June 3, 2017:

23

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

	June 2, 2018 (13 weeks)			June 3, 2017 (13 weeks)
Net loss from continuing operations	$	(41,727	)	$	(36,037	)
Interest expense	62,792			51,000
Income tax benefit	(9,497		)	(12,121		)
Depreciation and amortization expense	94,529			101,029
LIFO charge	9,966			10,173
Lease termination and impairment charges	9,859			4,038
Loss on debt retirements, net	554			—
Other	20,856			17,882
Adjusted EBITDA from continuing operations	$	147,332		$	135,964

13. Commitments, Contingencies and Guarantees

Legal Matters and Regulatory Proceedings

The Company is involved in legal proceedings and is subject to investigations, inspections, claims, audits, inquiries, and similar actions by governmental authorities arising in the ordinary course of its business, including, without limitation, the matters described below. The Company records accruals for outstanding legal matters and applicable regulatory proceedings when it believes it is probable that a loss will be incurred, and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters and regulatory proceedings that could affect the amount of any existing accrual and developments that would make a loss contingency both probable and reasonably estimable, and as a result, warrant an account. If a loss contingency is not both probable and estimable, the Company does not establish an accrued liability.  None of the Company’s accruals for outstanding legal matters or regulatory proceedings are material individually or in the aggregate to the Company’s consolidated financial position.

The Company’s contingencies are subject to significant uncertainties, many of which are beyond the Company’s control, including, among other factors: (i) proceedings are in early stages; (ii) whether class or collective action status is sought and the likelihood of a class being certified; (iii) the outcome of pending appeals or motions; (iv) the extent of potential damages, fines or penalties, which are often unspecified or indeterminate; (v) the impact of discovery on the matter; (vi) whether novel or unsettled legal theories are at issue; (vii) there are significant factual issues to be resolved; and/or (viii) in the case of certain government agency investigations, whether a qui tam lawsuit (“whistleblower” action) has been filed and whether the government agency makes a decision to intervene in the lawsuit following investigation.  While the Company cannot predict the outcome of any of the contingencies, the Company’s management does not believe that the outcome of any of these legal matters or regulatory proceedings will be material to the Company’s consolidated financial position.  It is possible, however, the Company’s results of operations or cash flows could be materially affected by unfavorable outcomes in outstanding legal matters or regulatory proceedings.

After the announcement of the then proposed merger between the Company and Walgreens Boots Alliance, Inc. (WBA), a putative class action lawsuit was filed in Pennsylvania in the Court of Common Pleas of Cumberland County (Wilson v. Rite Aid Corp., et al.) by a purported Company stockholder against the Company, its directors (the Individual Defendants, together with the Company, the Rite Aid Defendants), WBA and Victoria Merger Sub Inc. (Victoria) challenging the transactions contemplated by the merger agreement. The complaint alleged primarily that the Individual Defendants breached their fiduciary duties by, among other things, agreeing to an allegedly unfair and inadequate price, agreeing to deal protection devices that allegedly prevented the directors from obtaining higher offers from other interested buyers for the Company and allegedly failing to protect against certain purported conflicts of interest in connection with the merger. The complaint further alleged that the Company, WBA and/or Victoria aided and abetted these alleged breaches of fiduciary duty. The complaint sought, among other things, to enjoin the closing of the merger as well as money damages and attorneys’ and experts’ fees. The matter remains pending, but inactive.

Also in connection with that proposed merger, a lawsuit was filed in the United States District Court for the Middle District of Pennsylvania (the Pennsylvania District Court), asserting a claim for violations of Section 14(a) of the Exchange Act and SEC Rule 14a-9 against the Rite Aid Defendants, WBA and Victoria and a claim for violations of Section 20(a) of the Exchange Act against the Individual Defendants and WBA (Hering v. Rite Aid Corp., et al.). The complaint in the Hering action alleged, among other things, that the Rite Aid Defendants disseminated an allegedly false and materially misleading proxy and sought to enjoin the shareholder vote on the proposed merger, a declaration that the proxy was materially false and misleading in violation of federal securities laws and an award of money damages and attorneys’ and experts’ fees. On January 14 and 16, 2016, respectively, the plaintiff in the Hering action filed a motion for preliminary injunction and a motion for expedited discovery. On January 21, 2016, the Rite Aid Defendants filed a motion to dismiss the Hering complaint. At a hearing held on January 25, 2016, the Pennsylvania District Court orally denied the plaintiff’s motion for expedited discovery and subsequently denied the plaintiff’s motion for preliminary injunction on January 28, 2016. On March 14, 2016, the Pennsylvania District Court appointed Jerry Hering, Don Michael Hussey and

24

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

Joanna Pauli Hussey as lead plaintiffs for the putative class and approved their selection of Robbins Geller Rudman & Dowd LLP as lead counsel. On April 14, 2016, the Pennsylvania District Court granted the lead plaintiffs’ unopposed motion to stay the Hering action for all purposes pending consummation of the merger.

On March 17, 2017, the Hering plaintiffs filed a motion to lift the stay for the purpose of filing a proposed amended complaint. Defendants opposed the motion, and briefing concluded on April 17, 2017. The proposed amended complaint asserted state law breach of fiduciary duty claims against the Individual Defendants, a claim of aiding and abetting the alleged breaches of fiduciary duty against Rite Aid, WBA and Victoria, as well as claims for violations of Section 14(a) of the Exchange Act and SEC Rule 14a-9 against the Rite Aid Defendants, WBA and Victoria, claims for violations of Section 10(b) of the Exchange Act and SEC Rule 10b-5 against the Rite Aid Defendants, WBA, Victoria and certain WBA executives, and a claim for violations of Section 20(a) of the Exchange Act against the Individual Defendants, WBA and Victoria. On August 4, 2017, the Pennsylvania District Court entered an order lifting the stay, noting that the original claims in this matter are now moot, and directed the plaintiffs to file a motion for leave to amend the complaint, with brief in support thereof, on or before September 15, 2017 which deadline was subsequently extended to September 22, 2017. On September 22, 2017, the lead plaintiffs gave notice that plaintiffs Don Michael Hussey and Joanna Pauli Hussey were withdrawing as lead plaintiffs, and that plaintiff Jerry Hering (the Lead Plaintiff) would continue to represent the proposed class in the Hering action going forward. That same day, Lead Plaintiff filed a motion for leave to file an amended complaint, which the Pennsylvania District Court granted on November 27, 2017. On December 11, 2017, Lead Plaintiff filed the amended complaint (the Amended Complaint), which alleges a claim for violations of Section 10(b) of the Exchange Act and SEC Rule 10b-5 and a claim for violations of Section 20(a) of the Exchange Act against the Rite Aid Defendants, WBA, and certain WBA executives. On February 14 and 16, 2018, the Rite Aid Defendants filed a motion to dismiss the Amended Complaint, and an opening brief in support thereof.  Briefing concluded on June 7, 2018.

In connection with the proposed merger between the Company and Albertsons Companies, Inc. (ACI), on April 24, 2018, a Rite Aid stockholder filed a putative class action lawsuit in the Court of Chancery of the State of Delaware against Rite Aid, ACI, Ranch Acquisition Corp. (Merger Sub I), Ranch Acquisition II LLC (Merger Sub II, together with ACI and Merger Sub I, the ACI defendants) and each of the Rite Aid directors (the Director defendants, together with Rite Aid, the Rite Aid defendants), Del. C.A. No. 2018-0305-AGB.  Plaintiff contends that Rite Aid stockholders have appraisal rights under Section 262 of the DGCL.  Plaintiff alleges breach of fiduciary duty claims against the Director defendants for their alleged failure to provide alleged statutory appraisal rights under Delaware law and for allegedly falsely informing Rite Aid stockholders that they will not have appraisal rights.  Plaintiff further contends that the proxy statement/prospectus related to the proposed merger, and which was filed on April 6, 2018, was deficient under Section 262(d)(1) of the DGCL for failure to inform stockholders of their alleged appraisal rights.  Plaintiff seeks declarations from the Court of Chancery that the action is a proper class action and that the Director defendants breached their fiduciary duties by failing to adequately inform class members of their appraisal rights under Delaware law, to enjoin the proposed action from closing until such time as class members are afforded the ability to seek appraisal of their shares, or otherwise permit class members to petition the Court of Chancery for appraisal, and attorneys’ fees, expenses, and costs to Plaintiff.  On May 9, 2018, the Court of Chancery denied Plaintiff’s motion to expedite and declined to schedule a preliminary injunction hearing, ruling that Plaintiff failed to state a colorable claim.  Defendants oppose Plaintiff’s claims on the ground that Rite Aid stockholders have no appraisal rights under the DGCL because they have a right to receive all stock consideration as described in the proxy statement/prospectus previously filed on April 6, 2018.  On May 16, 2018, the Rite Aid defendants and the ACI defendants each filed a Motion to Dismiss Plaintiff’s Verified Class Action Complaint (collectively, the “Motions to Dismiss”).  On June 6, 2018, the parties jointly stipulated that the briefing submitted by the parties in support of, and in opposition to, Plaintiff’s Motion for Expedited Proceedings shall constitute the briefing with respect to the Motions to Dismiss. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential rage of loss with respect to the lawsuit and is vigorously defending this lawsuit.

On June 29, 2018, a purported stockholder of the Company filed a Verified Complaint to Compel Inspection of Books and Records under 8 Del. C. §220 in the Delaware Court of Chancery against the Company, seeking to inspect books and records in order to determine whether wrongdoing or mismanagement has taken place such that it would be appropriate to file claims for breach of fiduciary duty, and to investigate the independence and disinterestedness of the Company’s directors with respect to the proposed merger with ACI. The Company’s response to this complaint is due on July 23, 2018.

The Company is currently a defendant in several lawsuits filed in courts in California alleging violations of California wage-and-hour laws, rules and regulations pertaining primarily to failure to pay overtime, failure to pay for missed meals and rest periods, failure to reimburse business expenses and failure to provide employee seating (the “California Cases”). Some of the California Cases purport or may be determined to be class actions and seek substantial damages and penalties. The single-plaintiff and multi-plaintiff California Cases regarding violations of wage-and-hour laws, failure to pay overtime and failure to pay for missed meals and rest periods, in the aggregate, seek substantial damages. The Company believes that its defenses and assertions in the California Cases, as well as other lawsuits, have merit. The Company has aggressively challenged the merits of the lawsuits and, where applicable, the allegations that the lawsuits should be certified as class or representative actions. Additionally, at this time the Company is not able to predict either the outcome of or estimate a potential range of loss with respect to the California Cases and is vigorously defending them.

In the employee seating lawsuit (Hall v. Rite Aid Corporation, San Diego County Superior Court), the Court, in October 2011, granted the plaintiff’s motion for class certification. The Company filed its motion for decertification, which motion was granted in November 2012. Plaintiff subsequently appealed the Court’s order which appeal was granted in May 2014. The Company filed a petition for review of the appellate court’s decision with the California Supreme Court, which petition was denied in August 2014. Proceedings in the Hall case were stayed pending a decision by the California Supreme Court in two similar lawsuits. That

25

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

decision was rendered on April 4, 2016. A status conference in the case was held on November 18, 2016, at which time the court lifted the stay and scheduled the matter for trial on January 26, 2018. The trial scheduled to begin June 15, 2018 was adjourned by the Court.  A new trial date has not been scheduled by the Court. On February 2, 2018, the Court denied Rite Aid’s motion for summary judgment.

Following service of subpoenas on the Company in 2011 and 2013 by the United States Attorney’s Office for the Eastern District of Michigan (“USAO”) and the State of Indiana’s Office of the Attorney General, respectively, the Company cooperated with inquiries regarding the relationship of Rite Aid’s Rx Savings Program to the reporting of usual and customary charges to publicly funded health programs. In January 2017, the USAO, 18 states and the District of Columbia declined to intervene in a sealed False Claims Act (“FCA”) lawsuit filed by qui tam plaintiff Azam Rahimi (“Relator”) in the District Court for the Eastern District of Michigan. On January 19, 2017, the court unsealed Relator’s Second Amended Complaint against the Company; it alleges that the Company failed to report Rx Savings prices as its usual and customary charges under the Medicare Part D program and to federal and state Medicaid programs in 18 states and the District of Columbia; and that the Company is thus liable under the federal FCA and similar state statutes. In its ruling on the Company’s motion to dismiss the complaint, the Court held that Relator’s complaint was deficient, but allowed Relator the opportunity to re-plead.  Relator filed a Third Amended Complaint on May 11, 2018.  The Company filed a motion to dismiss the Third Amended Complaint on May 25, 2018, which is pending. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit and is vigorously defending this lawsuit.

On April 26, 2012, the Company received an administrative subpoena from the U.S. Drug Enforcement Administration (“DEA”), Albany, New York District Office, requesting information regarding the Company’s sale of products containing pseudoephedrine (“PSE”). In April 2012, it also received a communication from the U.S. Attorney’s Office (“USAO”) for the Northern District of New York concerning an investigation of possible civil violations of the Combat Methamphetamine Epidemic Act of 2005 (“CMEA”). Additional subpoenas were issued in 2013, 2014, and 2015 seeking broader documentation regarding PSE sales and recordkeeping requirements. Assistant U.S. Attorneys from the Northern and Eastern Districts of New York and the Southern District of West Virginia are currently investigating, but no lawsuits have been filed. Violations of the CMEA could result in the imposition of administrative and/or civil penalties against the Company. The Company has entered into tolling agreements with the United States, and discussions have been held to attempt to resolve these matters with those USAOs and the Department of Justice, but whether any agreements can be reached and on what terms is uncertain. At this stage of the investigation, the Company is not able to predict the outcome of the investigation.

In December 2017, Rite Aid executed a non-prosecution agreement with the United States Attorney’s Office for the Southern District of West Virginia (countersigned by the government in January 2018), which concluded the previous criminal investigation into Rite Aid’s PSE sales. Pursuant to that agreement, the government agreed not to bring any criminal charges against Rite Aid, and Rite Aid agreed to pay an immaterial amount of money as restitution.  The civil investigation is ongoing.

In June 2013, the Company was served with a Civil Investigative Demand (“CID”) by the United States Attorney’s Office for the Eastern District of California (the “USAO”) regarding (1) the Company’s Drug Utilization Review (“DUR”) and prescription dispensing protocol; and (2) the dispensing of drugs designated as “Code 1” by the State of California. The Company cooperated with the investigation, researched the government’s allegations, and refuted the government’s position. The Company produced documents including certain prescription files related to Code 1 drugs to the USAO’s office and the State of California Department of Justice’s Bureau of Medical Fraud and Elder Abuse (“CADOJ”). In August 2014, the USAO and 8 states’ attorneys general declined to intervene in a California False Claim Act (“FCA”) action (“Action”) filed under seal in the Eastern District of California by qui tam plaintiff Loyd F. Schmuckley (“Relator”) based on DUR and Code 1 allegations. In July 2016, the Commonwealth of Massachusetts and the District of Columbia also declined to intervene in the Action. On May 15, 2017, Relator and the CADOJ stipulated to dismiss all DUR-related claims and 18 other state-based claims. On September 21, 2017, the CADOJ filed a sealed complaint-in-intervention in the Action, asserting causes under the FCA, for unjust enrichment and for payment by mistake related to the Code 1 allegations. The Action was unsealed on September 26, 2017. On September 28, 2017, Relator filed a First Amended Complaint under the FCA also concerning the Code 1 allegations. The Company filed a motion to dismiss Relator’s and CADOJ’s respective complaints in January 2018, the hearing was held on March 23, 2018, and the court’s order remains pending. At this stage of the proceedings, the Company is not able to either predict the outcome of this matter or estimate a potential range of loss with respect to this matter and is vigorously defending this lawsuit.

The State of Mississippi, by and through its Attorney General, filed a First Amended Complaint against the Company and various purported related entities on September 27, 2016 alleging violations of the Mississippi Medicaid Fraud Control Act, violations of the Mississippi Unfair and Deceptive Trade Practices Act, fraud and unjust enrichment. The Complaint alleges the Company failed to accurately report usual and customary prices to Mississippi’s Division of Medicaid. On November 14, 2016, the Company filed motions to dismiss based on substantive and jurisdictional grounds, as well as a motion to transfer venue. These motions are pending and the lawsuit is stayed while related litigation is on appeal. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit and is vigorously defending this lawsuit.

26

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

In December 2017, the United States Judicial Panel on multidistrict litigation ordered consolidated numerous lawsuits filed against various defendants by plaintiffs such as counties, cities, hospitals, and third-party payors, alleging claims generally concerning the impacts of widespread opioid abuse. The consolidated multidistrict litigation is In re National Prescription Opiate Litigation (MDL No. 2804), pending in the U.S. District Court for the Northern District of Ohio. This multidistrict litigation presumptively includes relevant federal court lawsuits that name the Company, including lawsuits filed by counties and municipalities in California, Indiana, Maryland, Michigan, Missouri, New Jersey, North Carolina, Ohio, West Virginia, and Wisconsin.  Similar lawsuits that name the Company in some capacity have been filed in state courts, including lawsuits filed by Shelby County, Tennessee, Shelby County (Tennessee) v. Purdue Pharma, L.P. et al.; several counties and cities in West Virginia, Brooke County (West Virginia) et al. v. Purdue Pharma L.P., et al. and City of Huntington (West Virginia) et al. v. Express Scripts Holding Company, et al,; several counties in South Carolina, County of Spartanburg (South Carolina) v. Rite Aid of South Carolina, Inc. et al., County of Greenville (South Carolina) v. Rite Aid of South Carolina, Inc., et al., and County of Anderson v. Rite Aid of South Carolina, Inc., et al; Camden County, New Jersey, Camden County, New Jersey v. Purdue Pharma L.P., et al; two counties in Oklahoma, The Board of County Commissioners of Delaware County, State of Oklahoma v. Purdue Pharma L.P., et al. and The Board of County Commissioners of Ottawa County, State of Oklahoma v. Purdue Pharma L.P., et al.; the city of Parma Heights, Ohio, The City of Parma Heights, Ohio v. Purdue Pharma L.P., et al.; and the city of Atlanta, Georgia, The City of Atlanta v. Purdue Pharma, LP, et al. At this stage of the proceedings, the Company is not able to either predict the outcome of these lawsuits or estimate a potential range of loss with respect to the lawsuits and is vigorously defending them.

The Company is involved in two putative consumer class action lawsuits in the United States District Court for the Southern District of California, alleging that it has overcharged customers’ insurance companies for prescription drug purchases, resulting in overpayment of co-pays.  The first lawsuit, Byron Stafford v. Rite Aid Corp., Case No. 17-CV-01340-AJB-JLB, was filed on June 30, 2017, and the second case, Robert Josten v. Rite Aid Corp., Case No. 18-CV-00152-AJB-JLB, was filed on January 23, 2018.  Each lawsuit alleges that (1) the Company was obligated to charge the plaintiffs’ insurance companies a “usual and customary” price for their prescription drugs; and (2) the Company failed to do so properly because the prices it reported were not equal to or adjusted to account for the discount prices that Rite Aid offers to uninsured and underinsured customers through its Rx Savings Program.  On December 19, 2017, the court granted the Company’s motion to dismiss Stafford’s complaints with leave to amend for failure to plead compliance with the applicable statutes of limitations.  After Stafford amended the complaint on January 9, 2018, the Company filed another motion to dismiss on January 23, 2018, and a similar motion to dismiss Josten’s complaint on March 16, 2018.  Both motions are fully briefed and are awaiting a decision from the court.  At this stage of the proceedings, the Company is not able to either predict the outcome of these lawsuits or estimate a potential range of loss with respect to the lawsuit and is vigorously defending these lawsuits.

In addition to the above described matters, the Company is subject from time to time to various claims and lawsuits and governmental investigations arising in the ordinary course of business.  While the Company’s management cannot predict the outcome of any of the claims, the Company’s management does not believe that the outcome of any of these matters will be material to the Company’s consolidated financial position.  It is possible, however, that the Company’s results of operations or cash flows could be materially affected by an unfavorable resolution of pending litigation or contingencies.

14. Guarantor and Non-Guarantor Condensed Consolidating Financial Information

Rite Aid Corporation conducts the majority of its business through its subsidiaries. With the exception of EIC, substantially all of Rite Aid Corporation’s 100 percent owned subsidiaries guarantee the obligations under the Amended and Restated Senior Secured Credit Facility, second priority secured term loan facilities, secured guaranteed notes and unsecured guaranteed notes (the “Subsidiary Guarantors”). Additionally, with the exception of EIC, the subsidiaries, including joint ventures, that do not guarantee the Amended and Restated Senior Secured Credit Facility, second priority secured term loan facilities, secured guaranteed notes and unsecured guaranteed notes, are minor.

For the purposes of preparing the information below, Rite Aid Corporation uses the equity method to account for its investment in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in the non-guarantor subsidiaries. The subsidiary guarantees related to the Company’s Amended and Restated Senior Secured Credit Facility, second priority secured term loan facilities and secured guaranteed notes and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several. Presented below is condensed consolidating financial information for Rite Aid Corporation, the Subsidiary Guarantors, and the non-guarantor subsidiaries at June 2, 2018, March 3, 2018, and for the thirteen week periods ended June 2, 2018 and June 3, 2017. Separate financial statements for Subsidiary Guarantors are not presented.

27

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

	Rite Aid Corporation Condensed Consolidating Balance Sheet June 2, 2018 (unaudited)
	Rite Aid Corporation (Parent Company Only)		Subsidiary Guarantors		Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	138,400	$	8,692	$	—		$	147,092
Accounts receivable, net	—		1,390,296		518,659		—			1,908,955
Intercompany receivable	—		337,627		—		(337,627		)(a)	—
Inventories, net of LIFO reserve of $0, $591,056, $0, $0, and $591,056	—		1,809,595		—		—			1,809,595
Prepaid expenses and other current assets	—		147,760		3,299		—			151,059
Current assets held for sale	—		179,442		—		—			179,442
Total current assets	—		4,003,120		530,650		(337,627		)	4,196,143
Property, plant and equipment, net	—		1,401,924		—		—			1,401,924
Goodwill	—		1,421,120		—		—			1,421,120
Other intangibles, net	—		518,167		50,753		—			568,920
Deferred tax assets	—		522,674		—		—			522,674
Investment in subsidiaries	8,971,553		52,591		—		(9,024,144		)(b)	—
Intercompany receivable	—		3,949,896		—		(3,949,896		)(a)	—
Other assets	—		211,415		7,257		—			218,672
Total assets	$	8,971,553	$	12,080,907	$	588,660	$	(13,311,667	)	$	8,329,453
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	90	$	18,935	$	—	$	—		$	19,025
Accounts payable	—		1,762,078		5,699		—			1,767,777
Intercompany payable	—		—		337,627		(337,627		)(a)	—
Accrued salaries, wages and other current liabilities	74,552		781,315		174,425		—			1,030,292
Total current liabilities	74,642		2,562,328		517,751		(337,627		)	2,817,094
Long-term debt, less current maturities	3,134,704		—		—		—			3,134,704
Lease financing obligations, less current maturities	—		28,874		—		—			28,874
Intercompany payable	3,949,896		—		—		(3,949,896		)(a)	—
Other noncurrent liabilities	—		518,152		18,318		—			536,470
Total liabilities	7,159,242		3,109,354		536,069		(4,287,523		)	6,517,142
Commitments and contingencies	—		—		—		—			—
Total stockholders’ equity	1,812,311		8,971,553		52,591		(9,024,144		)(b)	1,812,311
Total liabilities and stockholders’ equity	$	8,971,553	$	12,080,907	$	588,660	$	(13,311,667	)	$	8,329,453

(a)Elimination of intercompany accounts receivable and accounts payable amounts.

(b)Elimination of investments in consolidated subsidiaries.

28

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

	Rite Aid Corporation Condensed Consolidating Balance Sheet March 3, 2018
	Rite Aid Corporation (Parent Company Only)		Subsidiary Guarantors		Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	441,244	$	6,090	$	—		$	447,334
Accounts receivable, net	—		1,502,507		366,593		—			1,869,100
Intercompany receivable			223,413		—		(223,413		)(a)	—
Inventories, net of LIFO reserve of $0, $581,090, $0, $0, and $581,090	—		1,799,539		—		—			1,799,539
Prepaid expenses and other current assets	—		176,678		4,503		—			181,181
Current assets held for sale	—		438,137		—		—			438,137
Total current assets	—		4,581,518		377,186		(223,413		)	4,735,291
Property, plant and equipment, net	—		1,431,246		—		—			1,431,246
Goodwill	—		1,421,120		—		—			1,421,120
Other intangibles, net	—		539,115		51,328		—			590,443
Deferred tax assets	—		594,019		—		—			594,019
Investment in subsidiaries	8,745,390		54,076		—		(8,799,466		)(b)	—
Intercompany receivable	—		3,189,419		—		(3,189,419		)(a)	—
Other assets	—		209,926		7,282		—			217,208
Noncurrent assets held for sale	—		—		—		—			—
Total assets	$	8,745,390	$	12,020,439	$	435,796	$	(12,212,298	)	$	8,989,327
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	90	$	20,671	$	—	$	—		$	20,761
Accounts payable	—		1,641,676		9,687		—			1,651,363
Intercompany payable	—		—		223,413		(223,413		)(a)	—
Accrued salaries, wages and other current liabilities	65,223		1,031,379		135,134		—			1,231,736
Current liabilities held for sales	549,549		10,656		—		—			560,205
Total current liabilities	614,862		2,704,382		368,234		(223,413		)	3,464,065
Long-term debt, less current maturities	3,340,099		—		—		—			3,340,099
Lease financing obligations, less current maturities	—		30,775		—		—			30,775
Intercompany payable	3,189,419		—		—		(3,189,419		)(a)	—
Other noncurrent liabilities	—		539,892		13,486		—			553,378
Noncurrent liabilities held for sale	—		—		—		—			—
Total liabilities	7,144,380		3,275,049		381,720		(3,412,832		)	7,388,317
Commitments and contingencies	—		—		—		—			—
Total stockholders’ equity	1,601,010		8,745,390		54,076		(8,799,466		)(b)	1,601,010
Total liabilities and stockholders’ equity	$	8,745,390	$	12,020,439	$	435,796	$	(12,212,298	)	$	8,989,327

(a)Elimination of intercompany accounts receivable and accounts payable amounts.

(b)Elimination of investments in consolidated subsidiaries.

29

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

	Rite Aid Corporation Condensed Consolidating Statement of Operations For the Thirteen Weeks Ended June 2, 2018 (unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Revenues	$	—		$	5,321,025		$	95,584		$	(28,119	)(a)	$	5,388,490
Costs and expenses:
Cost of revenues	—			4,158,627			89,032			(27,918		)(a)	4,219,741
Selling, general and administrative expenses	—			1,144,832			7,996			(201		)(a)	1,152,627
Lease termination and impairment charges	—			9,859			—			—			9,859
Interest expense	59,939			2,946			(93		)	—			62,792
Loss on debt retirements	—			554			—			—			554
Gain on sale of assets, net	—			(5,859		)	—			—			(5,859		)
Equity in earnings of subsidiaries, net of tax	(278,970		)	1,485			—			277,485		(b)	—
	(219,031		)	5,312,444			96,935			249,366			5,439,714
Income (loss) from continuing operations before income taxes	219,031			8,581			(1,351		)	(277,485		)	(51,224		)
Income tax expense (benefit)	—			(9,631		)	134			—			(9,497		)
Net income (loss) from continuing operations	$	219,031		$	18,212		$	(1,485	)	$	(277,485	)(b)	$	(41,727	)
Net income (loss) from discontinued operations	(4,615		)	260,758			—			—			256,143
Net income (loss)	214,416			278,970			(1,485		)	(277,485		)	214,416
Total other comprehensive income (loss)	364			364			—			(364		)	364
Comprehensive (loss) income	$	214,780		$	279,334		$	(1,485	)	$	(277,849	)	$	214,780

(a)Elimination of intercompany revenues and expenses.

(b)Elimination of equity in earnings of subsidiaries.

	Rite Aid Corporation Condensed Consolidating Statement of Operations For the Thirteen Weeks Ended June 3, 2017 (unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Revenues	$	—		$	5,415,128		$	39,450		$	(18,055	)(a)	$	5,436,523
Costs and expenses:
Cost of revenues	—			4,255,202			37,902			(18,524		)(a)	4,274,580
Selling, general and administrative expenses	—			1,157,270			3,201			469		(a)	1,160,940
Lease termination and impairment expenses	—			4,038			—			—			4,038
Interest expense	46,447			4,515			38			—			51,000
Gain on sale of assets, net	—			(5,877		)	—			—			(5,877		)
Equity in earnings of subsidiaries, net of tax	(30,035		)	1,312			—			28,723		(b)	—
	16,412			5,416,460			41,141			10,668			5,484,681
Earnings from continuing operations before income taxes	(16,412		)	(1,332		)	(1,691		)	(28,723		)	(48,158		)
Income tax expense (benefit)	—			(11,742		)	(379		)	—			(12,121		)
Net income (loss) from continuing operations	(16,412		)	10,410			(1,312		)	(28,723		)	(36,037		)
Net income (loss) from discontinued operations	(58,937		)	19,625			—			—			(39,312		)
Net income (loss)	$	(75,349	)	$	30,035		$	(1,312	)	$	(28,723	)(b)	$	(75,349	)
Total other comprehensive income (loss)	514			514			—			(514		)	514
Comprehensive (loss) income	$	(74,835	)	$	30,549		$	(1,312	)	$	(29,237	)	$	(74,835	)

(a)Elimination of intercompany revenues and expenses.

(b)Elimination of equity in earnings of subsidiaries.

30

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

	Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Thirteen Weeks Ended June 2, 2018(unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Operating activities:
Net cash (used in) provided by operating activities	$	(48,608	)	$	29,692		$	2,602	$	—		$	(16,314	)
Investing activities:
Payments for property, plant and equipment	—			(47,971		)	—		—			(47,971		)
Intangible assets acquired	—			(13,655		)	—		—			(13,655		)
Intercompany activity	—			(813,705		)	—		813,705			—
Proceeds from dispositions of assets and investments	—			9,916			—		—			9,916
Proceeds from sale-leaseback transactions	—			2,587			—		—			2,587
Net cash (used in) provided by investing activities	—			(862,828		)	—		813,705			(49,123		)
Financing activities:
Net proceeds from revolver	190,000			—			—		—			190,000
Principal payments on long-term debt	(426,361		)	(4,745		)	—		—			(431,106		)
Change in zero balance cash accounts	—			1,083			—		—			1,083
Net proceeds from issuance of common stock	910			—			—		—			910
Financing fees paid for early redemption	—			(13		)	—		—			(13		)
Intercompany activity	813,705			—			—		(813,705		)	—
Net cash provided by (used in) financing activities	578,254			(3,675		)	—		(813,705		)	(239,126		)
Cash flows of discontinued operations:
Operating activities of discontinued operations	(4,615		)	(69,435		)	—		—			(74,050		)
Investing activities of discontinued operations	—			603,402			—		—			603,402
Financing activities of discontinued operations	(525,031		)	—			—		—			(525,031		)
Net cash (used in) provided by discontinued operations	(529,646		)	533,967			—		—			4,321
(Decrease) increase in cash and cash equivalents	—			(302,844		)	2,602		—			(300,242		)
Cash and cash equivalents, beginning of period	—			441,244			6,090		—			447,334
Cash and cash equivalents, end of period	$	—		$	138,400		$	8,692	$	—		$	147,092

	Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Thirteen Weeks Ended June 3, 2017(unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Operating activities:
Net cash (used in) provided by operating activities	$	(13,020	)	$	60,294		$	495	$	—		$	47,769
Investing activities:
Payments for property, plant and equipment	—			(38,325		)	—		—			(38,325		)
Intangible assets acquired	—			(5,521		)	—		—			(5,521		)
Intercompany activity	—			(161,810		)	—		161,810			—
Proceeds from insured loss	—			8,639			—		—			8,639
Proceeds from dispositions of assets and investments	—			2,137			—		—			2,137
Net cash (used in) provided by investing activities	—			(194,880		)	—		161,810			(33,070		)
Financing activities:
Net payments to revolver	(90,000		)	—			—		—			(90,000		)
Principal payments on long-term debt	—			(3,503		)	—		—			(3,503		)
Change in zero balance cash accounts	—			28,768			—		—			28,768
Net proceeds from issuance of common stock	147			—			—		—			147
Payments for taxes related to net share settlement of equity awards	—			(147		)	—		—			(147		)
Intercompany activity	161,810			—			—		(161,810		)	—
Net cash provided by (used in) financing activities	71,957			25,118			—		(161,810		)	(64,735		)
Cash flows of discontinued operations:
Operating activities of discontinued operations	(58,937		)	103,902			—		—			44,965
Investing activities of discontinued operations	—			(25,126		)	—		—			(25,126		)
Financing activities of discontinued operations	—			(764		)	—		—			(764		)
Net cash (used in) provided by discontinued operations	(58,937		)	78,012			—		—			19,075
(Decrease) increase in cash and cash equivalents	—			(31,456		)	495		—			(30,961		)
Cash and cash equivalents, beginning of period	—			213,104			32,306		—			245,410
Cash and cash equivalents, end of period	$	—		$	181,648		$	32,801	$	—		$	214,449

31

RITE AID CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Thirteen Week Periods Ended June 2, 2018 and June 3, 2017

(Dollars and share information in thousands, except per share amounts)

(unaudited)

15. Tax Benefits Preservation Plan

On March 25, 2018, the Board of Directors of the Company approved, and on March 27, 2018, the Company and Broadridge Corporate Issuer Solutions, as rights agent, entered into an amendment to the Tax Benefits Preservation Plan that the Company entered into on January 3, 2018 (the “Amendment”). The Amendment changed the final expiration date with respect to the Rights issued under the Plan to 5:00 P.M. (New York City time) on March 27, 2018. In accordance with the terms of the Plan, as amended by the Amendment, all of the Rights then outstanding expired at 5:00 P.M. (New York City time) on March 27, 2018, and no Rights are to be issued from and after that time.

16. Supplementary Cash Flow Data

	Thirteen Weeks Ended
	June 2, 2018		June 3, 2017
Cash paid for interest(a)	$	53,553	$	75,535
Cash payments for income taxes, net(a)	$	591	$	1,461
Equipment financed under capital leases	$	1,963	$	3,857
Equipment received for noncash consideration	—		$	1,295
Reduction in lease financing obligation	—		$	2,416
Gross borrowings from revolver(a)	$	444,000	$	579,000
Gross repayments to revolver(a)	$	254,000	$	669,000

(a)—Amounts are presented on a total company basis.

ITEM 2.  Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations

Overview

We are a pharmacy retail healthcare company, providing our customers and communities with a high level of care and service through various programs we offer through our two reportable business segments, our Retail Pharmacy segment and our Pharmacy Services segment. We accomplish our goal of delivering comprehensive care to our customers through our retail drugstores, RediClinic walk-in retail health clinics and our transparent and traditional PBMs, EnvisionRxOptions and MedTrak. We also offer fully integrated mail-order and specialty pharmacy services through EnvisionPharmacies. Additionally through EIC, EnvisionRxOptions also serves one of the fastest-growing demographics in healthcare: seniors enrolled in Medicare Part D. When combined with our retail platform, this comprehensive suite of services allows us to provide value and choice to customers, patients and payors.

32

Retail Pharmacy Segment

Our Retail Pharmacy segment sells brand and generic prescription drugs, as well as an assortment of front-end products including health and beauty aids, personal care products, seasonal merchandise, and a large private brand product line. Our Retail Pharmacy segment generates the majority of its revenue through the sale of prescription drugs and front-end products at our 2,533 retail stores. We replenish our retail stores through a combination of direct store delivery of pharmaceutical products facilitated through our pharmacy Purchasing and Delivery Agreement with McKesson Corporation, and the majority of our front end products through our network of distribution centers. In addition, the Retail Pharmacy segment includes 74 RediClinic walk-in retail clinics, of which 38 are located within Rite Aid retail stores in the Philadelphia, Seattle and New Jersey markets.

Pharmacy Services Segment

Our Pharmacy Services segment provides a full range of pharmacy benefit services. The Pharmacy Services segment provides both transparent and traditional PBM options through its EnvisionRxOptions and MedTrak PBMs, respectively. EnvisionRxOptions also offers fully integrated mail-order and specialty pharmacy services through EnvisionPharmacies; access to the nation’s largest cash pay infertility discount drug program via Design Rx; an innovative claims adjudication software platform in Laker Software; and a national Medicare Part D prescription drug plan through EIC’s EnvisionRx Plus product offering. The segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans, Medicare plans, other sponsors of health benefit plans and individuals throughout the United States.

Merger Agreement with Albertsons Companies, Inc.

Agreement and Plan of Merger

On February 18, 2018, we entered into the Merger Agreement with Albertsons and the Merger Subs. Pursuant to the terms and subject to the conditions set forth in the Merger Agreement, (i) Merger Sub will merge with and into Rite Aid in the Merger, with Rite Aid surviving the Merger as the Surviving Corporation, a wholly-owned direct subsidiary of Merger Sub II, and (ii) immediately following the Merger, the Surviving Corporation will merge with and into Merger Sub II in the Subsequent Merger, with Merger Sub II surviving the Subsequent Merger as the Surviving Company, a wholly-owned direct subsidiary of Albertsons.

At the Effective Time, each share of our common stock issued and outstanding immediately prior to the Effective Time (other than shares of our common stock owned by Albertsons, Merger Sub or Rite Aid (including treasury stock held by Rite Aid), which will be cancelled) will be converted into the right to receive and become exchangeable for 0.1000 (the “Base Exchange Ratio”) of a fully paid and nonassessable share of Albertsons Common Stock (the “Base Consideration”), without interest, plus, at the election of the holder of our common stock, either (i) an amount in cash equal to $0.1832 per share (the “Additional Cash Consideration” and, together with the Base Consideration, the “Cash Election Consideration”), without interest, or (ii) 0.0079 (the “Additional Stock Election Exchange Ratio” and, together with the Base Exchange Ratio, the “Stock Election Exchange Ratio”) of a fully paid and nonassessable share of Albertsons Common Stock (the “Additional Stock Consideration” and, together with the Base Consideration, the “Stock Election Consideration”).

33

Consummation of the Merger is subject to various closing conditions, including but not limited to (i) approval of the Merger Agreement by holders of a majority of the outstanding shares of our common stock entitled to vote on the Merger, (ii) the expiration or earlier termination of the waiting period under the HSR Act (which condition was satisfied on March 28, 2018), (iii) the absence of any law or order prohibiting the Merger, (iv) the absence of a material adverse effect on Rite Aid and Albertsons, in each case, as defined in the Merger Agreement, (v) approval for listing, on the NYSE, of the shares of Albertsons Common Stock to be issued in the Merger and to be reserved for issuance in connection with the Merger (which approval was obtained on June 21, 2018), (vi) Albertsons’s registration statement on Form S-4 shall have become effective under the Securities Act (which Form S-4 was declared effective on June 25, 2018), and shall not be the subject of any stop order or proceedings seeking a stop order, (vii) approval of the Ohio Department of Insurance for the change of control of EIC, and (viii) Albertsons shall have delivered the Company a Lock-Up Agreement, No Action Agreement and Standstill Agreement, in each case, in the form agreed to by the parties to the Merger Agreement.  The special meeting of Rite Aid’s stockholders to, among other things, consider and vote on a proposal to approve the Merger Agreement has been scheduled on August 9, 2018.

34

On February 18, 2018, in connection with the Merger Agreement, Rite Aid entered into the Standstill Agreement with Albertsons and Cerberus, pursuant to which Cerberus has agreed not to: (i)purchase shares of Albertsons Common Stock or other securities issued by Albertsons, except Cerberus may acquire beneficial ownership of Albertsons Common Stock provided that such beneficial ownership does not result in ownership of 30% or more of the issued and outstanding shares of Albertsons Common Stock in the aggregate following such transaction, (ii) make any public statement or public disclosure regarding any intent, purpose, plan or proposal by Cerberus or any of its controlled affiliates to the composition of the Albertsons board of directors, any merger, consolidation or acquisition of Albertsons or its subsidiaries, (iii) engage in any solicitation of proxies or otherwise solicit the stockholders of Albertsons or (iv) enter into any agreements to make any investment with any person that engages or offers or proposes to engage in any of (i) through (iii) during the standstill period. The standstill period commences at the Effective Time and terminates upon the earliest to occur of (a) thirty days following the date that Cerberus does not have any of its designees on the Albertsons board of directors, (b) the date on which Cerberus no longer has the right to appoint (and has not appointed) at least one director to the Albertsons board of directors pursuant to the Merger Agreement and (c) the date on which Albertsons materially breaches or takes any action challenging the validity or enforceability of the provisions of the Merger Agreement that grant Cerberus certain rights to appoint directors to the Albertsons board of directors. In addition, pursuant to the Standstill Agreement, from February 18, 2018 until the Effective Time, Cerberus has agreed not to acquire or agree to acquire beneficial ownership of any shares of Albertsons Common Stock, Rite Aid common stock or other securities or debt issued by Albertsons or Rite Aid that would result in beneficial ownership of 30% or more of the issued and outstanding shares of Albertsons Common Stock at the Effective Time (assuming for the purposes of such calculation that the Effective Time occurred immediately after such acquisition).

Asset Sale to WBA

On September 18, 2017, we entered into the Amended and Restated Asset Purchase Agreement with WBA and Buyer, which amended and restated in its entirety the previously disclosed Original APA, dated as of June 28, 2017, by and among Rite Aid, WBA and Buyer. Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement, Buyer agreed to purchase from Rite Aid 1,932 Acquired Stores, three distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of approximately $4.375 billion, on a cash-free, debt-free basis, in the Sale.

We announced on September 19, 2017 that the waiting period under the HSR Act expired with respect to the Sale. As of March 27, 2018, we have completed the store transfer process, and all 1,932 stores and related assets have been transferred to WBA and we have received cash proceeds of $4.157 billion.  The transfer of the three distribution centers and related assets is expected to begin after September 1, 2018.  The transfer of the three distribution centers and related assets remains subject to minimal customary closing conditions applicable only to the distribution centers being transferred at such distribution center closings, as specified in the Amended and Restated Asset Purchase Agreement.  We recorded a pre-tax gain on the Sale of the stores of $2,489,389.

The parties to the Amended and Restated Asset Purchase Agreement have each made customary representations and warranties. We have agreed to various covenants and agreements, including, among others, our agreement to conduct its business at the distribution centers being sold to WBA in the ordinary course during the period between the execution of the Amended and Restated Asset Purchase Agreement and the distribution center closing. We have also agreed to provide transition services to Buyer for up to three (3) years after the initial closing of the Sale. Under the terms of the TSA, we provide various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general and administrative activities. In connection with these services, we purchase the related inventory and incurs cash payments for the selling, general and administrative activities, which, we bill on a cash neutral basis to WBA in accordance with terms as outlined in the TSA. Total billings for these items during the thirteen week period ended June 2, 2018 were $2,041.1 million, of which $447.3 million is included in Accounts receivable, net. We charged WBA TSA fees of $23.7 million during the thirteen week period ended June 2, 2018 which are reflected as a reduction to selling, general and administrative expenses. Albertsons is obligated to assume our remaining obligations under the TSA.

Under the terms of the Amended and Restated Asset Purchase Agreement, we have the option to purchase pharmaceutical drugs through an affiliate of WBA under terms, including cost, that are substantially equivalent to Walgreen’s for a period of ten (10) years, subject to certain terms and conditions.

35

Based on its magnitude and because we are exiting certain markets, the Sale represents a significant strategic shift that has a material effect on our operations and financial results. Accordingly, we have applied discontinued operations treatment for the Sale as required by GAAP.

Overview of Financial Results from Continuing Operations

Our net loss from continuing operations for the thirteen week period ended June 2, 2018 was $41.7 million or $0.04 per basic and diluted share compared to a net loss of $36.0 million or $0.03 per basic and diluted share for the thirteen week period ended June 3, 2017. The decline in our operating results for the thirteen week period ended June 2, 2018 was due to higher interest expense, higher lease termination and impairment charges and higher transaction costs, partially offset by an increase in in our Adjusted EBITDA.

Our Adjusted EBITDA from continuing operations for the thirteen week period ended June 2, 2018 was $147.3 million or 2.7 percent of revenues compared to $136.0 million or 2.5 percent of revenues for the thirteen week period ended June 3, 2017.  The increase in Adjusted EBITDA for the thirteen week period ended June 2, 2018 was due primarily to an increase of $26.1 million in the Retail Pharmacy segment. The increase in the Retail Pharmacy segment Adjusted EBITDA was due primarily to the receipt of TSA fees to support the stores sold to WBA of $23.7 million, improved pharmacy gross margin and good expense management.  The increase in the Retail Pharmacy segment Adjusted EBITDA was partially offset by a decline of $14.7 million in the Pharmacy Services segment.  The decline in the Pharmacy Services segment Adjusted EBITDA was driven by margin compression in its commercial business and other operating investments to support current year and future growth.  Please see the sections entitled “Segment Analysis” and “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” below for additional details.

Consolidated Results of Operations-Continuing Operations

Revenues and Other Operating Data

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
	(Dollars in thousands except per share amounts)
Revenues(a)	$	5,388,490		$	5,436,523
Revenue (decline) growth	(0.9		)%	(5.0		)%
Net loss	$	(41,727	)	$	(36,037	)
Net loss per diluted share	$	(0.04	)	$	(0.03	)
Adjusted EBITDA(b)	$	147,332		$	135,964
Adjusted Net Loss(b)	$	(11,494	)	$	(9,228	)
Adjusted Net Loss per Diluted Share(b)	$	(0.01	)	$	(0.01	)

(a)Revenues for the thirteen week periods ended June 2, 2018 and June 3, 2017 exclude $52,037 and $49,069, respectively, of inter-segment activity that is eliminated in consolidation.

(b)See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

36

Revenues

Revenues decreased 0.9% for the thirteen weeks ended June 2, 2018, compared to a decrease of 5.0% for the thirteen weeks ended June 3, 2017. Revenues for the thirteen week period ended June 2, 2018 were negatively impacted by a $74.6 million decrease in Retail Pharmacy segment revenues, partially offset by a $29.5 million increase in Pharmacy Services segment revenues.  Same store sales trends for the thirteen week periods ended June 2, 2018 and June 3, 2017 are described in the “Segment Analysis” section below.

Please see the section entitled “Segment Analysis” below for additional details regarding revenues.

Costs and Expenses

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
	(Dollars in thousands)
Cost of revenues(a)	$	4,219,741		$	4,274,580
Gross profit	1,168,749			1,161,943
Gross margin	21.7		%	21.4		%
Selling, general and administrative expenses	$	1,152,627		$	1,160,940
Selling, general and administrative expenses as a percentage of revenues	21.4		%	21.4		%
Lease termination and impairment charges	9,859			4,038
Interest expense	62,792			51,000
Loss on debt retirements, net	554			—
Gain on sale of assets, net	(5,859		)	(5,877		)

(a)Cost of revenues for the thirteen week periods ended June 2, 2018 and June 3, 2017 exclude $52,037 and $49,069, respectively, of inter-segment activity that is eliminated in consolidation.

Gross Profit and Cost of Revenues

Gross profit increased by $6.8 million for the thirteen week period ended June 2, 2018 compared to the thirteen week period ended June 3, 2017. Gross profit for the thirteen week period ended June 2, 2018 includes an increase of $12.5 million in our Retail Pharmacy segment, partially offset by decreased gross profit of $5.7 million in our Pharmacy Services segment. Gross margin was 21.7% for the thirteen week period ended June 2, 2018 compared to 21.4% for the thirteen week period ended June 3, 2017 due primarily to improved pharmacy gross margin in the Retail Pharmacy segment.  Please see the section entitled “Segment Analysis” for a more detailed description of gross profit and gross margin results by segment.

Selling, General and Administrative Expenses

SG&A decreased by $8.3 million for the thirteen week period ended June 2, 2018 compared to the thirteen week period ended June 3, 2017. The decrease in SG&A includes a decrease of $17.7 million relating to our Retail Pharmacy segment, partially offset by an increase of $9.3 million relating to our Pharmacy Services segment. Please see the section entitled “Segment Analysis” below for additional details regarding SG&A.

Lease Termination and Impairment Charges

Lease termination and impairment charges consist of amounts as follows:

	Thirteen Week Period Ended
	June 2, 2018		June 3, 2017
Impairment charges	$	283	$	659
Lease termination charges	9,576		3,379
	$	9,859	$	4,038

Please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Lease Termination and Impairment Charges” included in our Fiscal 2018 10-K for a detailed description of our impairment and lease termination methodology.

37

Interest Expense

Interest expense was $62.8 million for the thirteen week period ended June 2, 2018 compared to $51.0 million for the thirteen week period ended June 3, 2017. Interest expense was higher due to timing between the receipt of proceeds from the WBA asset sale and redemption of our higher priced notes which was caused by our required excess proceeds bond purchase offers. The weighted average interest rate on our indebtedness for the thirteen week periods ended June 2, 2018 and June 3, 2017 was 6.7% and 5.4%, respectively.

Income Taxes

We recorded an income tax benefit from continuing operations of $9.5 million and $12.1 million for the thirteen week periods ended June 2, 2018 and June 3, 2017, respectively. The effective tax rate for the thirteen week periods ended June 2, 2018 and June 3, 2017 was 18.5% and 25.2%, respectively.  The effective tax rate for the thirteen week period ended June 2, 2018 includes an adjustment of (2.3)% to increase the valuation allowance related to  certain state deferred  taxes.  The tax benefit for the thirteen week period ended June 3, 2017 is higher in comparison to 2018, as it is based on a federal statutory rate of 35%, offset by increases to the valuation allowance primarily related to state deferred taxes.

We recognize tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.

We believe that it is reasonably possible that a decrease of up to $13.5 million in unrecognized tax benefits related to state exposures may be necessary in the next twelve months however management does not expect the change to have a significant impact on the results of operations or the financial position of the Company.

We regularly evaluate valuation allowances established for deferred tax assets for which future realization is uncertain.  We will continue to monitor all available evidence related to the net deferred tax assets that may change the most recent assessment, including events that have occurred or are anticipated to occur. We continue to maintain a valuation allowance against net deferred tax assets of $903.3 million and $896.8 million, which relates primarily to state deferred tax assets at June 2, 2018 and March 3, 2018, respectively.

Segment Analysis

We evaluate the Retail Pharmacy and Pharmacy Services segments’ performance based on revenue, gross profit, and Adjusted EBITDA.  The following is a reconciliation of our segments to the condensed consolidated financial statements:

	Retail Pharmacy		Pharmacy Services		Intersegment Eliminations(1)			Consolidated
Thirteen Week Period Ended
June 2, 2018:
Revenues	$	3,897,765	$	1,542,762	$	(52,037	)	$	5,388,490
Gross Profit	1,069,457		99,292		—			1,168,749
Adjusted EBITDA(*)	113,469		33,863		—			147,332
June 3, 2017:
Revenues	$	3,972,351	$	1,513,241	$	(49,069	)	$	5,436,523
Gross Profit	1,056,971		104,972		—			1,161,943
Adjusted EBITDA(*)	87,365		48,599		—			135,964

(1)Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis.

38

(*)See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Retail Pharmacy Segment Results of Operations

Revenues and Other Operating Data

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
	(dollars in thousands)
Revenues	$	3,897,765		$	3,972,351
Revenue decline	(1.9		)%	(5.1		)%
Same store sales decline	(0.7		)%	(4.0		)%
Pharmacy sales decline	(1.3		)%	(6.0		)%
Same store prescription count decline, adjusted to 30-day equivalents	(1.5		)%	(1.2		)%
Same store pharmacy sales decline	(0.1		)%	(5.4		)%
Pharmacy sales as a % of total retail sales	66.4		%	66.0		%
Front-end sales decline	(2.9		)%	(1.6		)%
Same store front-end sales decline	(1.8		)%	(1.1		)%
Front-end sales as a % of total retail sales	33.6		%	34.0		%
Adjusted EBITDA(*)	$	113,469		$	87,365
Store data:
Total stores (beginning of period)	2,550			2,605
New stores	—			—
Store acquisitions	—			—
Closed stores	(17		)	(14		)
Total stores (end of period)	2,533			2,591
Relocated stores	—			3
Remodeled and expanded stores	49			26

(*)See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Revenues

Revenues decreased 1.9% for the thirteen weeks ended June 2, 2018 compared to a decrease of 5.1% for the thirteen weeks ended June 3, 2017. The decrease in revenues for the thirteen week period ended June 2, 2018 was primarily a result of store closings and a decrease in same store sales.

Pharmacy same store sales decreased by 0.1% for the thirteen week period ended June 2, 2018 compared to a decrease of 5.4% in the thirteen week period ended June 3, 2017. The decrease in the current period is due to the 1.5% decrease in same store prescription count due to our exclusion from certain Pharmacy networks that we participated in during the prior year partially offset by an increase in sales per script due to an increase in the number of 90 day prescriptions as a percent of total prescriptions.

Front-end same store sales decreased 1.8% during the thirteen week period ended June 2, 2018 compared to a decrease of 1.1% during the thirteen week period ended June 3, 2017. The decrease in front end same store sales is due to a shorter Easter selling season, weaker sales of summer categories, and a slow start to the allergy season.

We include in same store sales all stores that have been open at least one year. Relocation stores are not included in same store sales until one year has lapsed.

39

Costs and Expenses

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
	(dollars in thousands)
Cost of revenues	$	2,828,308		$	2,915,380
Gross profit	1,069,457			1,056,971
Gross margin	27.4		%	26.6		%
FIFO gross profit(*)	1,079,423			1,067,144
FIFO gross margin(*)	27.7		%	26.9		%
Selling, general and administrative expenses	1,064,387			1,082,041
Selling, general and administrative expenses as a percentage of revenues	27.3		%	27.2		%

(*)See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Gross Profit and Cost of Revenues

Gross profit increased $12.5 million for the thirteen week period ended June 2, 2018 compared to the thirteen week period ended June 3, 2017. Gross profit was positively impacted by improvements in generic drug costs that more than offset reimbursement rate declines, partially offset by a decrease in prescription count.

Gross margin was 27.4% of sales for the thirteen week period ended June 2, 2018 compared to 26.6% of sales for the thirteen week period ended June 3, 2017. The improvement in gross margin for the thirteen week period was due primarily to improvements in generic drug costs that more than offset reimbursement rate declines.

We use the last-in, first-out (“LIFO”) method of inventory valuation, which is estimated on a quarterly basis and is finalized at year end when inflation rates and inventory levels are final. Therefore, LIFO costs for interim period financial statements are estimated. LIFO charges were $10.0 million for the thirteen week period ended June 2, 2018 compared to a $10.2 million charge for the thirteen week period ended June 3, 2017.

Selling, General and Administrative Expenses

SG&A expenses decreased $17.7 million for the thirteen week period ended June 2, 2018 due primarily to WBA TSA fees of $23.7 million this year, partially offset by an increase in store operating costs.

SG&A as a percentage of revenues was 27.3% in the thirteen week period ended June 2, 2018 compared to 27.2% in the thirteen week period ended June 3, 2017. The increase in SG&A as a percentage of revenues was due primarily to declining Retail Pharmacy segment sales leverage.

Pharmacy Services Segment Results of Operations

EnvisionRx, our Pharmacy Services segment, is a full-service pharmacy benefit provider. EnvisionRx provides both transparent and traditional PBM options through its EnvisionRx and MedTrak PBMs. EnvisionRx also offers fully integrated mail-order and specialty pharmacy services through EnvisionPharmacies; access to the nation’s largest cash pay infertility discount drug program via Design Rx; an innovative claims adjudication software platform in Laker Software; and a national Medicare Part D prescription drug plan. EnvisionRx operates as our 100 percent owned subsidiary. EnvisionRx enables us to expand our retail healthcare platform and enhance our health and wellness offerings by combining EnvisionRx’s broad suite of PBM and pharmacy-related businesses with our established retail platform to provide our customers and patients with an integrated offering across retail, specialty and mail-order channels.

40

Revenues and Other Operating Data

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
	(dollars in thousands)
Revenues	$	1,542,762		$	1,513,241
Revenue (decline) growth	2.0		%	(5.6		)%
Adjusted EBITDA(*)	$	33,863		$	48,599

(*)See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Revenues

Pharmacy Services segment revenues for the thirteen week period ended June 2, 2018 were $1,542.8 million as compared to revenues of $1,513.2 million for the thirteen week period ended June 3, 2017. The increase in revenues for the segment is primarily due to an increase in covered lives in our Medicare Part D Membership.

Costs and Expenses

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
	(dollars in thousands)
Cost of revenues	$	1,443,470		$	1,408,269
Gross profit	99,292			104,972
Gross margin	6.4		%	6.9		%
Selling, general and administrative expenses	88,240			78,899
Selling, general and administrative expenses as a percentage of revenues	5.7		%	5.2		%

(*)See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” for additional details.

Gross Profit and Cost of Revenues

Gross profit for the thirteen week period ended June 2, 2018 was $99.3 million as compared to gross profit of $105.0 million for the thirteen week period ended June 3, 2017. The decrease in gross profit for the segment is primarily due to margin compression in our commercial business and other operating investments we made to invest in current year and future growth.

Gross margin was 6.4% of sales for the thirteen week period ended June 2, 2018 compared to 6.9% of sales for the thirteen week period ended June 3, 2017. The decrease in gross margin for the segment is due primarily to margin compression in our commercial business and other operating investments we made to invest in current year and future growth.

Selling, General and Administrative Expenses

Pharmacy Services segment selling, general and administrative expenses for the thirteen week period ended June 2, 2018 was $88.2 million as compared to $78.9 million for the thirteen week period ended June 3, 2017. The increase in selling, general and administrative expenses is primarily the result of strategic investments in infrastructure to support current year and future growth. Selling, general and administrative expenses as a percentage of Pharmacy Services segment revenue was 5.7% and 5.2% for the thirteen week periods ended June 2, 2018 and June 3, 2017, respectively.

41

Liquidity and Capital Resources

General

We have two primary sources of liquidity: (i) cash provided by operating activities and (ii) borrowings under our Amended and Restated Senior Secured Credit Facility. Our principal uses of cash are to provide working capital for operations, to service our obligations to pay interest and principal on debt and to fund capital expenditures. Total liquidity as of June 2, 2018 was $2,502.6 million, which consisted of revolver borrowing capacity of $2,454.2 million and invested cash of $48.4 million.

Credit Facilities

Our Amended and Restated Senior Secured Credit Facility has a borrowing capacity of $2.7 billion and matures in January 2020. Borrowings under the revolver bear interest at a rate per annum between (i) LIBOR plus 1.50% and LIBOR plus 2.00% with respect to Eurodollar borrowings and (ii) the alternate base rate plus 0.50% and the alternate base rate plus 1.00% with respect to ABR borrowings, in each case, based upon the average revolver availability (as defined in the Amended and Restated Senior Secured Credit Facility). We are required to pay fees between 0.250% and 0.375% per annum on the daily unused amount of the revolver, depending on the Average Revolver Availability (as defined in the Amended and Restated Senior Secured Credit Facility). Amounts drawn under the revolver become due and payable on January 13, 2020.

Our ability to borrow under the revolver is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At June 2, 2018, we had $190.0 million of borrowings outstanding under the revolver and had letters of credit outstanding against the revolver of $55.8 million, which resulted in additional borrowing capacity of $2,454.2 million. If at any time the total credit exposure outstanding under our Amended and Restated Senior Secured Credit Facility and the principal amount of our other senior obligations exceeds the borrowing base, we will be required to make certain other mandatory prepayments to eliminate such shortfall.

The Amended and Restated Senior Secured Credit Facility restricts us and all of our subsidiaries that guarantee our obligations under the Amended and Restated Senior Secured Credit Facility and unsecured guaranteed notes (the “Subsidiary Guarantors”) from accumulating cash on hand in excess of $200.0 million at any time when revolving loans are outstanding (not including cash located in our store and lockbox deposit accounts and cash necessary to cover our current liabilities) and from accumulating cash on hand with revolver borrowings in excess of $100.0 million over three consecutive business days. The Amended and Restated Senior Secured Credit Facility also states that if at any time (other than following the exercise of remedies or acceleration of any senior obligations or second priority debt and receipt of a triggering notice by the senior collateral agent from a representative of the senior obligations or the second priority debt) either (a) an event of default exists under our Amended and Restated Senior Secured Credit Facility or (b) the sum of revolver availability under our Amended and Restated Senior Secured Credit Facility and certain amounts held on deposit with the senior collateral agent in a concentration account is less than $275.0 million for three consecutive business days or less than or equal to $200.0 million on any day (a “cash sweep period”), the funds in our deposit accounts will be swept to a concentration account with the senior collateral agent and will be applied first to repay outstanding revolving loans under the Amended and Restated Senior Secured Credit Facility, and then held as collateral for the senior obligations until such cash sweep period is rescinded pursuant to the terms of our Amended and Restated Senior Secured Credit Facility.

The Amended and Restated Senior Secured Credit Facility allows us to have outstanding, at any time, up to $1.5 billion in secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock in addition to borrowings under the Amended and Restated Senior Secured Credit Facility and existing indebtedness, provided that not in excess of $750.0 million of such secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock shall mature or require scheduled payments of principal prior to 90 days after the latest of (a) the fifth anniversary of the effectiveness of the Amended and Restated Senior Secured Credit Facility and (b) the latest maturity date of any Term Loan or Other Revolving Loan (each as defined in the Amended and Restated Senior Secured Credit Facility) (excluding bridge facilities allowing extensions on customary terms to at least the date that is 90 days after such date and, with respect to any escrow notes issued by Rite Aid, excluding any special mandatory redemption of the type described in clause (iii) of the definition of “Escrow Notes” in the Amended and Restated Senior Secured Credit Facility). Subject to the limitations described in clauses (a) and (b) of the immediately preceding sentence, the Amended and Restated Senior Secured Credit Facility additionally allows us to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the Amended and Restated Senior Secured Credit Facility) is not in effect; provided, however, that certain of our other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The Amended and Restated Senior Secured Credit Facility also contains certain restrictions on the amount of secured first priority debt we are able to incur. The Amended and Restated Senior Secured Credit Facility also allows for the voluntary repurchase of any debt or other convertible debt, so long as the Amended and Restated Senior Secured Credit Facility is not in default and we maintain availability under our revolver of more than $365.0 million.

42

The Amended and Restated Senior Secured Credit Facility has a financial covenant that requires us to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (a) on any date on which availability under the revolver is less than $200.0 million or (b) on the third consecutive business day on which availability under the revolver is less than $250.0 million and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the revolver is equal to or greater than $250.0 million. As of June 2, 2018, we had availability under our revolver of $2,454.2 million, our fixed charge coverage ratio was greater than 1.00 to 1.00, and we were in compliance with the senior secured credit facility’s financial covenant. The Amended and Restated Senior Secured Credit Facility also contains covenants which place restrictions on the incurrence of debt, the payments of dividends, sale of assets, mergers and acquisitions and the granting of liens.

The Amended and Restated Senior Secured Credit Facility provides for customary events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It is also an event of default if we fail to make any required payment on debt having a principal amount in excess of $50.0 million or any event occurs that enables, or which with the giving of notice or the lapse of time would enable, the holder of such debt to accelerate the maturity or require the repayment repurchase, redemption or defeasance of such debt.

The indentures that govern our guaranteed unsecured notes contain restrictions on the amount of additional secured and unsecured debt that can be incurred by us. As of June 2, 2018, the amount of additional secured debt that could be incurred under the most restrictive covenant of the second priority secured term loan facilities and these indentures was approximately $1.7 billion (which amount does not include the ability to enter into certain sale and leaseback transactions). Assuming a fully drawn revolver and the outstanding letters of credit, we could incur an additional $350.0 million in secured debt. The ability to issue additional unsecured debt under these indentures is generally governed by an interest coverage ratio test. As of June 2, 2018, we had the ability to issue additional unsecured debt under the second lien credit facilities and other indentures.

Net Cash Provided by/Used in Operating, Investing and Financing Activities

Cash used in operating activities was $16.3 million for the thirteen week period ended June 2, 2018 as compared to cash provided by operating activities of $47.8 million for the thirteen week period ended June 3, 2017. Operating cash flow was negatively impacted by the timing of working capital items, including a build in the current year CMS receivable in our Pharmacy Services segment, which was not funded by reinsurance as it was in the prior year.

Cash used in investing activities was $49.1 million and $33.1 million for the thirteen week periods ended June 2, 2018 and June 3, 2017, respectively. Cash used for the purchase of property, plant, and equipment was higher than in the prior year primarily due to more Wellness store remodels in the current year. During the first quarter, we remodeled 49 stores and spent $13.7 million on file buys.

Cash used in financing activities was $239.1 million and $64.7 million for the thirteen week periods ended June 2, 2018 and June 3, 2017, respectively. Cash used by financing activities for the thirteen weeks ended June 2, 2018 reflects payments on our long-term debt and scheduled payments on our capital leases, partially offset by revolver borrowings.

Capital Expenditures

During the thirteen week periods ended June 2, 2018 and June 3, 2017 capital expenditures were as follows:

	Thirteen Week Period Ended
	June 2, 2018		June 3, 2017
New store construction, store relocation and store remodel projects	$	24,889	$	17,805
Technology enhancements, improvements to distribution centers and other corporate requirements	23,082		20,520
Purchase of prescription files from other retail pharmacies	13,655		5,521
Total capital expenditures	$	61,626	$	43,846

Future Liquidity

We are highly leveraged. Our high level of indebtedness could: (i) limit our ability to obtain additional financing; (ii) limit our flexibility in planning for, or reacting to, changes in our business and the industry; (iii) place us at a competitive disadvantage relative to our competitors with less debt; (iv) render us more vulnerable to general adverse economic and industry conditions; and (v) require us to dedicate a substantial portion of our cash flow to service our debt. Based upon our current levels of operations, we

43

believe that cash flow from operations together with available borrowings under the revolver and other sources of liquidity will be adequate to meet our requirements for working capital, debt service and capital expenditures at least for the next twelve months. Based on our liquidity position, which we expect to remain strong throughout the year, we do not expect to be subject to the fixed charge covenant in our Amended and Restated Senior Secured Credit Facility in the next twelve months. We will continue to assess our liquidity position and potential sources of supplemental liquidity in light of our operating performance, and other relevant circumstances. From time to time, we may seek deleveraging transactions, including entering into transactions to exchange debt for shares of common stock, issuance of equity (including preferred stock and convertible securities), repurchase or redemption of outstanding indebtedness, or seek to refinance our outstanding debt (including our Amended and Restated Senior Secured Credit Facility) or may otherwise seek transactions to reduce interest expense and extend debt maturities. Any of these transactions could impact our financial results.

Critical Accounting Policies and Estimates

For a description of the critical accounting policies that require the use of significant judgments and estimates by management, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates” included in our Fiscal 2018 10-K.

Factors Affecting Our Future Prospects

For a discussion of risks related to our financial condition, operations and industry, refer to “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Fiscal 2018 10-K.

Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures

In addition to net income (loss) determined in accordance with GAAP, we use certain non-GAAP measures, such as “Adjusted EBITDA”, in assessing our operating performance. We believe the non-GAAP metrics serve as an appropriate measure in evaluating the performance of our business. We define Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments, charges or credits for facility closing and impairment, inventory write-downs related to store closings, debt retirements, and other items (including stock-based compensation expense, severance for distribution center closures, gain or loss on sale of assets, and revenue deferrals related to our customer loyalty program). We reference this particular non-GAAP financial measure frequently in our decision-making because it provides supplemental information that facilitates internal comparisons to the historical periods and external comparisons to competitors. In addition, incentive compensation is primarily based on Adjusted EBITDA and we base certain of our forward-looking estimates on Adjusted EBITDA to facilitate quantification of planned business activities and enhance subsequent follow-up with comparisons of actual to planned Adjusted EBITDA.

The following is a reconciliation of our net loss to Adjusted EBITDA for the thirteen week periods ended June 2, 2018 and June 3, 2017:

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
	(dollars in thousands)
Net loss	$	(41,727	)	$	(36,037	)
Interest expense	62,792			51,000
Income tax benefit	(9,497		)	(12,121		)
Depreciation and amortization expense	94,529			101,029
LIFO charge	9,966			10,173
Lease termination and impairment charges	9,859			4,038
Loss on debt retirements, net	554			—
Other	20,856			17,882
Adjusted EBITDA	$	147,332		$	135,964

The following is a reconciliation of our net loss to Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share for the thirteen week periods ended June 2, 2018 and June 3, 2017. Adjusted Net Income (Loss) is defined as net income (loss) excluding the impact of amortization of EnvisionRx intangible assets, merger and acquisition-related costs, loss on debt retirements and LIFO adjustments. We calculate Adjusted Net Income (Loss) per Diluted Share using our above-referenced definition of Adjusted Net Income (Loss). We believe Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share serve as appropriate

44

measures to be used in evaluating the performance of our business and help our investors better compare our operating performance over multiple periods. Adjusted Net Income (Loss) per Diluted Share is calculated using our above-referenced definition of Adjusted Net Income (Loss):

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
	(dollars in thousands)
Net loss	$	(41,727	)	$	(36,037	)
Add back—Income tax benefit	(9,497		)	(12,121		)
Loss before income taxes	(51,224		)	(48,158		)
Adjustments:
Amortization of EnvisionRx intangible assets	19,139			20,716
LIFO charge	9,966			10,173
Merger and Acquisition-related costs	7,188			1,216
Adjusted loss before income taxes	(14,931		)	(16,053		)
Adjusted income tax benefit (a)	(3,437		)	(6,825		)
Adjusted net loss	$	(11,494	)	$	(9,228	)
Net loss per diluted share	$	(0.04	)	$	(0.03	)
Adjusted net loss per diluted share	$	(0.01	)	$	(0.01	)

(a)The fiscal year 2019 and 2018 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOL’s, state credits and valuation allowance, was used for the thirteen weeks ended June 2, 2018 and June 3, 2017, respectively.

In addition to Adjusted EBITDA, Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share, we occasionally refer to several other Non-GAAP measures, on a less frequent basis, in order to describe certain components of our business and how we utilize them to describe our results. These measures include but are not limited to Adjusted EBITDA Gross Margin and Gross Profit (gross margin/gross profit excluding non-Adjusted EBITDA items), Adjusted EBITDA SG&A (SG&A expenses excluding non-Adjusted EBITDA items), FIFO Gross Margin and FIFO Gross Profit (gross margin/gross profit before LIFO charges), and Free Cash Flow (Adjusted EBITDA less cash paid for interest, rent on closed stores, capital expenditures, acquisition costs and the change in working capital).

We include these non-GAAP financial measures in our earnings announcements in order to provide transparency to our investors and enable investors to better compare our operating performance with the operating performance of our competitors including with those of our competitors having different capital structures. Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share or other non-GAAP measures should not be considered in isolation from, and are not intended to represent an alternative measure of, operating results or of cash flows from operating activities, as determined in accordance with GAAP. Our definition of these non-GAAP measures may not be comparable to similarly titled measurements reported by other companies.

ITEM 3.  Quantitative and Qualitative Disclosures About Market Risk

Our future earnings, cash flow and fair values relevant to financial instruments are dependent upon prevalent market rates. Market risk is the risk of loss from adverse changes in market prices and interest rates. Our major market risk exposure is changing interest rates. Increases in interest rates would increase our interest expense. We enter into debt obligations to support capital expenditures, acquisitions, working capital needs and general corporate purposes. Our policy is to manage interest rates through the use of a combination of variable-rate credit facilities, fixed-rate long-term obligations and derivative transactions. We currently do not have any derivative transactions outstanding.

The table below provides information about our financial instruments that are sensitive to changes in interest rates. The table presents principal payments and the related weighted average interest rates by expected maturity dates as of June 2, 2018.

45

Fiscal Year	2019			2020			2021			2022			2023			Thereafter			Total			Fair Value at 06/02/2018
	(dollars in thousands)
Long-term debt, including current portion, excluding capital lease obligations
Fixed Rate	$	90		$	—		$	—		$	805,169		$	—		$	2,176,490		$	2,981,749		$	2,972,700
Average Interest Rate	7.61		%	0.00		%	0.00		%	6.75		%	0.00		%	6.38		%	6.48		%
Variable Rate	$	—		$	190,000		$	—		$	—		$	—		$	—		$	190,000		$	190,000
Average Interest Rate	0.00		%	3.34		%	0.00		%	0.00		%	0.00		%	0.00		%	3.34		%

Our ability to satisfy interest payment obligations on our outstanding debt will depend largely on our future performance, which, in turn, is subject to prevailing economic conditions and to financial, business and other factors beyond our control. If we do not have sufficient cash flow to service our interest payment obligations on our outstanding indebtedness and if we cannot borrow or obtain equity financing to satisfy those obligations, our business and results of operations could be materially adversely affected. We cannot be assured that any replacement borrowing or equity financing could be successfully completed.

The interest rate on our variable rate borrowings, which include our revolving credit facility, are based on LIBOR. If the market rates of interest for LIBOR changed by 100 basis points as of June 2, 2018, our annual interest expense would change by approximately $1.9 million.

A change in interest rates does not have an impact upon our future earnings and cash flow for fixed-rate debt instruments. As fixed-rate debt matures, however, and if additional debt is acquired to fund the debt repayment, future earnings and cash flow may be affected by changes in interest rates. This effect would be realized in the periods subsequent to the periods when the debt matures. Increases in interest rates would also impact our ability to refinance existing maturities on favorable terms.

ITEM 4.  Controls and Procedures

(a)  Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, our disclosure controls and procedures are effective.

(b)  Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.  Legal Proceedings

The information in response to this item is incorporated herein by reference to Note 13, Commitments, Contingencies and Guarantees, of the Consolidated Condensed Financial Statements of this Quarterly Report.

ITEM 1A.  Risk Factors

In addition to the information set forth in this Quarterly Report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” in our Fiscal 2018 10-K, which could materially affect our business, financial condition or future results.

ITEM 2.  Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Repurchases of Equity Securities.  The table below is a listing of repurchases of common stock during the first quarter of fiscal 2019.

46

Fiscal period:	Total Number of Shares Repurchased	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that may yet be Purchased under the Plans or Programs
March 4 to March 31, 2018	—	$	—	—	—
April 1 to April 28, 2018	—	$	—	—	—
April 29 to June 2, 2018	—	$	—	—	—

ITEM 3.  Defaults Upon Senior Securities

Not applicable.

ITEM 4.  Mine Safety Disclosures

Not applicable.

ITEM 5.  Other Information

Not applicable.

ITEM 6.  Exhibits

(a)The following exhibits are filed as part of this report.

ITEM 6.  Exhibits

(a)The following exhibits are filed as part of this report.

Exhibit Numbers	Description	Incorporation By Reference To
2.1	Amended and Restated Asset Purchase Agreement, dated September 18, 2017, among Rite Aid Corporation, Walgreens Boots Alliance, Inc. and Walgreen Co.	Exhibit 2.1 to Form 8-K, filed on September 19, 2017
2.2	Agreement and Plan of Merger, dated February 18, 2018, among Rite Aid Corporation, Albertsons Companies, Inc., Ranch Acquisition II LLC and Ranch Acquisition Corp.	Exhibit 2.1 to Form 8-K, filed on February 20, 2018
3.1	Amended and Restated Certificate of Incorporation, dated January 22, 2014	Exhibit 3.1 to Form 10-K, filed on April 23, 2014
3.2	Amended and Restated By-Laws	Exhibit 3.2 to Form 10-Q, filed on January 6, 2016
3.3	Certificate of Designations, Preferences and Rights of Series J Junior Participating Preferred Stock of Rite Aid Corporation	Exhibit 3.1 to Form 8-K, filed on January 3, 2018
4.1	Indenture, dated as of August 1, 1993, between Rite Aid Corporation, as issuer, and Morgan Guaranty Trust Company of New York, as trustee, related to the Company’s 7.70% Notes due 2027	Exhibit 4A to Registration Statement on Form S-3, File No. 033-63794, filed on June 3, 1993
4.2	Supplemental Indenture, dated as of February 3, 2000, between Rite Aid Corporation and U.S. Bank Trust National Association (as successor trustee to Morgan Guaranty Trust Company of New York) to the Indenture dated as of August 1, 1993, between Rite Aid Corporation and Morgan Guaranty Trust Company of New York, relating to the Company’s 7.70% Notes due 2027	Exhibit 4.1 to Form 8-K filed on February 7, 2000
4.3	Indenture, dated as of December 21, 1998, between Rite Aid Corporation, as issuer, and Harris Trust and Savings Bank, as trustee, related to the Company’s 6.875% Notes due 2028	Exhibit 4.1 to Registration Statement on Form S-4, File No. 333-74751, filed on March 19, 1999

47

4.4	Supplemental Indenture, dated as of February 3, 2000, between Rite Aid Corporation and Harris Trust and Savings Bank to the Indenture, dated December 21, 1998, between Rite Aid Corporation and Harris Trust and Savings Bank, related to the Company’s 6.875% Notes due 2028	Exhibit 4.4 to Form 8-K, filed on February 7, 2000
4.5	Registration Rights Agreement, dated as of February 10, 2015, by and among Rite Aid Corporation, TPG VI Envision, L.P., TPG VI DE BDH, L.P. and Envision Rx Options Holdings Inc.	Exhibit 10.3 to Form 8-K, filed on February 13, 2015
4.6	Indenture, dated as of April 2, 2015, among Rite Aid Corporation, as issuer, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company’s 6.125% Senior Notes due 2023	Exhibit 4.1 to Form 8-K, filed on April 2, 2015
4.7	Registration Rights Agreement, dated as of April 2, 2015, among Rite Aid Corporation, the subsidiary guarantors named therein and Citigroup Global Markets Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Wells Fargo Securities, LLC, Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co., as the initial purchasers of the Company’s 6.125% Senior Notes due 2023	Exhibit 10.1 to Form 8-K, filed on April 2, 2015
4.8	Tax Benefits Preservation Plan, dated as of January 3, 2018, between Rite Aid Corporation and Broadridge Corporate Issuer Solutions	Exhibit 4.1 to Form 8-K, filed on January 3, 2018
4.9	Specimen Common Stock Certificate	Exhibit 4.2 to Form 8-K, filed on January 3, 2018
4.10	Certificate of Designations, Preferences and Rights of Series J Junior Participating Preferred Stock of Rite Aid Corporation	Exhibit 3.1 to Form 8-K, filed on January 3, 2018
4.11	Certificate of Elimination of Series J Junior Participating Preferred Stock of Rite Aid Corporation	Exhibit 3.4 to Form 8-A/A, filed on March 28, 2018
4.12	First Amendment to Tax Benefits Preservation Plan, dated as of March 27, 2018, by and between Rite Aid Corporation and Broadridge Corporate Issuer Solutions	Exhibit 4.2 to Form 8-A/A, filed on March 28, 2018
10.1	2000 Omnibus Equity Plan	Included in Proxy Statement dated October 24, 2000
10.2	2001 Stock Option Plan	Exhibit 10.3 to Form 10-K, filed on May 21, 2001
10.3	2004 Omnibus Equity Plan	Exhibit 10.4 to Form 10-K, filed on April 29, 2005
10.4	2006 Omnibus Equity Plan	Exhibit 10 to Form 8-K, filed on January 22, 2007
10.5	2010 Omnibus Equity Plan	Exhibit 10.1 to Form 8-K, filed on June 25, 2010
10.6	Amendment No. 1, dated September 21, 2010, to the 2010 Omnibus Equity Plan	Exhibit 10.7 to Form 10-Q, filed on October 7, 2010
10.7	Amendment No. 2, dated January 16, 2013, to the 2010 Omnibus Equity Plan	Exhibit 10.8 to Form 10-K, filed on April 23, 2013
10.8	2012 Omnibus Equity Plan	Exhibit 10.1 to Form 8-K, filed on June 25, 2012
10.9	Amendment No. 1, dated January 16, 2013, to the 2012 Omnibus Equity Plan	Exhibit 10.10 to Form 10-K, filed on April 23, 2013
10.10	2014 Omnibus Equity Plan	Exhibit 10.1 to Form 8-K, filed on June 23, 2014
10.11	Form of Award Agreement	Exhibit 10.2 to Form 8-K, filed on May 15, 2012
10.12	Supplemental Executive Retirement Plan	Exhibit 10.6 to Form 10-K, filed on April 28, 2010
10.13	Executive Incentive Plan for Officers of Rite Aid Corporation	Exhibit 10.1 to Form 8-K, filed on February 24, 2012

48

10.14	Amended and Restated Employment Agreement by and between Rite Aid Corporation and John T. Standley, dated as of January 21, 2010	Exhibit 10.7 to Form 10-K, filed on April 28, 2010
10.15	Employment Agreement by and between Rite Aid Corporation and Douglas E. Donley, dated as of August 1, 2000	Exhibit 10.1 to Form 10-Q, filed on December 22, 2005
10.16	Amendment No. 1 to Employment Agreement by and between Rite Aid Corporation and Douglas E. Donley, dated as of December 18, 2008	Exhibit 10.4 to Form 10-Q, filed on January 7, 2009
10.17	Rite Aid Corporation Special Executive Retirement Plan	Exhibit 10.15 to Form 10-K, filed on April 26, 2004
10.18	Employment Agreement by and between Rite Aid Corporation and Ken Martindale, dated as of December 3, 2008	Exhibit 10.7 to Form 10-Q, filed on January 7, 2009
10.19	Letter Agreement, dated July 27, 2010, to the Employment Agreement by and between Rite Aid Corporation and Ken Martindale, dated as of December 3, 2008	Exhibit 10.6 to Form 10-Q, filed on October 7, 2010
10.20	Amendment to Employment Agreement by and between Rite Aid Corporation and Kenneth Martindale dated as of October 26, 2015	Exhibit 10.4 to Form 10-Q, filed on January 6, 2016
10.21	Amended and Restated Employment Agreement, dated as of June 23, 2011, between Rite Aid Corporation and Enio A. Montini, Jr.	Exhibit 10.1 to Form 10-Q, filed on October 5, 2011
10.22	Employment Agreement, dated as of March 24, 2014, by and between Rite Aid Corporation and Dedra N. Castle	Exhibit 10.2 to Form 10-Q, filed on July 3, 2014
10.23	Employment Agreement, dated as of July 24, 2014, by and between Rite Aid Corporation and Darren W. Karst	Exhibit 10.2 to Form 10-Q, filed on October 2, 2014
10.24	Letter Agreement, dated October 26, 2015, to the Employment Agreement by and between Rite Aid Corporation and Darren W. Karst, dated as of July 24, 2014	Exhibit 10.1 to Form 8-K, filed on October 28, 2015
10.25	Employment Agreement by and between Rite Aid Corporation and Jocelyn Konrad dated as of August 18, 2015	Exhibit 10.1 to Form 10-Q, filed on January 6, 2016
10.26	Employment Agreement by and between Rite Aid Corporation and Bryan Everett dated as of June 22, 2015	Exhibit 10.2 to Form 10-Q, filed on January 6, 2016
10.27	Employment Agreement by and between Rite Aid Corporation and David Abelman dated as of August 3, 2015	Exhibit 10.3 to Form 10-Q, filed on January 6, 2016
10.28	Form of Retention Award Agreement	Exhibit 10.1 to Form 8-K, filed on January 7, 2016
10.29	Form of December 31, 2015 Retention Award Agreement	Exhibit 10.2 to Form 8-K, filed on January 7, 2016
10.30	Amended and Restated Credit Agreement, dated as of June 27, 2001, as amended and restated as of January 13, 2015, among Rite Aid Corporation, the lenders from time to time party thereto and Citicorp North America, Inc., as administrative agent and collateral agent.	Exhibit 10.1 to Form 8-K, filed on January 14, 2015
10.31	First Amendment to Amended and Restated Credit Agreement, dated as of February 10, 2015, among Rite Aid Corporation, the lenders signatory thereto and Citicorp North America, Inc., as administrative agent and collateral agent.	Exhibit 10.1 to Form 8-K, filed on February 13, 2015
10.32	Amended and Restated Collateral Trust and Intercreditor Agreement, including the related definitions annex, dated as of June 5, 2009, among Rite Aid Corporation, each subsidiary named therein or which becomes a party thereto, Wilmington Trust Company, as collateral trustee, Citicorp North America, Inc., as senior collateral processing agent, The Bank of New York Trust Company, N.A., as trustee under the 2017 7.5% Note Indenture (as defined therein) and The Bank of New York Mellon Trust Company, N.A., as trustee under the 2016 10.375% Note Indenture (as defined therein), and each other Second Priority Representative and Senior Representative which becomes a party thereto	Exhibit 10.3 to Form 8-K, filed on June 11, 2009
10.33	Amended and Restated Senior Subsidiary Guarantee Agreement, dated as of June 5, 2009 among the subsidiary guarantors party thereto and Citicorp North America, Inc., as senior collateral agent	Exhibit 10.4 to Form 8-K, filed on June 11, 2009

49

10.34	Amended and Restated Senior Subsidiary Security Agreement, dated as of June 5, 2009, by the subsidiary guarantors party thereto in favor of the Citicorp North America, Inc., as senior collateral agent	Exhibit 10.5 to Form 8-K, filed on June 11, 2009
10.35	Amended and Restated Senior Indemnity, Subrogation and Contribution Agreement, dated as of May 28, 2003, and supplemented as of September 27, 2004, among Rite Aid Corporation, the Subsidiary Guarantors, and Citicorp North America, Inc. and JPMorgan Chase Bank, N.A., as collateral processing co-agents	Exhibit 4.27 to Form 10-K, filed on April 29, 2008
10.36	Second Priority Subsidiary Guarantee Agreement, dated as of June 27, 2001, as amended and restated as of May 28, 2003, and as supplemented as of January 5, 2005, among the Subsidiary Guarantors and Wilmington Trust Company, as collateral agent	Exhibit 4.36 to Form 10-K, filed on April 17, 2009
10.37	Second Priority Subsidiary Security Agreement, dated as of June 27, 2001, as amended and restated as of May 28, 2003, as supplemented as of January 5, 2005, and as amended in the Reaffirmation Agreement and Amendment dates as of January 11, 2005, by the Subsidiary Guarantors in favor of Wilmington Trust Company, as collateral trustee	Exhibit 4.37 to Form 10-K, filed on April 17, 2009
10.38	Amended and Restated Second Priority Indemnity, Subrogation and Contribution Agreement, dated as of May 28, 2003, and as supplemented as of January 5, 2005, among the Subsidiary Guarantors and Wilmington Trust Company, as collateral agent	Exhibit 4.33 to Form 10-K, filed on April 29, 2008
10.39	Intercreditor Agreement, dated as of February 18, 2009, by and among Citicorp North America, Inc. and Citicorp North America, Inc., and acknowledged and agreed to by Rite Aid Funding II	Exhibit 10.2 to Form 8-K, filed on February 20, 2009
10.40	Senior Lien Intercreditor Agreement dated as of June 12, 2009, among Rite Aid Corporation, the subsidiary guarantors named therein, Citicorp North America, Inc., as senior collateral agent for the Senior Secured Parties (as defined therein), Citicorp North America, Inc., as senior representative for the Senior Loan Secured Parties (as defined therein), The Bank of New York Mellon Trust Company, N.A., as Senior Representative (as defined therein) for the Initial Additional Senior Debt Parties (as defined therein), and each additional Senior Representative from time to time party thereto	Exhibit 10.2 to Form 8-K, filed on June 16, 2009
10.41	Standstill Agreement, dated as of February 18, 2018, among Rite Aid Corporation, Albertsons Companies, Inc. and Cerberus Capital Management, L.P.	Exhibit 10.1 to Form 8-K, filed on February 20, 2018
11	Statement regarding computation of earnings per share (See Note 4 to the consolidated financial statements)	Filed herewith
31.1	Certification of CEO pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended	Filed herewith
31.2	Certification of CFO pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended	Filed herewith
32	Certification of CEO and CFO pursuant to 18 United States Code, Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith
101.	The following materials are formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets at June 2, 2018 and March 3, 2018, (ii) Consolidated Statements of Operations for the thirteen weeks ended June 2, 2018 and June 3, 2017, (iii) Consolidated Statements of Comprehensive Income for the thirteen weeks ended June 2, 2018 and June 3, 2017, (iv)  Consolidated Statements of Cash Flows for the thirteen week period ended June 2, 2018 and June 3, 2017 and (v) Notes to Consolidated Financial Statements, tagged in detail.

50

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: July 6, 2018	RITE AID CORPORATION
	By:	/s/ DARREN W. KARST
		Darren W. Karst
		Senior Executive Vice President, Chief Financial Officer and Chief Administrative Officer
Date: July 6, 2018	By:	/s/ MATTHEW C. SCHROEDER
		Matthew C. Schroeder
		Senior Vice President, Chief Accounting Officer and Treasurer

51

EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer

I, John T. Standley, Chairman and Chief Executive Officer, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Rite Aid Corporation (the “Registrant”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors:

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: July 6, 2018
	By:	/s/ JOHN T. STANDLEY
		John T. Standley
		Chairman and Chief Executive Officer

EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer

I, Darren W. Karst, Senior Executive Vice President, Chief Financial Officer and Chief Administrative Officer, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Rite Aid Corporation (the “Registrant”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and

d.Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors:

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: July 6, 2018
	By:	/s/ DARREN W. KARST
		Darren W. Karst
		Senior Executive Vice President, Chief Financial Officer and Chief Administrative Officer

EX-32

Exhibit 32

Certification of CEO and CFO Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Rite Aid Corporation (the “Company”) for the quarterly period ended June 2, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), John T. Standley, as Chief Executive Officer of the Company, and Darren W. Karst, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ JOHN T. STANDLEY
Name:	John T. Standley
Title:	Chairman and Chief Executive Officer
Date:	July 6, 2018
/s/ DARREN W. KARST
Name:	Darren W. Karst
Title:	Senior Executive Vice President, Chief Financial Officer and Chief Administrative Officer
Date:	July 6, 2018

XML

Document and Entity Information - shares	3 Months Ended
	Jun. 02, 2018	Jun. 27, 2018
Document and Entity Information
Entity Registrant Name	RITE AID CORP
Entity Central Index Key	0000084129
Document Type	10-Q
Document Period End Date	Jun. 02, 2018
Amendment Flag	false
Current Fiscal Year End Date	--03-02
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		1,066,805,893
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 02, 2018	Mar. 03, 2018
Current assets:
Cash and cash equivalents	$ 147,092	$ 447,334
Accounts receivable, net	1,908,955	1,869,100
Inventories, net of LIFO reserve of $591,056 and $581,090	1,809,595	1,799,539
Prepaid expenses and other current assets	151,059	181,181
Current assets held for sale	179,442	438,137
Total current assets	4,196,143	4,735,291
Property, plant and equipment, net	1,401,924	1,431,246
Goodwill	1,421,120	1,421,120
Other intangibles, net	568,920	590,443
Deferred tax assets	522,674	594,019
Other assets	218,672	217,208
Total assets	8,329,453	8,989,327
Current liabilities:
Current maturities of long-term debt and lease financing obligations	19,025	20,761
Accounts payable	1,767,777	1,651,363
Accrued salaries, wages and other current liabilities	1,030,292	1,231,736
Current liabilities held for sale		560,205
Total current liabilities	2,817,094	3,464,065
Long-term debt, less current maturities	3,134,704	3,340,099
Lease financing obligations, less current maturities	28,874	30,775
Other noncurrent liabilities	536,470	553,378
Total liabilities	6,517,142	7,388,317
Commitments and contingencies
Stockholders' equity:
Common stock, par value $1 per share; 1,500,000 shares authorized; shares issued and outstanding 1,067,197 and 1,067,318	1,067,197	1,067,318
Additional paid-in capital	4,855,901	4,850,712
Accumulated deficit	(4,076,602)	(4,282,471)
Accumulated other comprehensive loss	(34,185)	(34,549)
Total stockholders' equity	1,812,311	1,601,010
Total liabilities and stockholders' equity	$ 8,329,453	$ 8,989,327

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Jun. 02, 2018	Mar. 03, 2018
CONDENSED CONSOLIDATED BALANCE SHEETS
Inventories, LIFO reserve (in dollars)	$ 591,056	$ 581,090
Common stock, par value (in dollars per share)	$ 1	$ 1
Common stock, shares authorized	1,500,000	1,500,000
Common stock, shares issued	1,067,197	1,067,318
Common stock, shares outstanding	1,067,197	1,067,318

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 5,388,490	$ 5,436,523
Costs and expenses:
Cost of revenues	4,219,741	4,274,580
Selling, general and administrative expenses	1,152,627	1,160,940
Lease termination and impairment charges	9,859	4,038
Interest expense	62,792	51,000
Loss on debt retirements, net	554
Gain on sale of assets, net	(5,859)	(5,877)
Total costs and expenses	5,439,714	5,484,681
Loss from continuing operations before income taxes	(51,224)	(48,158)
Income tax benefit	(9,497)	(12,121)
Net loss from continuing operations	(41,727)	(36,037)
Net income (loss) from discontinued operations, net of tax	256,143	(39,312)
Net income (loss)	214,416	(75,349)
Computation of (loss) income attributable to common stockholders:
Loss from continuing operations attributable to common stockholders-basic and diluted	(41,727)	(36,037)
Income (loss) from discontinued operations attributable to common stockholders-basic and diluted	256,143	(39,312)
Income (loss) attributable to common stockholders-basic and diluted	$ 214,416	$ (75,349)
Basic and diluted income (loss) per share:
Continuing operations	$ (0.04)	$ (0.03)
Discontinued operations	0.24	(0.04)
Net basic and diluted income (loss) per share	$ 0.20	$ (0.07)

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net income (loss)	$ 214,416	$ (75,349)
Defined benefit pension plans:
Amortization of prior service cost, net transition obligation and net actuarial losses included in net periodic pension cost, net of $144 and $342 tax expense	364	514
Total other comprehensive income	364	514
Comprehensive income (loss)	$ 214,780	$ (74,835)

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Amortization of prior service cost, net transition obligation and net actuarial losses included in net periodic pension cost, tax expense (benefit)	$ 144	$ 342

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017
Operating activities:
Net income (loss)	$ 214,416	$ (75,349)
Net income (loss) from discontinued operations, net of tax	256,143	(39,312)
Net loss from continuing operations	(41,727)	(36,037)
Adjustments to reconcile to net cash (used in) provided by operating activities of continuing operations:
Depreciation and amortization	94,529	101,029
Lease termination and impairment charges	9,859	4,038
LIFO charge	9,966	10,173
Gain on sale of assets, net	(5,859)	(5,877)
Stock-based compensation expense	5,031	9,038
Loss on debt retirements, net	554
Changes in deferred taxes	(12,355)	(38,160)
Changes in operating assets and liabilities:
Accounts receivable	(194,159)	(34,611)
Inventories	31,101	28,068
Accounts payable	207,960	(34,313)
Other assets and liabilities, net	(121,214)	44,421
Net cash (used in) provided by operating activities of continuing operations	(16,314)	47,769
Investing activities:
Payments for property, plant and equipment	(47,971)	(38,325)
Intangible assets acquired	(13,655)	(5,521)
Proceeds from insured loss		8,639
Proceeds from dispositions of assets and investments	9,916	2,137
Proceeds from sale-leaseback transactions	2,587
Net cash used in investing activities of continuing operations	(49,123)	(33,070)
Financing activities:
Net proceeds from (payments to) revolver	190,000	(90,000)
Principal payments on long-term debt	(431,106)	(3,503)
Change in zero balance cash accounts	1,083	28,768
Net proceeds from issuance of common stock	910	147
Payments for taxes related to net share settlement of equity awards		(147)
Financing fees paid for early debt redemption	(13)
Net cash used in financing activities of continuing operations	(239,126)	(64,735)
Cash flows from discontinued operations:
Operating activities of discontinued operations	(74,050)	44,965
Investing activities of discontinued operations	603,402	(25,126)
Financing activities of discontinued operations	(525,031)	(764)
Net cash provided by discontinued operations	4,321	19,075
Decrease in cash and cash equivalents	(300,242)	(30,961)
Cash and cash equivalents, beginning of period	447,334	245,410
Cash and cash equivalents, end of period	$ 147,092	$ 214,449

XML

Basis of Presentation

3 Months Ended

Jun. 02, 2018

Summary of Significant Accounting Policies

Basis of Presentation

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. The accompanying financial information reflects all adjustments which are of a recurring nature and, in the opinion of management, are necessary for a fair presentation of the results for the interim periods. The results of operations for the thirteen week period ended June 2, 2018 are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Rite Aid Corporation (“Rite Aid”) and Subsidiaries (together with Rite Aid, the “Company”) Fiscal 2018 10-K.

The discussion and presentation of the operating and financial results of our business segments have been impacted by the following event.

Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement (the “Amended and Restated Asset Purchase Agreement”), dated as of September 18, 2017, by and among Rite Aid, WBA and Walgreen Co., an Illinois corporation and wholly owned direct subsidiary of WBA (“Buyer”), Buyer agreed to purchase from Rite Aid 1,932 stores (the “Acquired Stores”), three distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of approximately $4.375 billion, on a cash free, debt free basis (the “Asset Sale” or the “Sale”). As of March 27, 2018, the Company has sold all 1,932 Acquired Stores and related assets to WBA in exchange for proceeds of $4,156.7 million, which were used to repay outstanding debt. Based on its magnitude and because the Company is exiting certain markets, the Sale represents a significant strategic shift that has a material effect on the Company’s operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Asset Sale as required by Accounting Standards Codification 210-05—Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the assets and liabilities to be sold, including the 1,932 Acquired Stores, three (3) distribution centers, related inventory and other specified assets and liabilities related thereto (collectively the “Assets to be Sold” or “Disposal Group”) to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended June 2, 2018 and March 3, 2018, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. Additionally, corporate support activities related to the Disposal Group were not reclassified to discontinued operations. Please see additional information as provided in Note 3 Asset Sale to WBA.

Recently adopted accounting pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU No. 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU No. 2016-08, “Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net),” which amends the principal-versus-agent implementation guidance and in April 2016, the FASB issued ASU No. 2016-10, “Identifying Performance Obligations and Licensing,” which amends the guidance in those areas in the new revenue recognition standard. These ASUs, collectively the “new revenue standard”, are effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018.

The Company adopted the new revenue standard as of March 4, 2018 using the modified retrospective method and applying the new standard to all contracts with customers.  Therefore, the comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods.  In connection with the adoption of the new revenue standard, the Company identified one difference in its Retail Pharmacy segment related to the timing of revenue recognition for third party prescription revenues, which was historically recognized at the time the prescription was filled.  Upon adoption of ASU No. 2014-09, this revenue is recognized at the time the customer takes possession of the merchandise. In connection with its March 4, 2018 adoption of the new revenue standard on a modified retrospective basis, the Company recorded a reduction to accounts receivable of $57,897, a reduction to deferred tax assets of $1,772, an increase to inventory of $51,121, and a corresponding increase to accumulated deficit of $8,548 within its Retail Pharmacy segment.

In addition, the Company identified revenues under one specific rebate administration program under which the Company’s Pharmacy Services segment was determined to be the principal and historically recognized revenues and cost of revenues on a gross basis of approximately $123,500 during fiscal 2018. Upon adoption of the new revenue standard, the Company is required to record revenue from this program on a net basis.   The Company expects the impact of the adoption of the new revenue standard to be immaterial to its revenues, net income, and cash flows on an ongoing basis.

The following is a discussion of the Company’s revenue recognition policies by segment under the new revenue recognition accounting standard:

Revenue Recognition

Retail Pharmacy Segment

For front end sales, the Retail Pharmacy segment recognizes revenues upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation at the point of sale for front end transactions. The Retail Pharmacy segment front end revenue is measured based on the amount of fixed consideration that we expect to receive, net of an allowance for estimated future returns. Return activity is immaterial to revenues and results of operations in all periods presented.

For pharmacy sales, the Retail Pharmacy segment recognizes revenue upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation, upon pickup by the customer, which is when the customer takes title to the product.  Each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims.  The Company’s revenue is measured based on the amount of fixed consideration that we expect to receive, reduced by refunds owed to the third party payor for pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not highly subjective or volatile.  The effect of adjustments between estimated and actual amounts have not been material to the Company’s results of operations or financial position. Prescriptions are generally not returnable.

The Retail Pharmacy segment offers a chain-wide loyalty card program titled wellness +. Individual customers are able to become members of the wellness + program.  Members participating in the wellness + loyalty card program earn points on a calendar year basis for eligible front end merchandise purchases and qualifying prescription purchases which may be redeemed to pay for future purchases. One point is awarded for each dollar spent towards front end merchandise and 25 points are awarded for each qualifying prescription.

Members reach specific wellness + tiers based on the points accumulated during the calendar year, which entitles such customers to certain future discounts and other benefits upon reaching that tier. For example, any customer that reaches 1,000 points in a calendar year achieves the “Gold” tier, enabling him or her to receive a 20% discount on qualifying purchases of front end merchandise for the remaining portion of the calendar year and also the next calendar year. There is also a similar “Silver” level with a lower threshold and benefit level.

Points earned pursuant to the wellness+ program represent a performance obligations and the Company allocates revenue between the merchandise purchased and the wellness + points based on the relative stand-alone selling price of each performance obligation. The relative value of the wellness + points is initially deferred as a contract liability (included in other current and noncurrent liabilities). As customers redeem the points to receive discounted front end merchandise or when the points expire, the Retail Pharmacy segment recognizes an allocable portion of the deferred contract liability into revenue. The Retail Pharmacy segment had accrued contract liabilities of $73,191 as of June 2, 2018, of which $49,793 is included in other current liabilities and $23,398 is included in noncurrent liabilities. The Retail Pharmacy segment had accrued contract liabilities of $63,851 as of March 3, 2018, of which $50,036 is included in other current liabilities and $13,815 is included in noncurrent liabilities.

The wellness + program also allows a customer to earn Bonus Cash based on qualifying purchases. Wellness + Rewards members have the opportunity to redeem his or her accumulated Bonus Cash on a future purchase with a 60 day expiration window. All Bonus Cash is redeemed using a FIFO methodology (i e., first Bonus Cash earned are the first to be redeemed).

For a majority of the Bonus Cash issuances, funding is provided by our vendors through contractual arrangements. This funding is treated as a contract liability and remains a contract liability until i) a wellness + Rewards members redeem their Bonus Cash, or ii) wellness + Rewards members allow the Bonus Cash to expire. Upon redemption or expiration, the Retail Pharmacy segment recognizes an allocable portion of the accrued contract liability into revenue. For Bonus Cash issuances that are not vendor funded, the contract liability is recorded at the time of issuance through a reduction to revenues, and not recognized until the Bonus Cash is redeemed or expires.

Pharmacy Services Segment

The Pharmacy Services segment sells prescription drugs indirectly through its retail pharmacy network and directly through its mail service dispensing pharmacy. The Pharmacy Services segment recognizes revenue from prescription drugs sold by (i) its mail service dispensing pharmacy and (ii) under retail pharmacy network contracts where it is the principal at the contract prices negotiated with its clients, primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans, Medicare plans, and other sponsors of health benefit plans, and individuals throughout the United States. Revenues include: (i) the portion of the price the client pays directly to the Pharmacy Services segment, net of any volume-related or other discounts paid back to the client (see “Drug Discounts” below), (ii) the price paid to the Pharmacy Services segment by client plan members for mail order prescriptions (“Mail Co-Payments”) (iii) client plan member copayments made directly to the retail pharmacy network, and (iv) administrative fees. Revenue is recognized when the Pharmacy Services segment meets its performance obligations relative to each transaction type, The following revenue recognition policies have been established for the Pharmacy Services segment:

· Revenues generated from prescription drugs sold by third party pharmacies in the Pharmacy Services segment’s retail pharmacy network and associated administrative fees are recognized at the Pharmacy Services segment’s point-of-sale, which is when the claim is adjudicated by the Pharmacy Services segment’s online claims processing system.  At this point the Company has performed all of its performance obligations.

· Revenues generated from prescription drugs sold by the Pharmacy Services segment’s mail service dispensing pharmacy are recognized when the prescription is shipped. At the time of shipment, the Pharmacy Services segment has performed all of its performance obligations under its client contracts, as control of and title to the product has passed to the clients plan member.  The Pharmacy Services segment does not experience a significant level of returns or reshipments.

· Revenues generated from administrative fees based on membership or claims volume are recognized monthly based on the terms within the individual contracts, either a monthly member based fee, or a claims volume based fee.

In the majority of its contracts, the Pharmacy Services segment is the principal because its client contracts give clients the right to obtain access to its pharmacy contracts under which the Pharmacy Services segment directs its pharmacy network to provide the services (drug dispensing, consultation, etc.) and goods (prescription drugs) to the clients’ members at its  negotiated pricing. The Pharmacy Services segment’s obligations under its client contracts are separate and distinct from its obligations to the third party pharmacies included in its retail pharmacy network contracts. Pursuant to these contracts, the Pharmacy Services segment is contractually required to pay the third party pharmacies in its retail pharmacy network for products sold after payment is received from its clients. The Pharmacy Services segment has control over these transactions until the prescription is transferred to the member and, thus, that it is acting as a principal. As such, the Pharmacy Services segment records the total prescription price contracted with clients in revenues.

Amounts paid to pharmacies and amounts charged to clients are exclusive of the applicable co-payment under Pharmacy Services segment contracts. Retail pharmacy co-payments, which we instruct retail pharmacies to collect from members, are included in our revenues and our cost of revenues.

For contracts under which the Pharmacy Services segment acts as an agent or does not control the prescription drugs prior to transfer to the client, no revenue is recognized.

Drug Discounts—The Pharmacy Services segment deducts from its revenues that are generated from prescription drugs sold by third party pharmacies any rebates, inclusive of discounts and fees, earned by its clients based on utilization levels and other factors as negotiated with the prescription drug manufacturers or suppliers. Rebates are paid to clients in accordance with the terms of client contracts.

Medicare Part D—The Pharmacy Services segment, through its EIC subsidiary, participates in the federal government’s Medicare Part D program as a Prescription Drug Plan (“PDP”). Please refer to Note 8, Medicare Part D.

Disaggregation of Revenue

The following table disaggregates the Company’s revenue by major source in each segment for the thirteen week period ended June 2, 2018:

In millions	For the thirteen week period ended June 2, 2018
Retail Pharmacy segment:
Pharmacy sales	$	2,565,286
Front end sales	1,296,147
Other revenue	36,332
Total Retail Pharmacy segment	$	3,897,765
Pharmacy Services segment	1,542,762
Intersegment elimination	(52,037		)
Total revenue	$	5,388,490

Impact of New Revenue Recognition Standard on Financial Statement Line Items

The Company adopted the new revenue standard using the modified retrospective method. The cumulative effect of applying the new standard to all contracts was recorded as an adjustment to accumulated deficit as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue standard, the following adjustments were made to accounts on the condensed consolidated balance sheet as of March 4, 2018:

	Impact of Change in Accounting Policy
	As Reported						Adjusted
In millions	March 3, 2018			Adjustments			March 4, 2018
Condensed Consolidated Balance Sheet:
Accounts receivable, net	$	1,869,100		$	(57,897	)	$	1,811,203
Inventories, net	1,799,539			51,121			1,850,660
Deferred tax assets	594,019			(1,772		)	592,247
Total assets	8,989,327			(8,548		)	8,980,779
Accumulated deficit	(4,282,471		)	(8,548		)	(4,291,019		)
Total shareholders’ equity	1,601,010			(8,548		)	1,592,462

Recently Issued Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU No. 2016-02, Leases, (Topic 842), which is intended to improve financial reporting around leasing transactions. The ASU affects all companies and other organizations that engage in lease transactions (both lessee and lessor) that lease assets such as real estate and manufacturing equipment. This ASU will require organizations that lease assets—referred to as “leases”—to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. ASU No. 2016-02 is effective for fiscal years and interim periods within those years beginning January 1, 2019 (fiscal 2020). On January 5, 2018 the FASB issued an exposure draft amending certain aspects of the new leasing standard. The proposed amendments include a provision to allow entities to elect not to restate comparative periods in the period of adoption when transitioning to the new standard and instead allow a modified retrospective approach. The Company believes that the new standard will have a material impact on its financial position. The Company is currently evaluating the impact this standard implementation will have on its results of operations and cash flows.

XML

Merger Agreement

3 Months Ended

Jun. 02, 2018

Merger Agreement

Merger Agreement

2. Merger Agreement

On February 18, 2018, Rite Aid entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Albertsons, Ranch Acquisition II LLC, a Delaware limited liability company and a wholly-owned direct subsidiary of Albertsons (“Merger Sub II”) and Ranch Acquisition Corp., a Delaware corporation and a wholly-owned direct subsidiary of Merger Sub II (“Merger Sub” and, together with Merger Sub II, the “Merger Subs”). Pursuant to the Merger Agreement, (i) Merger Sub will merge with and into Rite Aid (the “Merger”), with Rite Aid surviving the Merger as a wholly-owned direct subsidiary of Merger Sub II (the “Surviving Corporation”), and (ii) immediately following the Merger, the Surviving Corporation will merge with and into Merger Sub II (the “Subsequent Merger” and, together with the Merger, the “Mergers”) with Merger Sub II surviving the Subsequent Merger as a wholly-owned direct subsidiary of Albertsons (the “Surviving Company”).

At the effective time of the Merger (the “Effective Time”), each share of Rite Aid’s common stock, par value $1.00 per share, issued and outstanding immediately prior to the Effective Time (other than shares of Rite Aid common stock owned by Albertsons, Merger Sub or Rite Aid (including treasury stock held by Rite Aid), which will be cancelled) will be converted into the right to receive and become exchangeable for 0.1000 (the “Base Exchange Ratio”) of a fully paid and nonassessable share of Albertsons common stock, par value $0.01 per share (“Albertsons Common Stock”) (the “Base Consideration”), without interest, plus, at the election of the holder of Rite Aid common stock, either (i) an amount in cash equal to $0.1832 per share (the “Additional Cash Consideration” and, together with the Base Consideration, the “Cash Election Consideration”), without interest, or (ii) 0.0079 (the “Additional Stock Election Exchange Ratio” and, together with the Base Exchange Ratio, the “Stock Election Exchange Ratio”) of a fully paid and nonassessable share of Albertsons Common Stock (the “Additional Stock Consideration” and, together with the Base Consideration, the “Stock Election Consideration”).

Consummation of the Merger is subject to various closing conditions, including but not limited to (i) approval of the Merger Agreement by holders of a majority of the outstanding shares of our common stock entitled to vote on the Merger, (ii) the expiration or earlier termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) (which condition was satisfied on March 28, 2018), (iii) the absence of any law or order prohibiting the Merger, (iv) the absence of a material adverse effect on the Company and Albertsons, in each case, as defined in the Merger Agreement, (v) approval for listing, on the NYSE, of the shares of Albertsons Common Stock to be issued in the Merger and to be reserved for issuance in connection with the Merger (which approval was obtained on June 21, 2018), (vi) Albertsons’s registration statement on Form S 4 shall have become effective under the Securities Act (which Form S-4 was declared effective on June 25, 2018), and shall not be the subject of any stop order or proceedings seeking a stop order, (vii) approval of the Ohio Department of Insurance for the change of control of EIC, and (viii) Albertsons shall have delivered the Company a Lock Up Agreement, No Action Agreement and Standstill Agreement, in each case, in the form agreed to by the parties to the Merger Agreement.  The special meeting of Rite Aid’s stockholders to, among other things, consider and vote on a proposal to approve the Merger Agreement has been scheduled for August 9, 2018.

On February 18, 2018, in connection with the Merger Agreement, the Company entered into a standstill agreement (the “Standstill Agreement”) with Albertsons and Cerberus Capital Management, L.P. (“Cerberus”), pursuant to which Cerberus has agreed not to: (i) purchase shares of Albertsons Common Stock or other securities issued by Albertsons, except Cerberus may acquire beneficial ownership of Albertsons Common Stock provided that such beneficial ownership does not result in ownership of 30% or more of the issued and outstanding shares of Albertsons Common Stock in the aggregate following such transaction, (ii) make any public statement or public disclosure regarding any intent, purpose, plan or proposal by Cerberus or any of its controlled affiliates to the composition of the Albertsons board of directors, any merger, consolidation or acquisition of Albertsons or its subsidiaries, (iii) engage in any solicitation of proxies or otherwise solicit the stockholders of Albertsons or (iv) enter into any agreements to make any investment with any person that engages or offers or proposes to engage in any of (i) through (iii) during the standstill period. The standstill period commences at the Effective Time and terminates upon the earliest to occur of (a) thirty days following the date that Cerberus does not have any of its designees on the Albertsons board of directors, (b) the date on which Cerberus no longer has the right to appoint (and has not appointed) at least one director to the Albertsons board of directors and (c) the date on which Albertsons materially breaches or takes any action challenging the validity or enforceability of the provisions of the Merger Agreement that grant Cerberus certain rights to appoint directors to the Albertsons board of directors. In addition, pursuant to the Standstill Agreement, from February 18, 2018 until the Effective Time, Cerberus has agreed not to acquire or agree to acquire beneficial ownership of any shares of Albertsons Common Stock, Rite Aid common stock or other securities or debt issued by Albertsons or Rite Aid that would result in beneficial ownership of 30% or more of the issued and outstanding shares of Albertsons Common Stock at the Effective Time (assuming for the purposes of such calculation that the Effective Time occurred immediately after such acquisition).

XML

Asset Sale to WBA

3 Months Ended

Jun. 02, 2018

Asset Sale to WBA

Asset Sale to WBA

3. Asset Sale to WBA

On September 18, 2017, the Company entered into the Amended and Restated Asset Purchase Agreement with WBA and Buyer, which amended and restated in its entirety the previously disclosed Asset Purchase Agreement (the “Original APA”), dated as of June 28, 2017, by and among the Company, WBA and Buyer. Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement, Buyer agreed to purchase from the Company 1,932 Acquired Stores, three (3) distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of approximately $4,375,000, on a cash-free, debt-free basis in the Sale.

The Company announced on September 19, 2017 that the waiting period under the HSR Act, expired with respect to the Sale. As of March 27, 2018, the Company has completed the store transfer process, and all 1,932 stores and related assets have been transferred to WBA and the Company has received cash proceeds of $4,156,686. The transfer of the three (3) distribution centers and related assets is expected to begin after September 1, 2018. The majority of the closing conditions have been satisfied, and the transfer of the three distribution centers and related assets remains subject to minimal customary closing conditions applicable only to the distribution centers being transferred at such distribution center closings, as specified in the Amended and Restated Asset Purchase Agreement.  The Company has recorded a pre-tax gain on the Sale of the stores of $2,489,389.

The parties to the Amended and Restated Asset Purchase Agreement have each made customary representations and warranties. The Company has agreed to various covenants and agreements, including, among others, the Company’s agreement to conduct its business at the distribution centers being sold to WBA in the ordinary course during the period between the execution of the Amended and Restated Asset Purchase Agreement and the distribution center closing. The Company has also agreed to provide transition services to Buyer for up to three (3) years after the initial closing of the Sale. Under the terms of the TSA, the Company provides various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general and administrative activities. In connection with these services, the Company purchases the related inventory and incurs cash payments for the selling, general and administrative activities, which, the Company bills on a cash neutral basis to WBA in accordance with terms as outlined in the TSA. Total billings for these items during the thirteen week period ended June 2, 2018 were $2,041,075, of which $447,305 is included in Accounts receivable, net. The Company charged WBA TSA fees of $23,735 during the thirteen week period ended June 2, 2018 which are reflected as a reduction to selling, general and administrative expenses. Albertsons is obligated to assume the Company’s remaining obligations under the TSA.

Under the terms of the Amended and Restated Asset Purchase Agreement, the Company has the option to purchase pharmaceutical drugs through an affiliate of WBA under terms, including cost, that are substantially equivalent to Walgreen’s for a period of ten (10) years, subject to certain terms and conditions.

Based on its magnitude and because the Company is exiting certain markets, the Sale represents a significant strategic shift that has a material effect on the Company’s operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Sale as required by Accounting Standards Codification 210-05—Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the Disposal Group to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended June 2, 2018 and March 3, 2018, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. The Company also revised its discussion and presentation of operating and financial results to be reflective of its continuing operations as required by ASC 205-20.

The carrying amount of the Assets to be Sold, which were included in the Retail Pharmacy segment, have been reclassified from their historical balance sheet presentation to current assets and liabilities held for sale as follows:

	June 2, 2018		March 3, 2018
Inventories	$	111,001	$	264,286
Property and equipment	68,441		158,433
Goodwill(a)	—		4,629
Intangible assets	—		10,789
Current assets held for sale	$	179,442	$	438,137
Current maturities of long-term lease financing obligations	$	—	$	270
Accrued salaries, wages and other current liabilities	—		6,146
Long-term debt, less current maturities(b)	—		549,549
Lease financing obligations, less current maturities	—		838
Other noncurrent liabilities	—		3,402
Current liabilities held for sale	$	—	$	560,205

(a) The Company had $76,124 of goodwill in its Retail Pharmacy segment resulting from the acquisition of Health Dialog and RediClinic, which is accounted for as Retail Pharmacy segment enterprise goodwill. The Company has allocated a portion of its Retail Pharmacy segment enterprise goodwill to the discontinued operation.

(b) In connection with the Sale, the Company had estimated that the Sale would generate excess cash proceeds of approximately $4,027,400 which would be used to repay outstanding indebtedness. During the thirteen week period ended June 2, 2018, the Company has a use of cash for financing purposes of $525,031 in its discontinued operations and, based on refinements to its calculations, reduced its estimate of excess cash proceeds by approximately $24,500 and reclassified that amount to assets held and used. Consequently, the Company has classified $0 and $549,549 of estimated cash proceeds to be used for debt repayment to liabilities held for sale as of June 2, 2018 and March 3, 2018, respectively. As of June 2, 2018 and March 3, 2018, the Company repaid outstanding indebtedness of $525,031 and $3,135,000 with Sale proceeds.

The operating results of the discontinued operations that are reflected on the consolidated statements of operations within net income (loss) from discontinued operations are as follows:

	June 2, 2018 (13 weeks)			June 3, 2017 (13 weeks)
Revenues	$	23,400		$	2,377,857
Costs and expenses:
Cost of revenues(a)	17,081			1,780,765
Selling, general and administrative expenses(a)	13,875			600,640
Lease termination and impairment charges	—			48
Loss on debt retirements, net	4,570			—
Interest expense(b)	4,615			58,937
Gain on stores sold to Walgreens Boots Alliance	(360,557		)	—
(Gain) loss on sale of assets, net	—			(156		)
	(320,416		)	2,440,234
Income (loss) from discontinued operations before income taxes	343,816			(62,377		)
Income tax expense (benefit)	87,673			(23,065		)
Net income (loss) from discontinued operations, net of tax	$	256,143		$	(39,312	)

(a) Cost of revenues and selling, general and administrative expenses for the discontinued operations excludes corporate overhead. These charges are reflected in continuing operations.

(b) In accordance with ASC 205-20, the operating results for the thirteen week periods ended June 2, 2018 and June 3, 2017, respectively, for the discontinued operations include interest expense relating to the outstanding indebtedness repaid with the estimated excess proceeds from the Sale.

The operating results reflected above do not fully represent the Disposal Group’s historical operating results, as the results reported within net income from discontinued operations only include expenses that are directly attributable to the Disposal Group.

XML

Income (Loss) Per Share

3 Months Ended

Jun. 02, 2018

Income (Loss) Per Share

Income (Loss) Per Share

4. Income (Loss) Per Share

Basic income (loss) per share is computed by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company subject to anti-dilution limitations.

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
Basic and diluted income (loss) per share:
Numerator:
Net loss from continuing operations	$	(41,727	)	$	(36,037	)
Net income (loss) from discontinued operations	256,143			(39,312		)
Income (loss) attributable to common stockholders— basic and diluted	$	214,416		$	(75,349	)
Denominator:
Basic weighted average shares	1,054,381			1,046,826
Outstanding options and restricted shares, net	—			—
Diluted weighted-average shares	1,054,381			1,046,826
Basic and diluted income (loss) per share:
Continuing operations	$	(0.04	)	$	(0.03	)
Discontinued operations	0.24			(0.04		)
Net basic and diluted income (loss) per share	$	0.20		$	(0.07	)

Due to their antidilutive effect, 25,768 and 33,747 potential common shares related to stock options have been excluded from the computation of diluted income (loss) per share for the thirteen week period ended June 2, 2018 and June 3, 2017, respectively. Also, excluded from the computation of diluted income (loss) per share as of June 2, 2018 and June 3, 2017 are restricted shares of 11,339 and 5,623, respectively, which are included in shares outstanding.

XML

Lease Termination and Impairment Charges

3 Months Ended

Jun. 02, 2018

Lease Termination and Impairment Charges

Lease Termination and Impairment Charges

5. Lease Termination and Impairment Charges

Lease termination and impairment charges consist of amounts as follows:

	Thirteen Week Period Ended
	June 2, 2018		June 3, 2017
Impairment charges	$	283	$	659
Lease termination charges	9,576		3,379
	$	9,859	$	4,038

Impairment Charges

These amounts include the write-down of long-lived assets at locations that were assessed for impairment because of management’s intention to relocate or close the location or because of changes in circumstances that indicated the carrying value of an asset may not be recoverable.

Lease Termination Charges

As part of the Company’s ongoing business activities, the Company assesses stores and distribution centers for potential closure or relocation. Decisions to close or relocate stores or distribution centers in future periods would result in lease termination charges, lease exit costs and inventory liquidation charges, as well as impairment of assets at these locations. The following table reflects the closed store and distribution center charges that relate to new closures, changes in assumptions and interest accretion:

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
Balance—beginning of period	$	133,290		$	165,138
Provision for present value of noncancellable lease payments of closed stores	8,130			913
Changes in assumptions about future sublease income,  terminations and changes in interest rates	(1,038		)	(549		)
Interest accretion	2,685			3,095
Cash payments, net of sublease income	(11,885		)	(12,931		)
Balance—end of period	$	131,182		$	155,666

XML

Fair Value Measurements

3 Months Ended

Jun. 02, 2018

Fair Value Measurements

Fair Value Measurements

6. Fair Value Measurements

The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:

· Level 1—Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

· Level 2—Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.

· Level 3—Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.

Non-Financial Assets Measured on a Non-Recurring Basis

Long-lived non-financial assets are measured at fair value on a nonrecurring basis for purposes of calculating impairment using Level 2 and Level 3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level 2 inputs is determined by evaluating the current economic conditions in the geographic area for similar use assets. The fair value of long-lived assets using Level 3 inputs is determined by estimating the amount and timing of net future cash flows (which are unobservable inputs) and discounting them using a risk-adjusted rate of interest (which is Level 1). The Company estimates future cash flows based on its experience and knowledge of the market in which the store is located. Significant increases or decreases in actual cash flows may result in valuation changes. During the thirteen week period ended June 2, 2018, long-lived assets from continuing operations with a carrying value of $1,575, primarily store assets, were written down to their fair value of $1,292, resulting in an impairment charge of $283. During the thirteen week period ended June 3, 2017, long-lived assets from continuing operations with a carrying value of $964, primarily store assets, were written down to their fair value of $305, resulting in an impairment charge of $659.   If our actual future cash flows differ from our projections materially, certain stores that are either not impaired or partially impaired in the current period may be further impaired in future periods.

The following table presents fair values for those assets measured at fair value on a non-recurring basis at June 2, 2018 and June 3, 2017:

Fair Value Measurement Using

	Level 1		Level 2		Level 3		Total as of June 2, 2018
Long-lived assets held for use	$	—	$	—	$	—	$	—
Long-lived assets held for sale	$	—	$	1,292	$	—	$	1,292
Total	$	—	$	1,292	$	—	$	1,292

	Level 1		Level 2		Level 3		Total as of June 3, 2017
Long-lived assets held for use	$	—	$	—	$	201	$	201
Long-lived assets held for sale	$	—	$	104	$	—	$	104
Total	$	—	$	104	$	201	$	305

The above assets reflected in the caption Long-lived assets held for sale are separate and apart from the Assets to be Sold and do to their immateriality have not been reclassified to assets held for sale.

As of June 2, 2018 and June 3, 2017, the Company did not have any financial assets measured on a recurring basis.

Other Financial Instruments

Financial instruments other than long-term indebtedness include cash and cash equivalents, accounts receivable and accounts payable. These instruments are recorded at book value, which we believe approximate their fair values due to their short term nature.  In addition, as of June 2, 2018 and March 3, 2018 the Company has $7,257 and $7,282, respectively, of investments, carried at amortized cost as these investments are being held to maturity, which are included as a component of other assets.  The Company believes the carrying value of these investments approximates their fair value.

The fair value for LIBOR-based borrowings under the Company’s senior secured credit facility and first and second lien term loans are estimated based on the quoted market price of the financial instrument which is considered Level 1 of the fair value hierarchy. The fair values of substantially all of the Company’s other long-term indebtedness are estimated based on quoted market prices of the financial instruments which are considered Level 1 of the fair value hierarchy. The carrying amount and estimated fair value of the Company’s total long-term indebtedness was $3,134,794 and $3,162,700, respectively, as of June 2, 2018. There were no outstanding derivative financial instruments as of June 2, 2018 and March 3, 2018.

XML

Income Taxes

3 Months Ended

Jun. 02, 2018

Income Taxes

Income Taxes

7. Income Taxes

The new federal tax legislation commonly referred to as the Tax Cut and Jobs Act (the “Tax Act”) enacted on December 22, 2017 (the “Enactment Date”) introduced significant changes to U.S. income tax law. Effective for tax years beginning on or after January 1, 2018, the Tax Act reduced the U.S. federal corporate income tax rate from 35% to 21%.

The Company recorded an income tax benefit from continuing operations of $9,497 and $12,121 for the thirteen week periods ended June 2, 2018 and June 3, 2017. The effective tax rate for the thirteen week periods ended June 2, 2018 and June 3, 2017 was 18.5% and 25.2%, respectively. The effective tax rate for the thirteen week period ended June 2, 2018 includes an adjustment of (2.3)% to increase the valuation allowance related to certain state deferred taxes. The tax benefit for the thirteen week period ended June 3, 2017 is higher in comparison to 2018, as it is based on a federal statutory rate of 35%, offset by increases to the valuation allowance primarily related to state deferred taxes.

The Company recognizes tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.

The Company believes that it is reasonably possible that a decrease of up to $13,498 in unrecognized tax benefits related to state exposures may be necessary in the next twelve months however management does not expect the change to have a significant impact on the results of operations or the financial position of the Company.

The Company regularly evaluates valuation allowances established for deferred tax assets for which future realization is uncertain.  Management will continue to monitor all available evidence related to the net deferred tax assets that may change the most recent assessment, including events that have occurred or are anticipated to occur. The Company continues to maintain a valuation allowance against net deferred tax assets of $903,342 and $896,800, which relates primarily to state deferred tax assets at June 2, 2018 and March 3, 2018, respectively.

XML

Medicare Part D

3 Months Ended

Jun. 02, 2018

Medicare Part D

Medicare Part D

8. Medicare Part D

The Company offers Medicare Part D benefits through EIC, which has contracted with CMS to be a PDP and, pursuant to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, must be a risk-bearing entity regulated under state insurance laws or similar statutes.

EIC is a licensed domestic insurance company under the applicable laws and regulations. Pursuant to these laws and regulations, EIC must file quarterly and annual reports with the National Association of Insurance Commissioners (“NAIC”) and certain state regulators, must maintain certain minimum amounts of capital and surplus under formulas established by certain states and must, in certain circumstances, request and receive the approval of certain state regulators before making dividend payments or other capital distributions to the Company. The Company does not believe these limitations on dividends and distributions materially impact its financial position. EIC is subject to minimum capital and surplus requirements in certain states. The minimum amount of capital and surplus required to satisfy regulatory requirements in these states is $29,464 as of March 31, 2018. EIC was in excess of the minimum required amounts in these states as of June 2, 2018.

The Company has recorded estimates of various assets and liabilities arising from its participation in the Medicare Part D program based on information in its claims management and enrollment systems. Significant estimates arising from its participation in this program include: (i) estimates of low-income cost subsidies, reinsurance amounts, and coverage gap discount amounts ultimately payable to CMS based on a detailed claims reconciliation that will occur in the following year; (ii) an estimate of amounts receivable from CMS under a risk-sharing feature of the Medicare Part D program design, referred to as the risk corridor and (iii) estimates for claims that have been reported and are in the process of being paid or contested and for our estimate of claims that have been incurred but have not yet been reported.

As of June 2, 2018, accounts receivable, net included $442,690 due from CMS and accrued salaries, wages and other current liabilities included $163,134 of EIC liabilities under certain reinsurance contracts. As of March 3, 2018, accounts receivable, net included $350,563 due from CMS and accrued salaries, wages and other current liabilities included $183,318 of EIC liabilities under certain reinsurance contracts. During calendar 2017, EIC limited its exposure to loss and recovered a portion of benefits paid by utilizing quota-share reinsurance with a commercial reinsurance company. Beginning calendar 2018, EIC does not have a reinsurance agreement in place related to its individual and certain group Medicare Part D Plans.

XML

Goodwill and Other Intangible Assets

3 Months Ended

Jun. 02, 2018

Goodwill and Other Intangible Assets

Goodwill and Other Intangible Assets

9. Goodwill and Other Intangible Assets

There was no impairment charge for the thirteen week period ended June 2, 2018. At June 2, 2018 and March 3, 2018, accumulated impairment losses for the Pharmacy Services segment was $261,727.

The Company’s intangible assets are primarily finite-lived and amortized over their useful lives. Following is a summary of the Company’s finite-lived and indefinite-lived intangible assets as of June 2, 2018 and March 3, 2018.

	June 2, 2018								March 3, 2018
	Gross Carrying Amount		Accumulated Amortization			Net		Remaining Weighted Average Amortization Period	Gross Carrying Amount		Accumulated Amortization			Net		Remaining Weighted Average Amortization Period
Favorable leases and other(a)	$	379,809	$	(318,930	)	$	60,879	7 years	$	379,355	$	(316,798	)	$	62,557	7 years
Prescription files	906,181		(808,498		)	97,683		3 years	900,111		(801,706		)	98,405		3 years
Customer relationships(a)	465,000		(187,616		)	277,384		14 years	465,000		(172,635		)	292,365		15 years
CMS license	57,500		(6,747		)	50,753		22 years	57,500		(6,172		)	51,328		23 years
Claims adjudication and other developed software	58,985		(24,724		)	34,261		4 years	58,985		(22,617		)	36,368		5 years
Trademarks	20,100		(5,896		)	14,204		7 years	20,100		(5,394		)	14,706		8 years
Backlog	11,500		(11,244		)	256		1 year	11,500		(10,286		)	1,214		1 year
Total finite	$	1,899,075	$	(1,363,655	)	535,420			$	1,892,551	$	(1,335,608	)	$	556,943
Trademarks	33,500		—			33,500		Indefinite	33,500		—			33,500		Indefinite
Total	$	1,932,575	$	(1,363,655	)	$	568,920		$	1,926,051	$	(1,335,608	)	$	590,443

(a) Amortized on an accelerated basis which is determined based on the remaining useful economic lives of the customer relationships that are expected to contribute directly or indirectly to future cash flows.

Also included in other non-current liabilities as of June 2, 2018 and March 3, 2018 are unfavorable lease intangibles with a net carrying amount of $17,857 and $18,888, respectively. These intangible liabilities are amortized over their remaining lease terms at time of acquisition.

Amortization expense for these intangible assets and liabilities was $35,400 and $40,962 for the thirteen week periods ended June 2, 2018 and June 3, 2017, respectively. The anticipated annual amortization expense for these intangible assets and liabilities is 2019—$124,583; 2020—$100,875; 2021—$76,995; 2022—$55,206 and 2023—$38,953.

XML

Indebtedness and Credit Agreements

3 Months Ended

Jun. 02, 2018

Indebtedness and Credit Agreements

Indebtedness and Credit Agreements

10. Indebtedness and Credit Agreements

Following is a summary of indebtedness and lease financing obligations at June 2, 2018 and March 3, 2018:

	June 2, 2018			March 3, 2018
Secured Debt:
Senior secured revolving credit facility due January 2020 ($190,000 and $0 face value less unamortized debt issuance costs of $10,258 and $13,076)	$	179,742		$	(13,076	)
Other secured	90			90
	179,832			(12,986		)
Guaranteed Unsecured Debt:
9.25% senior notes due March 2020 ($0 and $902,000 face value plus unamortized premium of $0 and $1,400 and less unamortized debt issuance costs of $0 and $4,924 as of June 2, 2018 and March 3, 2018, respectively)	—			898,476
6.75% senior notes due June 2021 ($805,169 and $810,000 face value less unamortized debt issuance costs of $4,482 and $4,877)	800,687			805,123
6.125% senior notes due April 2023 ($1,753,490 and $1,800,000 face value less unamortized debt issuance costs of $20,106 and $21,708)	1,733,384			1,778,292
	2,534,071			3,481,891
Unguaranteed Unsecured Debt:
7.7% notes due February 2027 ($295,000 face value less unamortized debt issuance costs of $1,418 and $1,460)	293,582			293,540
6.875% fixed-rate senior notes due December 2028 ($128,000 face value less unamortized debt issuance costs of $691 and $707)	127,309			127,293
	420,891			420,833
Lease financing obligations	47,809			52,554
Total debt	3,182,603			3,942,292
Current maturities of long-term debt and lease financing obligations	(19,025		)	(21,031		)
Long-term debt and lease financing obligations, less current maturities	$	3,163,578		$	3,921,261

Reconciliation of indebtedness included in continuing operations and discontinued operations:

	March 3, 2018
	Debt			Lease Financing Obligations			Total Debt and Lease Financing Obligations
Balance, March 3, 2018—per above table	$	3,889,738		$	52,554		$	3,942,292
Amounts reclassified as current liabilities held for sale in connection with the Sale(a)	(549,549		)	(1,108		)	(550,657		)
Total debt and lease financing obligations	3,340,189			51,446			3,391,635
Current maturities of long-term debt and lease financing obligations—continuing operations	(90		)	(20,671		)	(20,761		)
Long-term debt and lease financing obligations, less current maturities—continuing operations	$	3,340,099		$	30,775		$	3,370,874

(a) In connection with the Sale, the Company had estimated that the Sale would generate excess cash proceeds of approximately $4,027,400 which would be used to repay outstanding indebtedness. During the thirteen week period ended June 2, 2018, the Company has a use of cash for financing purposes of $525,031 in its discontinued operations and, based on refinements to its calculations, reduced its estimate of excess cash proceeds by approximately $24,500 and reclassified that amount to assets held and used. Consequently, the Company has classified $0 and $549,549 of estimated cash proceeds to be used for debt repayment to liabilities held for sale as of June 2, 2018 and March 3, 2018, respectively. Additionally, as part of the Sale, the Company will be relieved of approximately $0 and $1,108, respectively, of capital lease obligations as of June 2, 2018 and March 3, 2018. These amounts are also reflected as liabilities held for sale. Please see Note 3 for additional details.

Credit Facility

The Company’s Amended and Restated Senior Secured Credit Facility has a borrowing capacity of $2,700,000 and matures in January 2020. Borrowings under the revolver bear interest at a rate per annum between (i) LIBOR plus 1.50% and LIBOR plus 2.00% with respect to Eurodollar borrowings and (ii) the alternate base rate plus 0.50% and the alternate base rate plus 1.00% with respect to ABR borrowings, in each case, based upon the Average Revolver Availability (as defined in the Amended and Restated Senior Secured Credit Facility). The Company is required to pay fees between 0.250% and 0.375% per annum on the daily unused amount of the revolver, depending on the Average Revolver Availability (as defined in the Amended and Restated Senior Secured Credit Facility). Amounts drawn under the revolver become due and payable on January 13, 2020.

The Company’s ability to borrow under the revolver is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At June 2, 2018, the Company had $190,000 of borrowings outstanding under the revolver and had letters of credit outstanding against the revolver of $55,790 which resulted in additional borrowing capacity of $2,454,210.

The Amended and Restated Senior Secured Credit Facility restricts the Company and the Subsidiary Guarantors (as defined herein) from accumulating cash on hand, and under certain circumstances, requires the funds in the Company’s deposit accounts to be applied first to the repayment of outstanding revolving loans under the Amended and Restated Senior Secured Credit Facility and then to be held as collateral for the senior obligations.

The Amended and Restated Senior Secured Credit Facility allows the Company to have outstanding, at any time, up to $1,500,000 in secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock in addition to borrowings under the Amended and Restated Senior Secured Credit Facility and existing indebtedness, provided that not in excess of $750,000 of such secured second priority debt, split-priority term loan debt, unsecured debt and disqualified preferred stock shall mature or require scheduled payments of principal prior to 90 days after the latest of (a) the fifth anniversary of the effectiveness of the Amended and Restated Senior Secured Credit Facility and (b) the latest maturity date of any Term Loan or Other Revolving Loan (each as defined in the Amended and Restated Senior Secured Credit Facility) (excluding bridge facilities allowing extensions on customary terms to at least the date that is 90 days after such date and, with respect to any escrow notes issued by Rite Aid, excluding any special mandatory redemption of the type described in clause (iii) of the definition of “Escrow Notes” in the Amended and Restated Senior Secured Credit Facility). Subject to the limitations described in clauses (a) and (b) of the immediately preceding sentence, the Amended and Restated Senior Secured Credit Facility additionally allows the Company to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the Amended and Restated Senior Secured Credit Facility) is not in effect; provided, however, that certain of the Company’s other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The Amended and Restated Senior Secured Credit Facility also contains certain restrictions on the amount of secured first priority debt the Company is able to incur. The Amended and Restated Senior Secured Credit Facility also allows for the voluntary repurchase of any debt or other convertible debt, so long as the Amended and Restated Senior Secured Credit Facility is not in default and the Company maintains availability under its revolver of more than $365,000.

The Amended and Restated Senior Secured Credit Facility has a financial covenant that requires the Company to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (a) on any date on which availability under the revolver is less than $200,000 or (b) on the third consecutive business day on which availability under the revolver is less than $250,000 and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the revolver is equal to or greater than $250,000. As of June 2, 2018, the Company had availability under its revolver of $2,454,210, its fixed charge coverage ratio was greater than 1.00 to 1.00, and the Company was in compliance with the senior secured credit facility’s financial covenant. The Amended and Restated Senior Secured Credit Facility also contains covenants which place restrictions on the incurrence of debt, the payments of dividends, sale of assets, mergers and acquisitions and the granting of liens.

The Amended and Restated Senior Secured Credit Facility also provides for customary events of default.

With the exception of EIC, substantially all of Rite Aid Corporation’s 100 percent owned subsidiaries guarantee the obligations under the Amended and Restated Senior Secured Credit Facility and unsecured guaranteed notes. The Amended and Restated Senior Secured Credit Facility is secured, on a senior priority basis, by a lien on, among other things, accounts receivable, inventory and prescription files of the Subsidiary Guarantors. The subsidiary guarantees related to the Company’s Amended and Restated Senior Secured Credit Facility and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several, and there are no restrictions on the ability of the Company to obtain funds from its subsidiaries. The Company has no independent assets or operations. Additionally, prior to the Acquisition, the subsidiaries, including joint ventures, that did not guarantee the Amended and Restated Senior Secured Credit Facility and applicable notes, were minor. Accordingly, condensed consolidating financial information for the Company and subsidiaries is not presented for those periods. Subsequent to the Acquisition, other than EIC, the subsidiaries, including joint ventures, that do not guarantee the credit facility and applicable notes, are minor. As such, condensed consolidating financial information for the Company, its guaranteeing subsidiaries and non-guaranteeing subsidiaries is presented for those periods subsequent to the Acquisition. See Note 14 “Guarantor and Non-Guarantor Condensed Consolidating Financial Information” for additional disclosure.

Fiscal 2018 and 2019 Transactions

During January 2018, the Company used proceeds from the Asset Sale to repay and retire all of its outstanding second lien $470,000 tranche 1 term loan and $500,000 tranche 2 term loan principal (the “Second Lien Term Loan Prepayment”). During February 2018, the Company reduced the borrowing capacity on its Amended and Restated Senior Secured Credit Facility from $3,700,000 to $3,000,000. In connection with the transactions, the Company recorded a loss on debt retirement of $8,180, which included interest and unamortized debt issuance costs. The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On February 27, 2018, the Company announced that it had commenced an offer to purchase up to $900,000 of the outstanding 9.25% senior notes due 2020 (the “9.25% Notes”), the 6.75% senior notes due 2021 (the “6.75% Notes”) and the 6.125% Senior Notes due 2023 (the “6.125% Notes”), pursuant to the asset sale provisions of the indentures of such notes. On March 29, 2018, the Company accepted for payment, pursuant to its offer to purchase, $3,454 principal amount of the 9.25% Notes, representing 0.38% of the outstanding principal amount of the 9.25% Notes, $3,471 principal amount of the 6.75% Notes, representing 0.43% of the outstanding principal amount of the 6.75% Notes, and $41,751 principal amount of the 6.125% Notes, representing 2.32% of the outstanding principal amount of the 6.125% Notes.  In connection therewith, the Company recorded a loss on debt retirement of $49 which included unamortized debt issuance costs, partially offset by unamortized discount.  The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of discontinued operations. The debt repayment and related loss on debt retirement of $498 for the 6.125% Notes is included in the results of operations and cash flows of continuing operations.

On March 13, 2018, the Company issued a notice of redemption for all of the 9.25%. Notes that were outstanding on April 12, 2018, pursuant to the terms of the indenture of the 9.25% Notes. On April 12, 2018, the Company redeemed 100% of the remaining outstanding 9.25% Notes.  In connection therewith, the Company recorded a loss on debt retirement of $3,422 which included unamortized debt issuance costs, partially offset by unamortized discount.  The debt repayment and related loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On April 19, 2018, the Company announced that it had commenced an offer to purchase up to $700,000 of its outstanding 6.75% Notes and its 6.125% Notes pursuant to the terms of such indentures. On May 21, 2018, the Company redeemed $1,360 aggregate principal amount of the 6.75% Notes and $4,759 aggregate principal amount of the 6.125% Notes.  The debt repayment and related loss on debt retirement of $8 for the 6.75% Notes is included in the results of operations and cash flows of discontinued operations.  The debt repayment and related loss on debt retirement of $56 for the 6.125% Notes is included in the results of operations and cash flows of continuing operations.

On April 29, 2018, the Company further reduced the borrowing capacity on its Amended and Restated Senior Secured Credit Facility from $3,000,000 to $2,700,000. In connection therewith, the Company recorded a loss on debt retirement of $1,091, which included unamortized debt issuance costs. The loss on debt retirement is included in the results of operations and cash flows of discontinued operations.

On May 25, 2018, the Company issued a notice of redemption for all of the 6.75% Notes that were outstanding on June 25 2018, pursuant to the terms of the indenture of the 6.75% Notes. On June 25, 2018, the Company redeemed 100% of the remaining outstanding 6.75% Notes, which resulted in a loss on debt retirement of $18,075. The debt repayment and related loss on debt retirement will be included in the results of operations and cash flows of discontinued operations during the second quarter ending September 1, 2018.

Maturities

The aggregate annual principal payments of long-term debt for the remainder of fiscal 2019 and thereafter are as follows: 2019—$90; 2020—$190,000; 2021—$0; 2022—$805,169; 2023—$0 and $2,176,490 thereafter.

XML

Retirement Plans

3 Months Ended

Jun. 02, 2018

Retirement Plans

Retirement Plans

11. Retirement Plans

Net periodic pension expense recorded in the thirteen week periods ended June 2, 2018 and June 3, 2017, for the Company’s defined benefit plan includes the following components:

	Defined Benefit Pension Plan
	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
Service cost	$	312		$	346
Interest cost	1,578			1,603
Expected return on plan assets	(1,434		)	(1,147		)
Amortization of unrecognized prior service cost	—			—
Amortization of unrecognized net loss	507			856
Net periodic pension expense	$	963		$	1,658

During the thirteen week period ended June 2, 2018 the Company contributed $813 to the Defined Benefit Pension Plan. During the remainder of fiscal 2018, the Company expects to contribute $3,800 to the Defined Benefit Pension Plan.

XML

Segment Reporting

3 Months Ended

Jun. 02, 2018

Segment Reporting

Segment Reporting

12. Segment Reporting

The Company has two reportable segments, its retail drug stores (“Retail Pharmacy”), and its pharmacy services (“Pharmacy Services”) segments, collectively the “Parent Company”.

The Retail Pharmacy segment’s primary business is the sale of prescription drugs and related consultation to its customers. Additionally, the Retail Pharmacy segment sells a full selection of health and beauty aids and personal care products, seasonal merchandise and a large private brand product line. The Pharmacy Services segment offers a full range of pharmacy benefit management services including plan design and administration, on both a transparent pass-through model and traditional model, formulary management and claims processing. Additionally, the Pharmacy Services segment offers specialty and mail order services, infertility treatment, and drug benefits to eligible beneficiaries under the federal government’s Medicare Part D program.

The Parent Company’s chief operating decision makers are its Parent Company Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, Chief Operating Officer—Retail Pharmacy, and the Chief Executive Officer—Pharmacy Services, (collectively the “CODM”). The CODM has ultimate responsibility for enterprise decisions. The CODM determines, in particular, resource allocation for, and monitors performance of, the consolidated enterprise, the Retail Pharmacy segment and the Pharmacy Services segment. The Retail Pharmacy and Pharmacy Services segment managers have responsibility for operating decisions, allocating resources and assessing performance within their respective segments. The CODM relies on internal management reporting that analyzes enterprise results on certain key performance indicators, namely, revenues, gross profit, and Adjusted EBITDA.

The following is balance sheet information for the Company’s reportable segments:

	Retail Pharmacy		Pharmacy Services		Eliminations(2)			Consolidated
June 2, 2018:
Total Assets	$	5,434,447	$	2,950,099	$	(55,093	)	$	8,329,453
Goodwill	43,493		1,377,627		—			1,421,120
Additions to property and equipment and intangible assets	58,067		3,559		—			61,626
March 3, 2018:
Total Assets	$	6,089,343	$	2,954,953	$	(54,969	)	$	8,989,327
Goodwill	43,492		1,377,628		—			1,421,120
Additions to property and equipment and intangible assets	199,437		15,327		—			214,764

(2)As of June 2, 2018 and March 3, 2018, intersegment eliminations include netting of the Pharmacy Services segment long-term deferred tax liability of $40,319 and $38,713, respectively, against the Retail Pharmacy segment long-term deferred tax asset for consolidation purposes in accordance with ASC 740, and intersegment accounts receivable of $14,774 and $16,256, respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products.

The following table is a reconciliation of the Company’s business segments to the consolidated financial statements for the thirteen week periods ended June 2, 2018 and June 3, 2017:

	Retail Pharmacy		Pharmacy Services		Intersegment Eliminations(1)			Consolidated
June 2, 2018:
Revenues	$	3,897,765	$	1,542,762	$	(52,037	)	$	5,388,490
Gross Profit	1,069,457		99,292		—			1,168,749
Adjusted EBITDA(2)	113,469		33,863		—			147,332
June 3, 2017:
Revenues	$	3,972,351	$	1,513,241	$	(49,069	)	$	5,436,523
Gross Profit	1,056,971		104,972		—			1,161,943
Adjusted EBITDA(2)	87,365		48,599		—			135,964

(1) Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis.

(2) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” in MD&A for additional details. The following is a reconciliation of net (loss) income to Adjusted EBITDA for the thirteen week periods ended June 2, 2018 and June 3, 2017:

	June 2, 2018 (13 weeks)			June 3, 2017 (13 weeks)
Net loss from continuing operations	$	(41,727	)	$	(36,037	)
Interest expense	62,792			51,000
Income tax benefit	(9,497		)	(12,121		)
Depreciation and amortization expense	94,529			101,029
LIFO charge	9,966			10,173
Lease termination and impairment charges	9,859			4,038
Loss on debt retirements, net	554			—
Other	20,856			17,882
Adjusted EBITDA from continuing operations	$	147,332		$	135,964

XML

Commitments, Contingencies and Guarantees

3 Months Ended

Jun. 02, 2018

Commitments, Contingencies and Guarantees

Commitments, Contingencies and Guarantees

13. Commitments, Contingencies and Guarantees

Legal Matters and Regulatory Proceedings

The Company is involved in legal proceedings and is subject to investigations, inspections, claims, audits, inquiries, and similar actions by governmental authorities arising in the ordinary course of its business, including, without limitation, the matters described below. The Company records accruals for outstanding legal matters and applicable regulatory proceedings when it believes it is probable that a loss will be incurred, and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters and regulatory proceedings that could affect the amount of any existing accrual and developments that would make a loss contingency both probable and reasonably estimable, and as a result, warrant an account. If a loss contingency is not both probable and estimable, the Company does not establish an accrued liability.  None of the Company’s accruals for outstanding legal matters or regulatory proceedings are material individually or in the aggregate to the Company’s consolidated financial position.

The Company’s contingencies are subject to significant uncertainties, many of which are beyond the Company’s control, including, among other factors: (i) proceedings are in early stages; (ii) whether class or collective action status is sought and the likelihood of a class being certified; (iii) the outcome of pending appeals or motions; (iv) the extent of potential damages, fines or penalties, which are often unspecified or indeterminate; (v) the impact of discovery on the matter; (vi) whether novel or unsettled legal theories are at issue; (vii) there are significant factual issues to be resolved; and/or (viii) in the case of certain government agency investigations, whether a qui tam lawsuit (“whistleblower” action) has been filed and whether the government agency makes a decision to intervene in the lawsuit following investigation.  While the Company cannot predict the outcome of any of the contingencies, the Company’s management does not believe that the outcome of any of these legal matters or regulatory proceedings will be material to the Company’s consolidated financial position.  It is possible, however, the Company’s results of operations or cash flows could be materially affected by unfavorable outcomes in outstanding legal matters or regulatory proceedings.

After the announcement of the then proposed merger between the Company and Walgreens Boots Alliance, Inc. (WBA), a putative class action lawsuit was filed in Pennsylvania in the Court of Common Pleas of Cumberland County (Wilson v. Rite Aid Corp., et al.) by a purported Company stockholder against the Company, its directors (the Individual Defendants, together with the Company, the Rite Aid Defendants), WBA and Victoria Merger Sub Inc. (Victoria) challenging the transactions contemplated by the merger agreement. The complaint alleged primarily that the Individual Defendants breached their fiduciary duties by, among other things, agreeing to an allegedly unfair and inadequate price, agreeing to deal protection devices that allegedly prevented the directors from obtaining higher offers from other interested buyers for the Company and allegedly failing to protect against certain purported conflicts of interest in connection with the merger. The complaint further alleged that the Company, WBA and/or Victoria aided and abetted these alleged breaches of fiduciary duty. The complaint sought, among other things, to enjoin the closing of the merger as well as money damages and attorneys’ and experts’ fees. The matter remains pending, but inactive.

Also in connection with that proposed merger, a lawsuit was filed in the United States District Court for the Middle District of Pennsylvania (the Pennsylvania District Court), asserting a claim for violations of Section 14(a) of the Exchange Act and SEC Rule 14a-9 against the Rite Aid Defendants, WBA and Victoria and a claim for violations of Section 20(a) of the Exchange Act against the Individual Defendants and WBA (Hering v. Rite Aid Corp., et al.). The complaint in the Hering action alleged, among other things, that the Rite Aid Defendants disseminated an allegedly false and materially misleading proxy and sought to enjoin the shareholder vote on the proposed merger, a declaration that the proxy was materially false and misleading in violation of federal securities laws and an award of money damages and attorneys’ and experts’ fees. On January 14 and 16, 2016, respectively, the plaintiff in the Hering action filed a motion for preliminary injunction and a motion for expedited discovery. On January 21, 2016, the Rite Aid Defendants filed a motion to dismiss the Hering complaint. At a hearing held on January 25, 2016, the Pennsylvania District Court orally denied the plaintiff’s motion for expedited discovery and subsequently denied the plaintiff’s motion for preliminary injunction on January 28, 2016. On March 14, 2016, the Pennsylvania District Court appointed Jerry Hering, Don Michael Hussey and Joanna Pauli Hussey as lead plaintiffs for the putative class and approved their selection of Robbins Geller Rudman & Dowd LLP as lead counsel. On April 14, 2016, the Pennsylvania District Court granted the lead plaintiffs’ unopposed motion to stay the Hering action for all purposes pending consummation of the merger.

On March 17, 2017, the Hering plaintiffs filed a motion to lift the stay for the purpose of filing a proposed amended complaint. Defendants opposed the motion, and briefing concluded on April 17, 2017. The proposed amended complaint asserted state law breach of fiduciary duty claims against the Individual Defendants, a claim of aiding and abetting the alleged breaches of fiduciary duty against Rite Aid, WBA and Victoria, as well as claims for violations of Section 14(a) of the Exchange Act and SEC Rule 14a-9 against the Rite Aid Defendants, WBA and Victoria, claims for violations of Section 10(b) of the Exchange Act and SEC Rule 10b-5 against the Rite Aid Defendants, WBA, Victoria and certain WBA executives, and a claim for violations of Section 20(a) of the Exchange Act against the Individual Defendants, WBA and Victoria. On August 4, 2017, the Pennsylvania District Court entered an order lifting the stay, noting that the original claims in this matter are now moot, and directed the plaintiffs to file a motion for leave to amend the complaint, with brief in support thereof, on or before September 15, 2017 which deadline was subsequently extended to September 22, 2017. On September 22, 2017, the lead plaintiffs gave notice that plaintiffs Don Michael Hussey and Joanna Pauli Hussey were withdrawing as lead plaintiffs, and that plaintiff Jerry Hering (the Lead Plaintiff) would continue to represent the proposed class in the Hering action going forward. That same day, Lead Plaintiff filed a motion for leave to file an amended complaint, which the Pennsylvania District Court granted on November 27, 2017. On December 11, 2017, Lead Plaintiff filed the amended complaint (the Amended Complaint), which alleges a claim for violations of Section 10(b) of the Exchange Act and SEC Rule 10b-5 and a claim for violations of Section 20(a) of the Exchange Act against the Rite Aid Defendants, WBA, and certain WBA executives. On February 14 and 16, 2018, the Rite Aid Defendants filed a motion to dismiss the Amended Complaint, and an opening brief in support thereof.  Briefing concluded on June 7, 2018.

In connection with the proposed merger between the Company and Albertsons Companies, Inc. (ACI), on April 24, 2018, a Rite Aid stockholder filed a putative class action lawsuit in the Court of Chancery of the State of Delaware against Rite Aid, ACI, Ranch Acquisition Corp. (Merger Sub I), Ranch Acquisition II LLC (Merger Sub II, together with ACI and Merger Sub I, the ACI defendants) and each of the Rite Aid directors (the Director defendants, together with Rite Aid, the Rite Aid defendants), Del. C.A. No. 2018-0305-AGB.  Plaintiff contends that Rite Aid stockholders have appraisal rights under Section 262 of the DGCL.  Plaintiff alleges breach of fiduciary duty claims against the Director defendants for their alleged failure to provide alleged statutory appraisal rights under Delaware law and for allegedly falsely informing Rite Aid stockholders that they will not have appraisal rights.  Plaintiff further contends that the proxy statement/prospectus related to the proposed merger, and which was filed on April 6, 2018, was deficient under Section 262(d)(1) of the DGCL for failure to inform stockholders of their alleged appraisal rights.  Plaintiff seeks declarations from the Court of Chancery that the action is a proper class action and that the Director defendants breached their fiduciary duties by failing to adequately inform class members of their appraisal rights under Delaware law, to enjoin the proposed action from closing until such time as class members are afforded the ability to seek appraisal of their shares, or otherwise permit class members to petition the Court of Chancery for appraisal, and attorneys’ fees, expenses, and costs to Plaintiff.  On May 9, 2018, the Court of Chancery denied Plaintiff’s motion to expedite and declined to schedule a preliminary injunction hearing, ruling that Plaintiff failed to state a colorable claim.  Defendants oppose Plaintiff’s claims on the ground that Rite Aid stockholders have no appraisal rights under the DGCL because they have a right to receive all stock consideration as described in the proxy statement/prospectus previously filed on April 6, 2018.  On May 16, 2018, the Rite Aid defendants and the ACI defendants each filed a Motion to Dismiss Plaintiff’s Verified Class Action Complaint (collectively, the “Motions to Dismiss”).  On June 6, 2018, the parties jointly stipulated that the briefing submitted by the parties in support of, and in opposition to, Plaintiff’s Motion for Expedited Proceedings shall constitute the briefing with respect to the Motions to Dismiss. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential rage of loss with respect to the lawsuit and is vigorously defending this lawsuit.

On June 29, 2018, a purported stockholder of the Company filed a Verified Complaint to Compel Inspection of Books and Records under 8 Del. C. §220 in the Delaware Court of Chancery against the Company, seeking to inspect books and records in order to determine whether wrongdoing or mismanagement has taken place such that it would be appropriate to file claims for breach of fiduciary duty, and to investigate the independence and disinterestedness of the Company's directors with respect to the proposed merger with ACI. The Company's response to this complaint is due on July 23, 2018.

The Company is currently a defendant in several lawsuits filed in courts in California alleging violations of California wage-and-hour laws, rules and regulations pertaining primarily to failure to pay overtime, failure to pay for missed meals and rest periods, failure to reimburse business expenses and failure to provide employee seating (the “California Cases”). Some of the California Cases purport or may be determined to be class actions and seek substantial damages and penalties. The single-plaintiff and multi-plaintiff California Cases regarding violations of wage-and-hour laws, failure to pay overtime and failure to pay for missed meals and rest periods, in the aggregate, seek substantial damages. The Company believes that its defenses and assertions in the California Cases, as well as other lawsuits, have merit. The Company has aggressively challenged the merits of the lawsuits and, where applicable, the allegations that the lawsuits should be certified as class or representative actions. Additionally, at this time the Company is not able to predict either the outcome of or estimate a potential range of loss with respect to the California Cases and is vigorously defending them.

In the employee seating lawsuit (Hall v. Rite Aid Corporation, San Diego County Superior Court), the Court, in October 2011, granted the plaintiff’s motion for class certification. The Company filed its motion for decertification, which motion was granted in November 2012. Plaintiff subsequently appealed the Court’s order which appeal was granted in May 2014. The Company filed a petition for review of the appellate court’s decision with the California Supreme Court, which petition was denied in August 2014. Proceedings in the Hall case were stayed pending a decision by the California Supreme Court in two similar lawsuits. That decision was rendered on April 4, 2016. A status conference in the case was held on November 18, 2016, at which time the court lifted the stay and scheduled the matter for trial on January 26, 2018. The trial scheduled to begin June 15, 2018 was adjourned by the Court.  A new trial date has not been scheduled by the Court. On February 2, 2018, the Court denied Rite Aid’s motion for summary judgment.

Following service of subpoenas on the Company in 2011 and 2013 by the United States Attorney’s Office for the Eastern District of Michigan (“USAO”) and the State of Indiana’s Office of the Attorney General, respectively, the Company cooperated with inquiries regarding the relationship of Rite Aid’s Rx Savings Program to the reporting of usual and customary charges to publicly funded health programs. In January 2017, the USAO, 18 states and the District of Columbia declined to intervene in a sealed False Claims Act (“FCA”) lawsuit filed by qui tam plaintiff Azam Rahimi (“Relator”) in the District Court for the Eastern District of Michigan. On January 19, 2017, the court unsealed Relator’s Second Amended Complaint against the Company; it alleges that the Company failed to report Rx Savings prices as its usual and customary charges under the Medicare Part D program and to federal and state Medicaid programs in 18 states and the District of Columbia; and that the Company is thus liable under the federal FCA and similar state statutes. In its ruling on the Company’s motion to dismiss the complaint, the Court held that Relator’s complaint was deficient, but allowed Relator the opportunity to re-plead.  Relator filed a Third Amended Complaint on May 11, 2018.  The Company filed a motion to dismiss the Third Amended Complaint on May 25, 2018, which is pending. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit and is vigorously defending this lawsuit.

On April 26, 2012, the Company received an administrative subpoena from the U.S. Drug Enforcement Administration (“DEA”), Albany, New York District Office, requesting information regarding the Company’s sale of products containing pseudoephedrine (“PSE”). In April 2012, it also received a communication from the U.S. Attorney’s Office (“USAO”) for the Northern District of New York concerning an investigation of possible civil violations of the Combat Methamphetamine Epidemic Act of 2005 (“CMEA”). Additional subpoenas were issued in 2013, 2014, and 2015 seeking broader documentation regarding PSE sales and recordkeeping requirements. Assistant U.S. Attorneys from the Northern and Eastern Districts of New York and the Southern District of West Virginia are currently investigating, but no lawsuits have been filed. Violations of the CMEA could result in the imposition of administrative and/or civil penalties against the Company. The Company has entered into tolling agreements with the United States, and discussions have been held to attempt to resolve these matters with those USAOs and the Department of Justice, but whether any agreements can be reached and on what terms is uncertain. At this stage of the investigation, the Company is not able to predict the outcome of the investigation.

In December 2017, Rite Aid executed a non-prosecution agreement with the United States Attorney’s Office for the Southern District of West Virginia (countersigned by the government in January 2018), which concluded the previous criminal investigation into Rite Aid’s PSE sales. Pursuant to that agreement, the government agreed not to bring any criminal charges against Rite Aid, and Rite Aid agreed to pay an immaterial amount of money as restitution.  The civil investigation is ongoing.

In June 2013, the Company was served with a Civil Investigative Demand (“CID”) by the United States Attorney’s Office for the Eastern District of California (the “USAO”) regarding (1) the Company’s Drug Utilization Review (“DUR”) and prescription dispensing protocol; and (2) the dispensing of drugs designated as “Code 1” by the State of California. The Company cooperated with the investigation, researched the government’s allegations, and refuted the government’s position. The Company produced documents including certain prescription files related to Code 1 drugs to the USAO’s office and the State of California Department of Justice’s Bureau of Medical Fraud and Elder Abuse (“CADOJ”). In August 2014, the USAO and 8 states’ attorneys general declined to intervene in a California False Claim Act (“FCA”) action (“Action”) filed under seal in the Eastern District of California by qui tam plaintiff Loyd F. Schmuckley (“Relator”) based on DUR and Code 1 allegations. In July 2016, the Commonwealth of Massachusetts and the District of Columbia also declined to intervene in the Action. On May 15, 2017, Relator and the CADOJ stipulated to dismiss all DUR-related claims and 18 other state-based claims. On September 21, 2017, the CADOJ filed a sealed complaint-in-intervention in the Action, asserting causes under the FCA, for unjust enrichment and for payment by mistake related to the Code 1 allegations. The Action was unsealed on September 26, 2017. On September 28, 2017, Relator filed a First Amended Complaint under the FCA also concerning the Code 1 allegations. The Company filed a motion to dismiss Relator’s and CADOJ’s respective complaints in January 2018, the hearing was held on March 23, 2018, and the court’s order remains pending. At this stage of the proceedings, the Company is not able to either predict the outcome of this matter or estimate a potential range of loss with respect to this matter and is vigorously defending this lawsuit.

The State of Mississippi, by and through its Attorney General, filed a First Amended Complaint against the Company and various purported related entities on September 27, 2016 alleging violations of the Mississippi Medicaid Fraud Control Act, violations of the Mississippi Unfair and Deceptive Trade Practices Act, fraud and unjust enrichment. The Complaint alleges the Company failed to accurately report usual and customary prices to Mississippi’s Division of Medicaid. On November 14, 2016, the Company filed motions to dismiss based on substantive and jurisdictional grounds, as well as a motion to transfer venue. These motions are pending and the lawsuit is stayed while related litigation is on appeal. At this stage of the proceedings, the Company is not able to either predict the outcome of this lawsuit or estimate a potential range of loss with respect to the lawsuit and is vigorously defending this lawsuit.

In December 2017, the United States Judicial Panel on multidistrict litigation ordered consolidated numerous lawsuits filed against various defendants by plaintiffs such as counties, cities, hospitals, and third-party payors, alleging claims generally concerning the impacts of widespread opioid abuse. The consolidated multidistrict litigation is In re National Prescription Opiate Litigation (MDL No. 2804), pending in the U.S. District Court for the Northern District of Ohio. This multidistrict litigation presumptively includes relevant federal court lawsuits that name the Company, including lawsuits filed by counties and municipalities in California, Indiana, Maryland, Michigan, Missouri, New Jersey, North Carolina, Ohio, West Virginia, and Wisconsin.  Similar lawsuits that name the Company in some capacity have been filed in state courts, including lawsuits filed by Shelby County, Tennessee, Shelby County (Tennessee) v. Purdue Pharma, L.P. et al.; several counties and cities in West Virginia, Brooke County (West Virginia) et al. v. Purdue Pharma L.P., et al. and City of Huntington (West Virginia) et al. v. Express Scripts Holding Company, et al,; several counties in South Carolina, County of Spartanburg (South Carolina) v. Rite Aid of South Carolina, Inc. et al., County of Greenville (South Carolina) v. Rite Aid of South Carolina, Inc., et al., and County of Anderson v. Rite Aid of South Carolina, Inc., et al; Camden County, New Jersey, Camden County, New Jersey v. Purdue Pharma L.P., et al; two counties in Oklahoma, The Board of County Commissioners of Delaware County, State of Oklahoma v. Purdue Pharma L.P., et al. and The Board of County Commissioners of Ottawa County, State of Oklahoma v. Purdue Pharma L.P., et al.; the city of Parma Heights, Ohio, The City of Parma Heights, Ohio v. Purdue Pharma L.P., et al.; and the city of Atlanta, Georgia, The City of Atlanta v. Purdue Pharma, LP, et al. At this stage of the proceedings, the Company is not able to either predict the outcome of these lawsuits or estimate a potential range of loss with respect to the lawsuits and is vigorously defending them.

The Company is involved in two putative consumer class action lawsuits in the United States District Court for the Southern District of California, alleging that it has overcharged customers’ insurance companies for prescription drug purchases, resulting in overpayment of co-pays.  The first lawsuit, Byron Stafford v. Rite Aid Corp., Case No. 17-CV-01340-AJB-JLB, was filed on June 30, 2017, and the second case, Robert Josten v. Rite Aid Corp., Case No. 18-CV-00152-AJB-JLB, was filed on January 23, 2018.  Each lawsuit alleges that (1) the Company was obligated to charge the plaintiffs’ insurance companies a “usual and customary” price for their prescription drugs; and (2) the Company failed to do so properly because the prices it reported were not equal to or adjusted to account for the discount prices that Rite Aid offers to uninsured and underinsured customers through its Rx Savings Program.  On December 19, 2017, the court granted the Company’s motion to dismiss Stafford’s complaints with leave to amend for failure to plead compliance with the applicable statutes of limitations.  After Stafford amended the complaint on January 9, 2018, the Company filed another motion to dismiss on January 23, 2018, and a similar motion to dismiss Josten’s complaint on March 16, 2018.  Both motions are fully briefed and are awaiting a decision from the court.  At this stage of the proceedings, the Company is not able to either predict the outcome of these lawsuits or estimate a potential range of loss with respect to the lawsuit and is vigorously defending these lawsuits.

In addition to the above described matters, the Company is subject from time to time to various claims and lawsuits and governmental investigations arising in the ordinary course of business.  While the Company’s management cannot predict the outcome of any of the claims, the Company’s management does not believe that the outcome of any of these matters will be material to the Company’s consolidated financial position.  It is possible, however, that the Company’s results of operations or cash flows could be materially affected by an unfavorable resolution of pending litigation or contingencies.

XML

Guarantor and Non-Guarantor Condensed Consolidating Financial Information

3 Months Ended

Jun. 02, 2018

Guarantor and Non-Guarantor Condensed Consolidating Financial Information

Guarantor and Non-Guarantor Condensed Consolidating Financial Information

14. Guarantor and Non-Guarantor Condensed Consolidating Financial Information

Rite Aid Corporation conducts the majority of its business through its subsidiaries. With the exception of EIC, substantially all of Rite Aid Corporation’s 100 percent owned subsidiaries guarantee the obligations under the Amended and Restated Senior Secured Credit Facility, second priority secured term loan facilities, secured guaranteed notes and unsecured guaranteed notes (the “Subsidiary Guarantors”). Additionally, with the exception of EIC, the subsidiaries, including joint ventures, that do not guarantee the Amended and Restated Senior Secured Credit Facility, second priority secured term loan facilities, secured guaranteed notes and unsecured guaranteed notes, are minor.

For the purposes of preparing the information below, Rite Aid Corporation uses the equity method to account for its investment in subsidiaries. The equity method has been used by Subsidiary Guarantors with respect to investments in the non-guarantor subsidiaries. The subsidiary guarantees related to the Company’s Amended and Restated Senior Secured Credit Facility, second priority secured term loan facilities and secured guaranteed notes and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several. Presented below is condensed consolidating financial information for Rite Aid Corporation, the Subsidiary Guarantors, and the non-guarantor subsidiaries at June 2, 2018, March 3, 2018, and for the thirteen week periods ended June 2, 2018 and June 3, 2017. Separate financial statements for Subsidiary Guarantors are not presented.

	Rite Aid Corporation Condensed Consolidating Balance Sheet June 2, 2018 (unaudited)
	Rite Aid Corporation (Parent Company Only)		Subsidiary Guarantors		Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	138,400	$	8,692	$	—		$	147,092
Accounts receivable, net	—		1,390,296		518,659		—			1,908,955
Intercompany receivable	—		337,627		—		(337,627		)(a)	—
Inventories, net of LIFO reserve of $0, $591,056, $0, $0, and $591,056	—		1,809,595		—		—			1,809,595
Prepaid expenses and other current assets	—		147,760		3,299		—			151,059
Current assets held for sale	—		179,442		—		—			179,442
Total current assets	—		4,003,120		530,650		(337,627		)	4,196,143
Property, plant and equipment, net	—		1,401,924		—		—			1,401,924
Goodwill	—		1,421,120		—		—			1,421,120
Other intangibles, net	—		518,167		50,753		—			568,920
Deferred tax assets	—		522,674		—		—			522,674
Investment in subsidiaries	8,971,553		52,591		—		(9,024,144		)(b)	—
Intercompany receivable	—		3,949,896		—		(3,949,896		)(a)	—
Other assets	—		211,415		7,257		—			218,672
Total assets	$	8,971,553	$	12,080,907	$	588,660	$	(13,311,667	)	$	8,329,453
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	90	$	18,935	$	—	$	—		$	19,025
Accounts payable	—		1,762,078		5,699		—			1,767,777
Intercompany payable	—		—		337,627		(337,627		)(a)	—
Accrued salaries, wages and other current liabilities	74,552		781,315		174,425		—			1,030,292
Total current liabilities	74,642		2,562,328		517,751		(337,627		)	2,817,094
Long-term debt, less current maturities	3,134,704		—		—		—			3,134,704
Lease financing obligations, less current maturities	—		28,874		—		—			28,874
Intercompany payable	3,949,896		—		—		(3,949,896		)(a)	—
Other noncurrent liabilities	—		518,152		18,318		—			536,470
Total liabilities	7,159,242		3,109,354		536,069		(4,287,523		)	6,517,142
Commitments and contingencies	—		—		—		—			—
Total stockholders’ equity	1,812,311		8,971,553		52,591		(9,024,144		)(b)	1,812,311
Total liabilities and stockholders’ equity	$	8,971,553	$	12,080,907	$	588,660	$	(13,311,667	)	$	8,329,453

(a) Elimination of intercompany accounts receivable and accounts payable amounts.

(b) Elimination of investments in consolidated subsidiaries.

	Rite Aid Corporation Condensed Consolidating Balance Sheet March 3, 2018
	Rite Aid Corporation (Parent Company Only)		Subsidiary Guarantors		Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	441,244	$	6,090	$	—		$	447,334
Accounts receivable, net	—		1,502,507		366,593		—			1,869,100
Intercompany receivable			223,413		—		(223,413		)(a)	—
Inventories, net of LIFO reserve of $0, $581,090, $0, $0, and $581,090	—		1,799,539		—		—			1,799,539
Prepaid expenses and other current assets	—		176,678		4,503		—			181,181
Current assets held for sale	—		438,137		—		—			438,137
Total current assets	—		4,581,518		377,186		(223,413		)	4,735,291
Property, plant and equipment, net	—		1,431,246		—		—			1,431,246
Goodwill	—		1,421,120		—		—			1,421,120
Other intangibles, net	—		539,115		51,328		—			590,443
Deferred tax assets	—		594,019		—		—			594,019
Investment in subsidiaries	8,745,390		54,076		—		(8,799,466		)(b)	—
Intercompany receivable	—		3,189,419		—		(3,189,419		)(a)	—
Other assets	—		209,926		7,282		—			217,208
Noncurrent assets held for sale	—		—		—		—			—
Total assets	$	8,745,390	$	12,020,439	$	435,796	$	(12,212,298	)	$	8,989,327
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	90	$	20,671	$	—	$	—		$	20,761
Accounts payable	—		1,641,676		9,687		—			1,651,363
Intercompany payable	—		—		223,413		(223,413		)(a)	—
Accrued salaries, wages and other current liabilities	65,223		1,031,379		135,134		—			1,231,736
Current liabilities held for sales	549,549		10,656		—		—			560,205
Total current liabilities	614,862		2,704,382		368,234		(223,413		)	3,464,065
Long-term debt, less current maturities	3,340,099		—		—		—			3,340,099
Lease financing obligations, less current maturities	—		30,775		—		—			30,775
Intercompany payable	3,189,419		—		—		(3,189,419		)(a)	—
Other noncurrent liabilities	—		539,892		13,486		—			553,378
Noncurrent liabilities held for sale	—		—		—		—			—
Total liabilities	7,144,380		3,275,049		381,720		(3,412,832		)	7,388,317
Commitments and contingencies	—		—		—		—			—
Total stockholders’ equity	1,601,010		8,745,390		54,076		(8,799,466		)(b)	1,601,010
Total liabilities and stockholders’ equity	$	8,745,390	$	12,020,439	$	435,796	$	(12,212,298	)	$	8,989,327

(a) Elimination of intercompany accounts receivable and accounts payable amounts.

(b) Elimination of investments in consolidated subsidiaries.

	Rite Aid Corporation Condensed Consolidating Statement of Operations For the Thirteen Weeks Ended June 2, 2018 (unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Revenues	$	—		$	5,321,025		$	95,584		$	(28,119	)(a)	$	5,388,490
Costs and expenses:
Cost of revenues	—			4,158,627			89,032			(27,918		)(a)	4,219,741
Selling, general and administrative expenses	—			1,144,832			7,996			(201		)(a)	1,152,627
Lease termination and impairment charges	—			9,859			—			—			9,859
Interest expense	59,939			2,946			(93		)	—			62,792
Loss on debt retirements	—			554			—			—			554
Gain on sale of assets, net	—			(5,859		)	—			—			(5,859		)
Equity in earnings of subsidiaries, net of tax	(278,970		)	1,485			—			277,485		(b)	—
	(219,031		)	5,312,444			96,935			249,366			5,439,714
Income (loss) from continuing operations before income taxes	219,031			8,581			(1,351		)	(277,485		)	(51,224		)
Income tax expense (benefit)	—			(9,631		)	134			—			(9,497		)
Net income (loss) from continuing operations	$	219,031		$	18,212		$	(1,485	)	$	(277,485	)(b)	$	(41,727	)
Net income (loss) from discontinued operations	(4,615		)	260,758			—			—			256,143
Net income (loss)	214,416			278,970			(1,485		)	(277,485		)	214,416
Total other comprehensive income (loss)	364			364			—			(364		)	364
Comprehensive (loss) income	$	214,780		$	279,334		$	(1,485	)	$	(277,849	)	$	214,780

(a) Elimination of intercompany revenues and expenses.

(b) Elimination of equity in earnings of subsidiaries.

	Rite Aid Corporation Condensed Consolidating Statement of Operations For the Thirteen Weeks Ended June 3, 2017 (unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Revenues	$	—		$	5,415,128		$	39,450		$	(18,055	)(a)	$	5,436,523
Costs and expenses:
Cost of revenues	—			4,255,202			37,902			(18,524		)(a)	4,274,580
Selling, general and administrative expenses	—			1,157,270			3,201			469		(a)	1,160,940
Lease termination and impairment expenses	—			4,038			—			—			4,038
Interest expense	46,447			4,515			38			—			51,000
Gain on sale of assets, net	—			(5,877		)	—			—			(5,877		)
Equity in earnings of subsidiaries, net of tax	(30,035		)	1,312			—			28,723		(b)	—
	16,412			5,416,460			41,141			10,668			5,484,681
Earnings from continuing operations before income taxes	(16,412		)	(1,332		)	(1,691		)	(28,723		)	(48,158		)
Income tax expense (benefit)	—			(11,742		)	(379		)	—			(12,121		)
Net income (loss) from continuing operations	(16,412		)	10,410			(1,312		)	(28,723		)	(36,037		)
Net income (loss) from discontinued operations	(58,937		)	19,625			—			—			(39,312		)
Net income (loss)	$	(75,349	)	$	30,035		$	(1,312	)	$	(28,723	)(b)	$	(75,349	)
Total other comprehensive income (loss)	514			514			—			(514		)	514
Comprehensive (loss) income	$	(74,835	)	$	30,549		$	(1,312	)	$	(29,237	)	$	(74,835	)

(a) Elimination of intercompany revenues and expenses.

(b) Elimination of equity in earnings of subsidiaries.

	Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Thirteen Weeks Ended June 2, 2018 (unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Operating activities:
Net cash (used in) provided by operating activities	$	(48,608	)	$	29,692		$	2,602	$	—		$	(16,314	)
Investing activities:
Payments for property, plant and equipment	—			(47,971		)	—		—			(47,971		)
Intangible assets acquired	—			(13,655		)	—		—			(13,655		)
Intercompany activity	—			(813,705		)	—		813,705			—
Proceeds from dispositions of assets and investments	—			9,916			—		—			9,916
Proceeds from sale-leaseback transactions	—			2,587			—		—			2,587
Net cash (used in) provided by investing activities	—			(862,828		)	—		813,705			(49,123		)
Financing activities:
Net proceeds from revolver	190,000			—			—		—			190,000
Principal payments on long-term debt	(426,361		)	(4,745		)	—		—			(431,106		)
Change in zero balance cash accounts	—			1,083			—		—			1,083
Net proceeds from issuance of common stock	910			—			—		—			910
Financing fees paid for early redemption	—			(13		)	—		—			(13		)
Intercompany activity	813,705			—			—		(813,705		)	—
Net cash provided by (used in) financing activities	578,254			(3,675		)	—		(813,705		)	(239,126		)
Cash flows of discontinued operations:
Operating activities of discontinued operations	(4,615		)	(69,435		)	—		—			(74,050		)
Investing activities of discontinued operations	—			603,402			—		—			603,402
Financing activities of discontinued operations	(525,031		)	—			—		—			(525,031		)
Net cash (used in) provided by discontinued operations	(529,646		)	533,967			—		—			4,321
(Decrease) increase in cash and cash equivalents	—			(302,844		)	2,602		—			(300,242		)
Cash and cash equivalents, beginning of period	—			441,244			6,090		—			447,334
Cash and cash equivalents, end of period	$	—		$	138,400		$	8,692	$	—		$	147,092

	Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Thirteen Weeks Ended June 3, 2017 (unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Operating activities:
Net cash (used in) provided by operating activities	$	(13,020	)	$	60,294		$	495	$	—		$	47,769
Investing activities:
Payments for property, plant and equipment	—			(38,325		)	—		—			(38,325		)
Intangible assets acquired	—			(5,521		)	—		—			(5,521		)
Intercompany activity	—			(161,810		)	—		161,810			—
Proceeds from insured loss	—			8,639			—		—			8,639
Proceeds from dispositions of assets and investments	—			2,137			—		—			2,137
Net cash (used in) provided by investing activities	—			(194,880		)	—		161,810			(33,070		)
Financing activities:
Net payments to revolver	(90,000		)	—			—		—			(90,000		)
Principal payments on long-term debt	—			(3,503		)	—		—			(3,503		)
Change in zero balance cash accounts	—			28,768			—		—			28,768
Net proceeds from issuance of common stock	147			—			—		—			147
Payments for taxes related to net share settlement of equity awards	—			(147		)	—		—			(147		)
Intercompany activity	161,810			—			—		(161,810		)	—
Net cash provided by (used in) financing activities	71,957			25,118			—		(161,810		)	(64,735		)
Cash flows of discontinued operations:
Operating activities of discontinued operations	(58,937		)	103,902			—		—			44,965
Investing activities of discontinued operations	—			(25,126		)	—		—			(25,126		)
Financing activities of discontinued operations	—			(764		)	—		—			(764		)
Net cash (used in) provided by discontinued operations	(58,937		)	78,012			—		—			19,075
(Decrease) increase in cash and cash equivalents	—			(31,456		)	495		—			(30,961		)
Cash and cash equivalents, beginning of period	—			213,104			32,306		—			245,410
Cash and cash equivalents, end of period	$	—		$	181,648		$	32,801	$	—		$	214,449

XML

Tax Benefits Preservation Plan

3 Months Ended

Jun. 02, 2018

Tax Benefits Preservation Plan

Tax Benefits Preservation Plan

15. Tax Benefits Preservation Plan

On March 25, 2018, the Board of Directors of the Company approved, and on March 27, 2018, the Company and Broadridge Corporate Issuer Solutions, as rights agent, entered into an amendment to the Tax Benefits Preservation Plan that the Company entered into on January 3, 2018 (the “Amendment”). The Amendment changed the final expiration date with respect to the Rights issued under the Plan to 5:00 P.M. (New York City time) on March 27, 2018. In accordance with the terms of the Plan, as amended by the Amendment, all of the Rights then outstanding expired at 5:00 P.M. (New York City time) on March 27, 2018, and no Rights are to be issued from and after that time.

XML

Supplementary Cash Flow Data

3 Months Ended

Jun. 02, 2018

Supplementary Cash Flow Data

Supplementary Cash Flow Data

16. Supplementary Cash Flow Data

	Thirteen Weeks Ended
	June 2, 2018		June 3, 2017
Cash paid for interest(a)	$	53,553	$	75,535
Cash payments for income taxes, net(a)	$	591	$	1,461
Equipment financed under capital leases	$	1,963	$	3,857
Equipment received for noncash consideration	—		$	1,295
Reduction in lease financing obligation	—		$	2,416
Gross borrowings from revolver(a)	$	444,000	$	579,000
Gross repayments to revolver(a)	$	254,000	$	669,000

(a)—Amounts are presented on a total company basis.

XML

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Jun. 02, 2018

Summary of Significant Accounting Policies

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. The accompanying financial information reflects all adjustments which are of a recurring nature and, in the opinion of management, are necessary for a fair presentation of the results for the interim periods. The results of operations for the thirteen week period ended June 2, 2018 are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Rite Aid Corporation (“Rite Aid”) and Subsidiaries (together with Rite Aid, the “Company”) Fiscal 2018 10-K.

The discussion and presentation of the operating and financial results of our business segments have been impacted by the following event.

Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement (the “Amended and Restated Asset Purchase Agreement”), dated as of September 18, 2017, by and among Rite Aid, WBA and Walgreen Co., an Illinois corporation and wholly owned direct subsidiary of WBA (“Buyer”), Buyer agreed to purchase from Rite Aid 1,932 stores (the “Acquired Stores”), three distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of approximately $4.375 billion, on a cash free, debt free basis (the “Asset Sale” or the “Sale”). As of March 27, 2018, the Company has sold all 1,932 Acquired Stores and related assets to WBA in exchange for proceeds of $4,156.7 million, which were used to repay outstanding debt. Based on its magnitude and because the Company is exiting certain markets, the Sale represents a significant strategic shift that has a material effect on the Company’s operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Asset Sale as required by Accounting Standards Codification 210-05—Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the assets and liabilities to be sold, including the 1,932 Acquired Stores, three (3) distribution centers, related inventory and other specified assets and liabilities related thereto (collectively the “Assets to be Sold” or “Disposal Group”) to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended June 2, 2018 and March 3, 2018, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. Additionally, corporate support activities related to the Disposal Group were not reclassified to discontinued operations. Please see additional information as provided in Note 3 Asset Sale to WBA.

Revenue Recognition

Revenue Recognition

Retail Pharmacy Segment

For front end sales, the Retail Pharmacy segment recognizes revenues upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation at the point of sale for front end transactions. The Retail Pharmacy segment front end revenue is measured based on the amount of fixed consideration that we expect to receive, net of an allowance for estimated future returns. Return activity is immaterial to revenues and results of operations in all periods presented.

For pharmacy sales, the Retail Pharmacy segment recognizes revenue upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation, upon pickup by the customer, which is when the customer takes title to the product.  Each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims.  The Company’s revenue is measured based on the amount of fixed consideration that we expect to receive, reduced by refunds owed to the third party payor for pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not highly subjective or volatile.  The effect of adjustments between estimated and actual amounts have not been material to the Company’s results of operations or financial position. Prescriptions are generally not returnable.

The Retail Pharmacy segment offers a chain-wide loyalty card program titled wellness +. Individual customers are able to become members of the wellness + program.  Members participating in the wellness + loyalty card program earn points on a calendar year basis for eligible front end merchandise purchases and qualifying prescription purchases which may be redeemed to pay for future purchases. One point is awarded for each dollar spent towards front end merchandise and 25 points are awarded for each qualifying prescription.

Members reach specific wellness + tiers based on the points accumulated during the calendar year, which entitles such customers to certain future discounts and other benefits upon reaching that tier. For example, any customer that reaches 1,000 points in a calendar year achieves the “Gold” tier, enabling him or her to receive a 20% discount on qualifying purchases of front end merchandise for the remaining portion of the calendar year and also the next calendar year. There is also a similar “Silver” level with a lower threshold and benefit level.

Points earned pursuant to the wellness+ program represent a performance obligations and the Company allocates revenue between the merchandise purchased and the wellness + points based on the relative stand-alone selling price of each performance obligation. The relative value of the wellness + points is initially deferred as a contract liability (included in other current and noncurrent liabilities). As customers redeem the points to receive discounted front end merchandise or when the points expire, the Retail Pharmacy segment recognizes an allocable portion of the deferred contract liability into revenue. The Retail Pharmacy segment had accrued contract liabilities of $73,191 as of June 2, 2018, of which $49,793 is included in other current liabilities and $23,398 is included in noncurrent liabilities. The Retail Pharmacy segment had accrued contract liabilities of $63,851 as of March 3, 2018, of which $50,036 is included in other current liabilities and $13,815 is included in noncurrent liabilities.

The wellness + program also allows a customer to earn Bonus Cash based on qualifying purchases. Wellness + Rewards members have the opportunity to redeem his or her accumulated Bonus Cash on a future purchase with a 60 day expiration window. All Bonus Cash is redeemed using a FIFO methodology (i e., first Bonus Cash earned are the first to be redeemed).

For a majority of the Bonus Cash issuances, funding is provided by our vendors through contractual arrangements. This funding is treated as a contract liability and remains a contract liability until i) a wellness + Rewards members redeem their Bonus Cash, or ii) wellness + Rewards members allow the Bonus Cash to expire. Upon redemption or expiration, the Retail Pharmacy segment recognizes an allocable portion of the accrued contract liability into revenue. For Bonus Cash issuances that are not vendor funded, the contract liability is recorded at the time of issuance through a reduction to revenues, and not recognized until the Bonus Cash is redeemed or expires.

Pharmacy Services Segment

The Pharmacy Services segment sells prescription drugs indirectly through its retail pharmacy network and directly through its mail service dispensing pharmacy. The Pharmacy Services segment recognizes revenue from prescription drugs sold by (i) its mail service dispensing pharmacy and (ii) under retail pharmacy network contracts where it is the principal at the contract prices negotiated with its clients, primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans, Medicare plans, and other sponsors of health benefit plans, and individuals throughout the United States. Revenues include: (i) the portion of the price the client pays directly to the Pharmacy Services segment, net of any volume-related or other discounts paid back to the client (see “Drug Discounts” below), (ii) the price paid to the Pharmacy Services segment by client plan members for mail order prescriptions (“Mail Co-Payments”) (iii) client plan member copayments made directly to the retail pharmacy network, and (iv) administrative fees. Revenue is recognized when the Pharmacy Services segment meets its performance obligations relative to each transaction type, The following revenue recognition policies have been established for the Pharmacy Services segment:

· Revenues generated from prescription drugs sold by third party pharmacies in the Pharmacy Services segment’s retail pharmacy network and associated administrative fees are recognized at the Pharmacy Services segment’s point-of-sale, which is when the claim is adjudicated by the Pharmacy Services segment’s online claims processing system.  At this point the Company has performed all of its performance obligations.

· Revenues generated from prescription drugs sold by the Pharmacy Services segment’s mail service dispensing pharmacy are recognized when the prescription is shipped. At the time of shipment, the Pharmacy Services segment has performed all of its performance obligations under its client contracts, as control of and title to the product has passed to the clients plan member.  The Pharmacy Services segment does not experience a significant level of returns or reshipments.

· Revenues generated from administrative fees based on membership or claims volume are recognized monthly based on the terms within the individual contracts, either a monthly member based fee, or a claims volume based fee.

In the majority of its contracts, the Pharmacy Services segment is the principal because its client contracts give clients the right to obtain access to its pharmacy contracts under which the Pharmacy Services segment directs its pharmacy network to provide the services (drug dispensing, consultation, etc.) and goods (prescription drugs) to the clients’ members at its  negotiated pricing. The Pharmacy Services segment’s obligations under its client contracts are separate and distinct from its obligations to the third party pharmacies included in its retail pharmacy network contracts. Pursuant to these contracts, the Pharmacy Services segment is contractually required to pay the third party pharmacies in its retail pharmacy network for products sold after payment is received from its clients. The Pharmacy Services segment has control over these transactions until the prescription is transferred to the member and, thus, that it is acting as a principal. As such, the Pharmacy Services segment records the total prescription price contracted with clients in revenues.

Amounts paid to pharmacies and amounts charged to clients are exclusive of the applicable co-payment under Pharmacy Services segment contracts. Retail pharmacy co-payments, which we instruct retail pharmacies to collect from members, are included in our revenues and our cost of revenues.

For contracts under which the Pharmacy Services segment acts as an agent or does not control the prescription drugs prior to transfer to the client, no revenue is recognized.

Drug Discounts—The Pharmacy Services segment deducts from its revenues that are generated from prescription drugs sold by third party pharmacies any rebates, inclusive of discounts and fees, earned by its clients based on utilization levels and other factors as negotiated with the prescription drug manufacturers or suppliers. Rebates are paid to clients in accordance with the terms of client contracts.

Medicare Part D—The Pharmacy Services segment, through its EIC subsidiary, participates in the federal government’s Medicare Part D program as a Prescription Drug Plan (“PDP”). Please refer to Note 8, Medicare Part D.

Disaggregation of Revenue

The following table disaggregates the Company’s revenue by major source in each segment for the thirteen week period ended June 2, 2018:

In millions	For the thirteen week period ended June 2, 2018
Retail Pharmacy segment:
Pharmacy sales	$	2,565,286
Front end sales	1,296,147
Other revenue	36,332
Total Retail Pharmacy segment	$	3,897,765
Pharmacy Services segment	1,542,762
Intersegment elimination	(52,037		)
Total revenue	$	5,388,490

Impact of New Revenue Recognition Standard on Financial Statement Line Items

The Company adopted the new revenue standard using the modified retrospective method. The cumulative effect of applying the new standard to all contracts was recorded as an adjustment to accumulated deficit as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue standard, the following adjustments were made to accounts on the condensed consolidated balance sheet as of March 4, 2018:

	Impact of Change in Accounting Policy
	As Reported						Adjusted
In millions	March 3, 2018			Adjustments			March 4, 2018
Condensed Consolidated Balance Sheet:
Accounts receivable, net	$	1,869,100		$	(57,897	)	$	1,811,203
Inventories, net	1,799,539			51,121			1,850,660
Deferred tax assets	594,019			(1,772		)	592,247
Total assets	8,989,327			(8,548		)	8,980,779
Accumulated deficit	(4,282,471		)	(8,548		)	(4,291,019		)
Total shareholders’ equity	1,601,010			(8,548		)	1,592,462

Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted

Recently adopted accounting pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU No. 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU No. 2016-08, “Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net),” which amends the principal-versus-agent implementation guidance and in April 2016, the FASB issued ASU No. 2016-10, “Identifying Performance Obligations and Licensing,” which amends the guidance in those areas in the new revenue recognition standard. These ASUs, collectively the “new revenue standard”, are effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018.

The Company adopted the new revenue standard as of March 4, 2018 using the modified retrospective method and applying the new standard to all contracts with customers.  Therefore, the comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods.  In connection with the adoption of the new revenue standard, the Company identified one difference in its Retail Pharmacy segment related to the timing of revenue recognition for third party prescription revenues, which was historically recognized at the time the prescription was filled.  Upon adoption of ASU No. 2014-09, this revenue is recognized at the time the customer takes possession of the merchandise. In connection with its March 4, 2018 adoption of the new revenue standard on a modified retrospective basis, the Company recorded a reduction to accounts receivable of $57,897, a reduction to deferred tax assets of $1,772, an increase to inventory of $51,121, and a corresponding increase to accumulated deficit of $8,548 within its Retail Pharmacy segment.

In addition, the Company identified revenues under one specific rebate administration program under which the Company’s Pharmacy Services segment was determined to be the principal and historically recognized revenues and cost of revenues on a gross basis of approximately $123,500 during fiscal 2018. Upon adoption of the new revenue standard, the Company is required to record revenue from this program on a net basis.   The Company expects the impact of the adoption of the new revenue standard to be immaterial to its revenues, net income, and cash flows on an ongoing basis.

The following is a discussion of the Company’s revenue recognition policies by segment under the new revenue recognition accounting standard:

Recently Issued Accounting Pronouncements Not Yet Adopted

In February 2016, the FASB issued ASU No. 2016-02, Leases, (Topic 842), which is intended to improve financial reporting around leasing transactions. The ASU affects all companies and other organizations that engage in lease transactions (both lessee and lessor) that lease assets such as real estate and manufacturing equipment. This ASU will require organizations that lease assets—referred to as “leases”—to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. ASU No. 2016-02 is effective for fiscal years and interim periods within those years beginning January 1, 2019 (fiscal 2020). On January 5, 2018 the FASB issued an exposure draft amending certain aspects of the new leasing standard. The proposed amendments include a provision to allow entities to elect not to restate comparative periods in the period of adoption when transitioning to the new standard and instead allow a modified retrospective approach. The Company believes that the new standard will have a material impact on its financial position. The Company is currently evaluating the impact this standard implementation will have on its results of operations and cash flows.

XML

Basis of Presentation (Tables)

3 Months Ended

Jun. 02, 2018

Summary of Significant Accounting Policies

Schedule of revenues

In millions	For the thirteen week period ended June 2, 2018
Retail Pharmacy segment:
Pharmacy sales	$	2,565,286
Front end sales	1,296,147
Other revenue	36,332
Total Retail Pharmacy segment	$	3,897,765
Pharmacy Services segment	1,542,762
Intersegment elimination	(52,037		)
Total revenue	$	5,388,490

Schedule of impact of the Company's adoption of the ASU on the prior period consolidated balance sheet

	Impact of Change in Accounting Policy
	As Reported						Adjusted
In millions	March 3, 2018			Adjustments			March 4, 2018
Condensed Consolidated Balance Sheet:
Accounts receivable, net	$	1,869,100		$	(57,897	)	$	1,811,203
Inventories, net	1,799,539			51,121			1,850,660
Deferred tax assets	594,019			(1,772		)	592,247
Total assets	8,989,327			(8,548		)	8,980,779
Accumulated deficit	(4,282,471		)	(8,548		)	(4,291,019		)
Total shareholders’ equity	1,601,010			(8,548		)	1,592,462

XML

Asset Sale to WBA (Tables)

3 Months Ended

Jun. 02, 2018

Asset Sale to WBA

Schedule of discontinued operations

	June 2, 2018		March 3, 2018
Inventories	$	111,001	$	264,286
Property and equipment	68,441		158,433
Goodwill(a)	—		4,629
Intangible assets	—		10,789
Current assets held for sale	$	179,442	$	438,137
Current maturities of long-term lease financing obligations	$	—	$	270
Accrued salaries, wages and other current liabilities	—		6,146
Long-term debt, less current maturities(b)	—		549,549
Lease financing obligations, less current maturities	—		838
Other noncurrent liabilities	—		3,402
Current liabilities held for sale	$	—	$	560,205

(a) The Company had $76,124 of goodwill in its Retail Pharmacy segment resulting from the acquisition of Health Dialog and RediClinic, which is accounted for as Retail Pharmacy segment enterprise goodwill. The Company has allocated a portion of its Retail Pharmacy segment enterprise goodwill to the discontinued operation.

(b) In connection with the Sale, the Company had estimated that the Sale would generate excess cash proceeds of approximately $4,027,400 which would be used to repay outstanding indebtedness. During the thirteen week period ended June 2, 2018, the Company has a use of cash for financing purposes of $525,031 in its discontinued operations and, based on refinements to its calculations, reduced its estimate of excess cash proceeds by approximately $24,500 and reclassified that amount to assets held and used. Consequently, the Company has classified $0 and $549,549 of estimated cash proceeds to be used for debt repayment to liabilities held for sale as of June 2, 2018 and March 3, 2018, respectively. As of June 2, 2018 and March 3, 2018, the Company repaid outstanding indebtedness of $525,031 and $3,135,000 with Sale proceeds.

Reconciliation of Revenue from Segments to Consolidated

	June 2, 2018 (13 weeks)			June 3, 2017 (13 weeks)
Revenues	$	23,400		$	2,377,857
Costs and expenses:
Cost of revenues(a)	17,081			1,780,765
Selling, general and administrative expenses(a)	13,875			600,640
Lease termination and impairment charges	—			48
Loss on debt retirements, net	4,570			—
Interest expense(b)	4,615			58,937
Gain on stores sold to Walgreens Boots Alliance	(360,557		)	—
(Gain) loss on sale of assets, net	—			(156		)
	(320,416		)	2,440,234
Income (loss) from discontinued operations before income taxes	343,816			(62,377		)
Income tax expense (benefit)	87,673			(23,065		)
Net income (loss) from discontinued operations, net of tax	$	256,143		$	(39,312	)

(a) Cost of revenues and selling, general and administrative expenses for the discontinued operations excludes corporate overhead. These charges are reflected in continuing operations.

(b) In accordance with ASC 205-20, the operating results for the thirteen week periods ended June 2, 2018 and June 3, 2017, respectively, for the discontinued operations include interest expense relating to the outstanding indebtedness repaid with the estimated excess proceeds from the Sale.

XML

Income (Loss) Per Share (Tables)

3 Months Ended

Jun. 02, 2018

Income (Loss) Per Share

Schedule of calculation of basic and diluted income (loss) per share

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
Basic and diluted income (loss) per share:
Numerator:
Net loss from continuing operations	$	(41,727	)	$	(36,037	)
Net income (loss) from discontinued operations	256,143			(39,312		)
Income (loss) attributable to common stockholders— basic and diluted	$	214,416		$	(75,349	)
Denominator:
Basic weighted average shares	1,054,381			1,046,826
Outstanding options and restricted shares, net	—			—
Diluted weighted-average shares	1,054,381			1,046,826
Basic and diluted income (loss) per share:
Continuing operations	$	(0.04	)	$	(0.03	)
Discontinued operations	0.24			(0.04		)
Net basic and diluted income (loss) per share	$	0.20		$	(0.07	)

XML

Lease Termination and Impairment Charges (Tables)

3 Months Ended

Jun. 02, 2018

Lease Termination and Impairment Charges

Schedule of amounts relating to lease termination and impairment charges

	Thirteen Week Period Ended
	June 2, 2018		June 3, 2017
Impairment charges	$	283	$	659
Lease termination charges	9,576		3,379
	$	9,859	$	4,038

Schedule of closed store and distribution center charges related to new closures, changes in assumptions and interest accretion

	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
Balance—beginning of period	$	133,290		$	165,138
Provision for present value of noncancellable lease payments of closed stores	8,130			913
Changes in assumptions about future sublease income,  terminations and changes in interest rates	(1,038		)	(549		)
Interest accretion	2,685			3,095
Cash payments, net of sublease income	(11,885		)	(12,931		)
Balance—end of period	$	131,182		$	155,666

XML

Fair Value Measurements (Tables)

3 Months Ended

Jun. 02, 2018

Fair Value Measurements

Schedule of fair value of assets measured on non-recurring basis

	Level 1		Level 2		Level 3		Total as of June 2, 2018
Long-lived assets held for use	$	—	$	—	$	—	$	—
Long-lived assets held for sale	$	—	$	1,292	$	—	$	1,292
Total	$	—	$	1,292	$	—	$	1,292

	Level 1		Level 2		Level 3		Total as of June 3, 2017
Long-lived assets held for use	$	—	$	—	$	201	$	201
Long-lived assets held for sale	$	—	$	104	$	—	$	104
Total	$	—	$	104	$	201	$	305

XML

Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Jun. 02, 2018

Goodwill and Other Intangible Assets

Summary of the company's finite-lived and indefinite-lived intangible assets

	June 2, 2018								March 3, 2018
	Gross Carrying Amount		Accumulated Amortization			Net		Remaining Weighted Average Amortization Period	Gross Carrying Amount		Accumulated Amortization			Net		Remaining Weighted Average Amortization Period
Favorable leases and other(a)	$	379,809	$	(318,930	)	$	60,879	7 years	$	379,355	$	(316,798	)	$	62,557	7 years
Prescription files	906,181		(808,498		)	97,683		3 years	900,111		(801,706		)	98,405		3 years
Customer relationships(a)	465,000		(187,616		)	277,384		14 years	465,000		(172,635		)	292,365		15 years
CMS license	57,500		(6,747		)	50,753		22 years	57,500		(6,172		)	51,328		23 years
Claims adjudication and other developed software	58,985		(24,724		)	34,261		4 years	58,985		(22,617		)	36,368		5 years
Trademarks	20,100		(5,896		)	14,204		7 years	20,100		(5,394		)	14,706		8 years
Backlog	11,500		(11,244		)	256		1 year	11,500		(10,286		)	1,214		1 year
Total finite	$	1,899,075	$	(1,363,655	)	535,420			$	1,892,551	$	(1,335,608	)	$	556,943
Trademarks	33,500		—			33,500		Indefinite	33,500		—			33,500		Indefinite
Total	$	1,932,575	$	(1,363,655	)	$	568,920		$	1,926,051	$	(1,335,608	)	$	590,443

(a) Amortized on an accelerated basis which is determined based on the remaining useful economic lives of the customer relationships that are expected to contribute directly or indirectly to future cash flows.

XML

Indebtedness and Credit Agreements (Tables)

3 Months Ended

Jun. 02, 2018

Indebtedness and Credit Agreements

Summary of indebtedness and lease financing obligations

	June 2, 2018			March 3, 2018
Secured Debt:
Senior secured revolving credit facility due January 2020 ($190,000 and $0 face value less unamortized debt issuance costs of $10,258 and $13,076)	$	179,742		$	(13,076	)
Other secured	90			90
	179,832			(12,986		)
Guaranteed Unsecured Debt:
9.25% senior notes due March 2020 ($0 and $902,000 face value plus unamortized premium of $0 and $1,400 and less unamortized debt issuance costs of $0 and $4,924 as of June 2, 2018 and March 3, 2018, respectively)	—			898,476
6.75% senior notes due June 2021 ($805,169 and $810,000 face value less unamortized debt issuance costs of $4,482 and $4,877)	800,687			805,123
6.125% senior notes due April 2023 ($1,753,490 and $1,800,000 face value less unamortized debt issuance costs of $20,106 and $21,708)	1,733,384			1,778,292
	2,534,071			3,481,891
Unguaranteed Unsecured Debt:
7.7% notes due February 2027 ($295,000 face value less unamortized debt issuance costs of $1,418 and $1,460)	293,582			293,540
6.875% fixed-rate senior notes due December 2028 ($128,000 face value less unamortized debt issuance costs of $691 and $707)	127,309			127,293
	420,891			420,833
Lease financing obligations	47,809			52,554
Total debt	3,182,603			3,942,292
Current maturities of long-term debt and lease financing obligations	(19,025		)	(21,031		)
Long-term debt and lease financing obligations, less current maturities	$	3,163,578		$	3,921,261

Schedule of debt instruments included in continuing operations and discontinued operations

	March 3, 2018
	Debt			Lease Financing Obligations			Total Debt and Lease Financing Obligations
Balance, March 3, 2018—per above table	$	3,889,738		$	52,554		$	3,942,292
Amounts reclassified as current liabilities held for sale in connection with the Sale(a)	(549,549		)	(1,108		)	(550,657		)
Total debt and lease financing obligations	3,340,189			51,446			3,391,635
Current maturities of long-term debt and lease financing obligations—continuing operations	(90		)	(20,671		)	(20,761		)
Long-term debt and lease financing obligations, less current maturities—continuing operations	$	3,340,099		$	30,775		$	3,370,874

(a) In connection with the Sale, the Company had estimated that the Sale would generate excess cash proceeds of approximately $4,027,400 which would be used to repay outstanding indebtedness. During the thirteen week period ended June 2, 2018, the Company has a use of cash for financing purposes of $525,031 in its discontinued operations and, based on refinements to its calculations, reduced its estimate of excess cash proceeds by approximately $24,500 and reclassified that amount to assets held and used. Consequently, the Company has classified $0 and $549,549 of estimated cash proceeds to be used for debt repayment to liabilities held for sale as of June 2, 2018 and March 3, 2018, respectively. Additionally, as part of the Sale, the Company will be relieved of approximately $0 and $1,108, respectively, of capital lease obligations as of June 2, 2018 and March 3, 2018. These amounts are also reflected as liabilities held for sale. Please see Note 3 for additional details.

XML

Retirement Plans (Tables)

3 Months Ended

Jun. 02, 2018

Retirement Plans

Summary of net periodic pension expense for the defined benefit plans

	Defined Benefit Pension Plan
	Thirteen Week Period Ended
	June 2, 2018			June 3, 2017
Service cost	$	312		$	346
Interest cost	1,578			1,603
Expected return on plan assets	(1,434		)	(1,147		)
Amortization of unrecognized prior service cost	—			—
Amortization of unrecognized net loss	507			856
Net periodic pension expense	$	963		$	1,658

XML

Segment Reporting (Tables)

3 Months Ended

Jun. 02, 2018

Segment Reporting

Schedule of balance sheet information for the Company's reportable segments

	Retail Pharmacy		Pharmacy Services		Eliminations(2)			Consolidated
June 2, 2018:
Total Assets	$	5,434,447	$	2,950,099	$	(55,093	)	$	8,329,453
Goodwill	43,493		1,377,627		—			1,421,120
Additions to property and equipment and intangible assets	58,067		3,559		—			61,626
March 3, 2018:
Total Assets	$	6,089,343	$	2,954,953	$	(54,969	)	$	8,989,327
Goodwill	43,492		1,377,628		—			1,421,120
Additions to property and equipment and intangible assets	199,437		15,327		—			214,764

(2)As of June 2, 2018 and March 3, 2018, intersegment eliminations include netting of the Pharmacy Services segment long-term deferred tax liability of $40,319 and $38,713, respectively, against the Retail Pharmacy segment long-term deferred tax asset for consolidation purposes in accordance with ASC 740, and intersegment accounts receivable of $14,774 and $16,256, respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products.

Schedule of reconciliation of the Company's business segments to the condensed consolidated financial statements

	Retail Pharmacy		Pharmacy Services		Intersegment Eliminations(1)			Consolidated
June 2, 2018:
Revenues	$	3,897,765	$	1,542,762	$	(52,037	)	$	5,388,490
Gross Profit	1,069,457		99,292		—			1,168,749
Adjusted EBITDA(2)	113,469		33,863		—			147,332
June 3, 2017:
Revenues	$	3,972,351	$	1,513,241	$	(49,069	)	$	5,436,523
Gross Profit	1,056,971		104,972		—			1,161,943
Adjusted EBITDA(2)	87,365		48,599		—			135,964

(1) Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis.

(2) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” in MD&A for additional details. The following is a reconciliation of net (loss) income to Adjusted EBITDA for the thirteen week periods ended June 2, 2018 and June 3, 2017:

Schedule of reconciliation of net income to Adjusted EBITDA

	June 2, 2018 (13 weeks)			June 3, 2017 (13 weeks)
Net loss from continuing operations	$	(41,727	)	$	(36,037	)
Interest expense	62,792			51,000
Income tax benefit	(9,497		)	(12,121		)
Depreciation and amortization expense	94,529			101,029
LIFO charge	9,966			10,173
Lease termination and impairment charges	9,859			4,038
Loss on debt retirements, net	554			—
Other	20,856			17,882
Adjusted EBITDA from continuing operations	$	147,332		$	135,964

XML

Guarantor and Non-Guarantor Condensed Consolidating Financial Information (Tables)

3 Months Ended

Jun. 02, 2018

Guarantor and Non-Guarantor Condensed Consolidating Financial Information

Schedule of condensed consolidating balance sheet

	Rite Aid Corporation Condensed Consolidating Balance Sheet June 2, 2018 (unaudited)
	Rite Aid Corporation (Parent Company Only)		Subsidiary Guarantors		Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	138,400	$	8,692	$	—		$	147,092
Accounts receivable, net	—		1,390,296		518,659		—			1,908,955
Intercompany receivable	—		337,627		—		(337,627		)(a)	—
Inventories, net of LIFO reserve of $0, $591,056, $0, $0, and $591,056	—		1,809,595		—		—			1,809,595
Prepaid expenses and other current assets	—		147,760		3,299		—			151,059
Current assets held for sale	—		179,442		—		—			179,442
Total current assets	—		4,003,120		530,650		(337,627		)	4,196,143
Property, plant and equipment, net	—		1,401,924		—		—			1,401,924
Goodwill	—		1,421,120		—		—			1,421,120
Other intangibles, net	—		518,167		50,753		—			568,920
Deferred tax assets	—		522,674		—		—			522,674
Investment in subsidiaries	8,971,553		52,591		—		(9,024,144		)(b)	—
Intercompany receivable	—		3,949,896		—		(3,949,896		)(a)	—
Other assets	—		211,415		7,257		—			218,672
Total assets	$	8,971,553	$	12,080,907	$	588,660	$	(13,311,667	)	$	8,329,453
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	90	$	18,935	$	—	$	—		$	19,025
Accounts payable	—		1,762,078		5,699		—			1,767,777
Intercompany payable	—		—		337,627		(337,627		)(a)	—
Accrued salaries, wages and other current liabilities	74,552		781,315		174,425		—			1,030,292
Total current liabilities	74,642		2,562,328		517,751		(337,627		)	2,817,094
Long-term debt, less current maturities	3,134,704		—		—		—			3,134,704
Lease financing obligations, less current maturities	—		28,874		—		—			28,874
Intercompany payable	3,949,896		—		—		(3,949,896		)(a)	—
Other noncurrent liabilities	—		518,152		18,318		—			536,470
Total liabilities	7,159,242		3,109,354		536,069		(4,287,523		)	6,517,142
Commitments and contingencies	—		—		—		—			—
Total stockholders’ equity	1,812,311		8,971,553		52,591		(9,024,144		)(b)	1,812,311
Total liabilities and stockholders’ equity	$	8,971,553	$	12,080,907	$	588,660	$	(13,311,667	)	$	8,329,453

(a) Elimination of intercompany accounts receivable and accounts payable amounts.

(b) Elimination of investments in consolidated subsidiaries.

	Rite Aid Corporation Condensed Consolidating Balance Sheet March 3, 2018
	Rite Aid Corporation (Parent Company Only)		Subsidiary Guarantors		Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	441,244	$	6,090	$	—		$	447,334
Accounts receivable, net	—		1,502,507		366,593		—			1,869,100
Intercompany receivable			223,413		—		(223,413		)(a)	—
Inventories, net of LIFO reserve of $0, $581,090, $0, $0, and $581,090	—		1,799,539		—		—			1,799,539
Prepaid expenses and other current assets	—		176,678		4,503		—			181,181
Current assets held for sale	—		438,137		—		—			438,137
Total current assets	—		4,581,518		377,186		(223,413		)	4,735,291
Property, plant and equipment, net	—		1,431,246		—		—			1,431,246
Goodwill	—		1,421,120		—		—			1,421,120
Other intangibles, net	—		539,115		51,328		—			590,443
Deferred tax assets	—		594,019		—		—			594,019
Investment in subsidiaries	8,745,390		54,076		—		(8,799,466		)(b)	—
Intercompany receivable	—		3,189,419		—		(3,189,419		)(a)	—
Other assets	—		209,926		7,282		—			217,208
Noncurrent assets held for sale	—		—		—		—			—
Total assets	$	8,745,390	$	12,020,439	$	435,796	$	(12,212,298	)	$	8,989,327
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations	$	90	$	20,671	$	—	$	—		$	20,761
Accounts payable	—		1,641,676		9,687		—			1,651,363
Intercompany payable	—		—		223,413		(223,413		)(a)	—
Accrued salaries, wages and other current liabilities	65,223		1,031,379		135,134		—			1,231,736
Current liabilities held for sales	549,549		10,656		—		—			560,205
Total current liabilities	614,862		2,704,382		368,234		(223,413		)	3,464,065
Long-term debt, less current maturities	3,340,099		—		—		—			3,340,099
Lease financing obligations, less current maturities	—		30,775		—		—			30,775
Intercompany payable	3,189,419		—		—		(3,189,419		)(a)	—
Other noncurrent liabilities	—		539,892		13,486		—			553,378
Noncurrent liabilities held for sale	—		—		—		—			—
Total liabilities	7,144,380		3,275,049		381,720		(3,412,832		)	7,388,317
Commitments and contingencies	—		—		—		—			—
Total stockholders’ equity	1,601,010		8,745,390		54,076		(8,799,466		)(b)	1,601,010
Total liabilities and stockholders’ equity	$	8,745,390	$	12,020,439	$	435,796	$	(12,212,298	)	$	8,989,327

(a) Elimination of intercompany accounts receivable and accounts payable amounts.

(b) Elimination of investments in consolidated subsidiaries.

Schedule of condensed consolidating statement of operations

	Rite Aid Corporation Condensed Consolidating Statement of Operations For the Thirteen Weeks Ended June 2, 2018 (unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Revenues	$	—		$	5,321,025		$	95,584		$	(28,119	)(a)	$	5,388,490
Costs and expenses:
Cost of revenues	—			4,158,627			89,032			(27,918		)(a)	4,219,741
Selling, general and administrative expenses	—			1,144,832			7,996			(201		)(a)	1,152,627
Lease termination and impairment charges	—			9,859			—			—			9,859
Interest expense	59,939			2,946			(93		)	—			62,792
Loss on debt retirements	—			554			—			—			554
Gain on sale of assets, net	—			(5,859		)	—			—			(5,859		)
Equity in earnings of subsidiaries, net of tax	(278,970		)	1,485			—			277,485		(b)	—
	(219,031		)	5,312,444			96,935			249,366			5,439,714
Income (loss) from continuing operations before income taxes	219,031			8,581			(1,351		)	(277,485		)	(51,224		)
Income tax expense (benefit)	—			(9,631		)	134			—			(9,497		)
Net income (loss) from continuing operations	$	219,031		$	18,212		$	(1,485	)	$	(277,485	)(b)	$	(41,727	)
Net income (loss) from discontinued operations	(4,615		)	260,758			—			—			256,143
Net income (loss)	214,416			278,970			(1,485		)	(277,485		)	214,416
Total other comprehensive income (loss)	364			364			—			(364		)	364
Comprehensive (loss) income	$	214,780		$	279,334		$	(1,485	)	$	(277,849	)	$	214,780

(a) Elimination of intercompany revenues and expenses.

(b) Elimination of equity in earnings of subsidiaries.

	Rite Aid Corporation Condensed Consolidating Statement of Operations For the Thirteen Weeks Ended June 3, 2017 (unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries			Eliminations			Consolidated
	(in thousands)
Revenues	$	—		$	5,415,128		$	39,450		$	(18,055	)(a)	$	5,436,523
Costs and expenses:
Cost of revenues	—			4,255,202			37,902			(18,524		)(a)	4,274,580
Selling, general and administrative expenses	—			1,157,270			3,201			469		(a)	1,160,940
Lease termination and impairment expenses	—			4,038			—			—			4,038
Interest expense	46,447			4,515			38			—			51,000
Gain on sale of assets, net	—			(5,877		)	—			—			(5,877		)
Equity in earnings of subsidiaries, net of tax	(30,035		)	1,312			—			28,723		(b)	—
	16,412			5,416,460			41,141			10,668			5,484,681
Earnings from continuing operations before income taxes	(16,412		)	(1,332		)	(1,691		)	(28,723		)	(48,158		)
Income tax expense (benefit)	—			(11,742		)	(379		)	—			(12,121		)
Net income (loss) from continuing operations	(16,412		)	10,410			(1,312		)	(28,723		)	(36,037		)
Net income (loss) from discontinued operations	(58,937		)	19,625			—			—			(39,312		)
Net income (loss)	$	(75,349	)	$	30,035		$	(1,312	)	$	(28,723	)(b)	$	(75,349	)
Total other comprehensive income (loss)	514			514			—			(514		)	514
Comprehensive (loss) income	$	(74,835	)	$	30,549		$	(1,312	)	$	(29,237	)	$	(74,835	)

(a) Elimination of intercompany revenues and expenses.

(b) Elimination of equity in earnings of subsidiaries.

Schedule of condensed consolidating statement of cash flows

	Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Thirteen Weeks Ended June 2, 2018 (unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Operating activities:
Net cash (used in) provided by operating activities	$	(48,608	)	$	29,692		$	2,602	$	—		$	(16,314	)
Investing activities:
Payments for property, plant and equipment	—			(47,971		)	—		—			(47,971		)
Intangible assets acquired	—			(13,655		)	—		—			(13,655		)
Intercompany activity	—			(813,705		)	—		813,705			—
Proceeds from dispositions of assets and investments	—			9,916			—		—			9,916
Proceeds from sale-leaseback transactions	—			2,587			—		—			2,587
Net cash (used in) provided by investing activities	—			(862,828		)	—		813,705			(49,123		)
Financing activities:
Net proceeds from revolver	190,000			—			—		—			190,000
Principal payments on long-term debt	(426,361		)	(4,745		)	—		—			(431,106		)
Change in zero balance cash accounts	—			1,083			—		—			1,083
Net proceeds from issuance of common stock	910			—			—		—			910
Financing fees paid for early redemption	—			(13		)	—		—			(13		)
Intercompany activity	813,705			—			—		(813,705		)	—
Net cash provided by (used in) financing activities	578,254			(3,675		)	—		(813,705		)	(239,126		)
Cash flows of discontinued operations:
Operating activities of discontinued operations	(4,615		)	(69,435		)	—		—			(74,050		)
Investing activities of discontinued operations	—			603,402			—		—			603,402
Financing activities of discontinued operations	(525,031		)	—			—		—			(525,031		)
Net cash (used in) provided by discontinued operations	(529,646		)	533,967			—		—			4,321
(Decrease) increase in cash and cash equivalents	—			(302,844		)	2,602		—			(300,242		)
Cash and cash equivalents, beginning of period	—			441,244			6,090		—			447,334
Cash and cash equivalents, end of period	$	—		$	138,400		$	8,692	$	—		$	147,092

	Rite Aid Corporation Condensed Consolidating Statement of Cash Flows For the Thirteen Weeks Ended June 3, 2017 (unaudited)
	Rite Aid Corporation (Parent Company Only)			Subsidiary Guarantors			Non- Guarantor Subsidiaries		Eliminations			Consolidated
	(in thousands)
Operating activities:
Net cash (used in) provided by operating activities	$	(13,020	)	$	60,294		$	495	$	—		$	47,769
Investing activities:
Payments for property, plant and equipment	—			(38,325		)	—		—			(38,325		)
Intangible assets acquired	—			(5,521		)	—		—			(5,521		)
Intercompany activity	—			(161,810		)	—		161,810			—
Proceeds from insured loss	—			8,639			—		—			8,639
Proceeds from dispositions of assets and investments	—			2,137			—		—			2,137
Net cash (used in) provided by investing activities	—			(194,880		)	—		161,810			(33,070		)
Financing activities:
Net payments to revolver	(90,000		)	—			—		—			(90,000		)
Principal payments on long-term debt	—			(3,503		)	—		—			(3,503		)
Change in zero balance cash accounts	—			28,768			—		—			28,768
Net proceeds from issuance of common stock	147			—			—		—			147
Payments for taxes related to net share settlement of equity awards	—			(147		)	—		—			(147		)
Intercompany activity	161,810			—			—		(161,810		)	—
Net cash provided by (used in) financing activities	71,957			25,118			—		(161,810		)	(64,735		)
Cash flows of discontinued operations:
Operating activities of discontinued operations	(58,937		)	103,902			—		—			44,965
Investing activities of discontinued operations	—			(25,126		)	—		—			(25,126		)
Financing activities of discontinued operations	—			(764		)	—		—			(764		)
Net cash (used in) provided by discontinued operations	(58,937		)	78,012			—		—			19,075
(Decrease) increase in cash and cash equivalents	—			(31,456		)	495		—			(30,961		)
Cash and cash equivalents, beginning of period	—			213,104			32,306		—			245,410
Cash and cash equivalents, end of period	$	—		$	181,648		$	32,801	$	—		$	214,449

XML

Supplementary Cash Flow Data (Tables)

3 Months Ended

Jun. 02, 2018

Supplementary Cash Flow Data

Schedule of supplementary cash flow data

	Thirteen Weeks Ended
	June 2, 2018		June 3, 2017
Cash paid for interest(a)	$	53,553	$	75,535
Cash payments for income taxes, net(a)	$	591	$	1,461
Equipment financed under capital leases	$	1,963	$	3,857
Equipment received for noncash consideration	—		$	1,295
Reduction in lease financing obligation	—		$	2,416
Gross borrowings from revolver(a)	$	444,000	$	579,000
Gross repayments to revolver(a)	$	254,000	$	669,000

(a)—Amounts are presented on a total company basis.

XML

Basis of Presentation (Details) $ in Thousands			3 Months Ended		12 Months Ended
	Mar. 27, 2018 USD ($) store item	Sep. 18, 2017 USD ($) store item	Jun. 02, 2018 USD ($) store item	Jun. 03, 2017 USD ($)	Mar. 03, 2018 USD ($)	Mar. 04, 2018 USD ($)	Jun. 28, 2017 item
Basis of presentation
Revenues reported under this contract			$ 5,388,490	$ 5,436,523
Accounts receivable, net			1,908,955		$ 1,869,100	$ 1,811,203
Inventories, net			1,809,595		1,799,539	1,850,660
Accumulated deficit			(4,076,602)		(4,282,471)	$ (4,291,019)
Accounting Standards Update 2016-09
Basis of presentation
Revenues reported under this contract			123,500
Accounts receivable, net			(57,897)
Deferred tax asset			(1,772)
Inventories, net			51,121
Accumulated deficit			8,548
WBA and Walgreen Co.
Basis of presentation
Proceeds from assets sold			$ 525,031		$ 3,135,000
WBA and Walgreen Co. | Rite Aid
Basis of presentation
Proceeds from assets sold	$ 4,156,686
Asset Sale | WBA and Walgreen Co. | Rite Aid
Basis of presentation
Purchase price		$ 4,375,000
Numbers of stores | store	1,932
Number of stores Rite Aid agreed to sell | store		1,932	1,932
Number of distribution centers agreed to sell | item	3	3	3				3

XML

Basis of Presentation (Details) - Revenue Recognition $ in Thousands	3 Months Ended
	Jun. 02, 2018 USD ($) Point	Jun. 03, 2017 USD ($)	Mar. 04, 2018 USD ($)	Mar. 03, 2018 USD ($)
Revenue Recognition
Revenues	$ 5,388,490	$ 5,436,523
Accounts receivable, net	1,908,955		$ 1,811,203	$ 1,869,100
Inventories, net	1,809,595		1,850,660	1,799,539
Deferred tax assets	522,674		592,247	594,019
Total assets	8,329,453		8,980,779	8,989,327
Accumulated deficit	(4,076,602)		(4,291,019)	(4,282,471)
Total stockholders' equity	1,812,311		1,592,462	1,601,010
Accounting Standards Update 2016-09
Revenue Recognition
Revenues	123,500
Accounts receivable, net	(57,897)
Inventories, net	51,121
Accumulated deficit	$ 8,548
Difference between Revenue Guidance in Effect before and after Topic 606
Revenue Recognition
Accounts receivable, net			(57,897)
Inventories, net			51,121
Deferred tax assets			(1,772)
Total assets			(8,548)
Accumulated deficit			(8,548)
Total stockholders' equity			$ (8,548)
Retail Pharmacy
Revenue Recognition
Number of points awarded for each dollar spent towards front end merchandise | Point	1
Number of points awarded for each qualifying prescription | Point	25
Accumulated number of points in a calendar year to achieve the "Gold" tier | Point	1,000
Percentage discount on qualifying purchases of front end merchandise on achieving "Gold" tier	20.00%
Accrued contract liabilities	$ 73,191			63,851
Accrued contract liabilities included in other current liabilities	49,793			50,036
Accrued contract liabilities included in noncurrent liabilities	23,398			$ 13,815
Pharmacy sales	2,565,286
Front end sales	1,296,147
Revenues	3,897,765
Retail Pharmacy | Other
Revenue Recognition
Revenues	36,332
Pharmacy Services
Revenue Recognition
Revenues	$ 1,542,762

XML

Merger Agreement (Details)	Feb. 18, 2018 $ / shares	Jun. 02, 2018 $ / shares	Mar. 03, 2018 $ / shares
Merger Agreement
Common stock, par value (in dollars per share)		$ 1	$ 1
Albertsons and the Merger Subs | Merger Agreement
Merger Agreement
Base Exchange Ratio	0.1000
Common stock, par value (in dollars per share)	$ 0.01
Cash Election Consideration, price per share	$ 0.1832
Stock Election Exchange Ratio	0.0079
Cerberus | Standstill Agreement | Minimum
Merger Agreement
Ownership interest (as percent)	30.00%

XML

Asset Sale to WBA (Details) $ in Thousands				3 Months Ended		12 Months Ended
	Mar. 27, 2018 USD ($) store item	Sep. 18, 2017 USD ($) store item	Jun. 28, 2017 USD ($) item	Jun. 02, 2018 USD ($) store item	Jun. 03, 2017 USD ($)	Mar. 03, 2018 USD ($)	Sep. 01, 2018 item	Dec. 02, 2017
Termination of the Merger Agreement with WBA and Asset Sale to WBA
Noncontrolling Interest, Ownership Percentage by Parent				100.00%				100.00%
Gain on the sale of stores				$ 5,859	$ 5,877
Total billings for purchase of inventory				47,971	$ 38,325
Asset Sale
Termination of the Merger Agreement with WBA and Asset Sale to WBA
Gain on the sale of stores				2,489,389
WBA and Victoria Merger Sub | Rite Aid | Forecast
Termination of the Merger Agreement with WBA and Asset Sale to WBA
Number of distribution centers agreed to sell | item							3
WBA and Walgreen Co.
Termination of the Merger Agreement with WBA and Asset Sale to WBA
Proceeds from assets sold				$ 525,031		$ 3,135,000
TSA fees from initial closing			$ 23,735
WBA and Walgreen Co. | Rite Aid
Termination of the Merger Agreement with WBA and Asset Sale to WBA
Proceeds from assets sold	$ 4,156,686
WBA and Walgreen Co. | Rite Aid | Asset Sale
Termination of the Merger Agreement with WBA and Asset Sale to WBA
Number of stores Rite Aid agreed to sell | store		1,932		1,932
Number of distribution centers agreed to sell | item	3	3	3	3
Purchase price		$ 4,375,000
Number of stores and related assets transferred | store	1,932
Maximum period for transition services (in years)				3 years
Option to purchase pharmaceutical drugs (in years)				10 years
WBA | Selling, general and administrative expenses
Termination of the Merger Agreement with WBA and Asset Sale to WBA
Total billings for purchase of inventory				$ 2,041,075
Payments incurred but not yet been paid				$ 447,305

XML

Asset Sale to WBA - Carrying amount of assets sold (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 02, 2018	Jun. 03, 2017	Mar. 03, 2018	Mar. 04, 2017
Current assets held for sale
Current assets held for sale	$ 179,442		$ 438,137
Current liabilities held for sale
Current liabilities held for sale			560,205
Noncurrent liabilities held for sale
Goodwill	1,421,120		1,421,120
Estimated excess cash proceeds decrease from sale of debt	24,500
Use of cash for financing purposes	(525,031)	$ (764)
WBA and Walgreen Co.
Noncurrent liabilities held for sale
Proceeds from assets sold	525,031		3,135,000
Assets under Retail Pharmacy to be Sold | WBA | Assets held for sale
Current assets held for sale
Inventories	111,001		264,286
Property and equipment	68,441		158,433
Goodwill			4,629
Intangible assets			10,789
Current assets held for sale	179,442		438,137
Current liabilities held for sale
Current maturities of long-term lease financing obligations			270
Accrued salaries, wages and other current liabilities			6,146
Long-term debt, less current maturities			549,549
Lease financing obligations, less current maturities			838
Other noncurrent liabilities			3,402
Current liabilities held for sale			$ 560,205
Noncurrent liabilities held for sale
Goodwill	$ 76,124
Amounts reclassified as current and noncurrent liabilities held for sale in connection with the Sale, Debt				$ 4,027,400

XML

Asset Sale to WBA - Operating results of discontinued operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017
Income statement disclosures
Revenues	$ 23,400	$ 2,377,857
Costs and expenses:
Cost of revenues	17,081	1,780,765
Selling, general and administrative expenses	13,875	600,640
Lease termination and impairment charges		48
Loss on debt retirements, net	4,570
Interest expense	4,615	58,937
Gain on stores sold to Walgreens Boots Alliance	(360,557)
(Gain) loss on sale of assets, net		(156)
Cost and expenses	(320,416)	2,440,234
Income (loss) from discontinued operations before income taxes	343,816	(62,377)
Income tax expense (benefit)	87,673	(23,065)
Net income (loss) from discontinued operations, net of tax	$ 256,143	$ (39,312)

XML

Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017
Numerator:
Net loss from continuing operations	$ (41,727)	$ (36,037)
Net income (loss) from discontinued operations	256,143	(39,312)
Income (loss) attributable to common stockholders-basic and diluted	$ 214,416	$ (75,349)
Denominator:
Basic weighted average shares	1,054,381	1,046,826
Diluted weighted average shares	1,054,381	1,046,826
Continuing operations	$ (0.04)	$ (0.03)
Discontinued operations	0.24	(0.04)
Net basic and diluted income (loss) per share	$ 0.20	$ (0.07)
Stock options
Antidilutive securities excluded from computation of income per share
Shares excluded from the computation of diluted income per share	25,768	33,747
Restricted stock
Antidilutive securities excluded from computation of income per share
Shares excluded from the computation of diluted income per share	11,339	5,623

XML

Lease Termination and Impairment Charges (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017
Lease termination and impairment charges
Lease termination and impairment charges	$ 9,859	$ 4,038
Impairment charges
Lease termination and impairment charges
Lease termination and impairment charges	283	659
Lease termination charges
Lease termination and impairment charges
Lease termination and impairment charges	9,576	3,379
Closed store and distribution center charges
Balance-beginning of period	133,290	165,138
Provision for present value of noncancellable lease payments of closed stores	8,130	913
Changes in assumptions about future sublease income, terminations and changes in interest rates	(1,038)	(549)
Interest accretion	2,685	3,095
Cash payments, net of sublease income	(11,885)	(12,931)
Balance-end of period	$ 131,182	$ 155,666

XML

Fair Value Measurements (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017	Mar. 03, 2018
Non-financial assets measured on a non-recurring basis
Outstanding derivative financial instruments	$ 0		$ 0
Other assets
Non-financial assets measured on a non-recurring basis
Investment at amortized cost	7,257		$ 7,282
Nonrecurring basis
Non-financial assets measured on a non-recurring basis
Carrying value of long-lived assets	1,575	$ 964
Impairment charges	283	659
Nonrecurring basis | Fair Value
Non-financial assets measured on a non-recurring basis
Fair value of Long-lived assets held for use		201
Fair value of Long-lived assets held for sale	1,292	104
Fair value of Total	1,292	305
Nonrecurring basis | Level 1
Non-financial assets measured on a non-recurring basis
Carrying value of total long-term indebtedness	3,134,794
Estimated fair value of total long-term indebtedness	3,162,700
Nonrecurring basis | Level 2
Non-financial assets measured on a non-recurring basis
Fair value of Long-lived assets held for sale	1,292	104
Fair value of Total	$ 1,292	104
Nonrecurring basis | Level 3
Non-financial assets measured on a non-recurring basis
Fair value of Long-lived assets held for use		201
Fair value of Total		$ 201

XML

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		10 Months Ended
	Jun. 02, 2018	Jun. 03, 2017	Dec. 31, 2017	Mar. 03, 2018
Income Taxes
Federal statutory rate (as a percent)	21.00%		35.00%
Income tax expense (benefit)	$ (9,497)	$ (12,121)
Estimated effective tax rate (as a percent)	18.50%	25.20%
Increase in valuation allowance to offset the current year deferred state tax benefits (as a percent)	(2.30%)
Decrease in unrecognized tax benefits related to state exposures	$ 13,498
Valuation allowance against net deferred tax assets	$ 903,342			$ 896,800

XML

Medicare Part D (Details) - USD ($) $ in Thousands	Jun. 02, 2018	Mar. 31, 2018	Mar. 03, 2018
Medicare Part D
Accounts receivable, net	$ 442,690		$ 350,563
Accrued salaries, wages and other current liabilities
Medicare Part D
Liabilities under reinsurance contracts	$ 163,134		$ 183,318
EIC
Medicare Part D
Minimum amount of capital and surplus required by regulatory requirements		$ 29,464

XML

Goodwill and Other Intangibles - Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 02, 2018	Mar. 03, 2018
Carrying amount of goodwill
Goodwill impairment	$ 0
Pharmacy Services
Carrying amount of goodwill
Goodwill impairment	$ 261,727	$ 261,727

XML

Goodwill and Other Intangibles (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 02, 2018	Mar. 03, 2018
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 1,899,075	$ 1,892,551
Accumulated Amortization	(1,363,655)	(1,335,608)
Net	535,420	556,943
Gross Carrying Amount of Indefinite Lived	33,500
Gross Carrying Amount, Total	1,932,575	1,926,051
Net, Total	568,920	590,443
Trademarks
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Indefinite Lived	33,500	33,500
Favorable leases and other
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	379,809	379,355
Accumulated Amortization	(318,930)	(316,798)
Net	$ 60,879	$ 62,557
Remaining Weighted Average Amortization Period	7 years	7 years
Prescription files
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 906,181	$ 900,111
Accumulated Amortization	(808,498)	(801,706)
Net	$ 97,683	$ 98,405
Remaining Weighted Average Amortization Period	3 years	3 years
Customer relationships
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 465,000	$ 465,000
Accumulated Amortization	(187,616)	(172,635)
Net	$ 277,384	$ 292,365
Remaining Weighted Average Amortization Period	14 years	15 years
CMS license
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 57,500	$ 57,500
Accumulated Amortization	(6,747)	(6,172)
Net	$ 50,753	$ 51,328
Remaining Weighted Average Amortization Period	22 years	23 years
Claims adjudication and other developed software
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 58,985	$ 58,985
Accumulated Amortization	(24,724)	(22,617)
Net	$ 34,261	$ 36,368
Remaining Weighted Average Amortization Period	4 years	5 years
Trademarks
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 20,100	$ 20,100
Accumulated Amortization	(5,896)	(5,394)
Net	$ 14,204	$ 14,706
Remaining Weighted Average Amortization Period	7 years	8 years
Backlog
Finite Lived And Indefinite Lived Intangible Assets By Major Class
Gross Carrying Amount of Finite Lived	$ 11,500	$ 11,500
Accumulated Amortization	(11,244)	(10,286)
Net	$ 256	$ 1,214
Remaining Weighted Average Amortization Period	1 year	1 year

XML

Goodwill and Other Intangibles - Summary of reclassified noncurrent assets held for sale (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017	Mar. 03, 2018
Goodwill and Other Intangible Assets
Unfavorable lease intangibles	$ 17,857		$ 18,888
Amortization expense for intangible assets and liabilities	35,400	$ 40,962
Anticipated annual amortization expense for intangible assets and liabilities
2019	124,583
2020	100,875
2021	76,995
2022	55,206
2023	$ 38,953

XML

Indebtedness and Credit Agreements (Details) - Indebtedness and lease financing obligations - USD ($) $ in Thousands								1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 25, 2018	May 21, 2018	Apr. 29, 2018	Apr. 19, 2018	Apr. 12, 2018	Mar. 29, 2018	Feb. 27, 2018	Feb. 28, 2018	Jun. 02, 2018	Dec. 02, 2017	Apr. 28, 2018	Mar. 03, 2018	Jan. 31, 2018	Mar. 04, 2017	Jan. 15, 2015
Indebtedness and credit agreements
Long-term debt												$ 3,889,738
Lease financing obligations									$ 47,809			52,554
Total Debt									3,182,603			3,942,292
Current Maturities of Long-Term Debt and Lease Financing Obligations									(19,025)			(21,031)
Long-term debt and lease financing obligations, less current maturities									3,163,578			3,921,261
Loss on debt retirements, net								$ 8,180	554
Secured Debt
Indebtedness and credit agreements
Long-term debt												(12,986)
Long-term debt									179,832
Senior secured revolving credit facility due January 2020
Indebtedness and credit agreements
Long-term debt												(13,076)
Long-term debt									179,742
Principal amount of debt									190,000			0
Unamortized debt issuance costs									10,258			13,076
Maximum borrowing capacity			$ 2,700,000					$ 3,000,000			$ 3,000,000		$ 3,700,000		$ 2,700,000
Loss on debt retirements, net			$ 1,091
Senior secured revolving credit facility due January 2020 | LIBOR | Minimum
Indebtedness and credit agreements
Percentage points added to the reference rate										1.50%
Senior secured revolving credit facility due January 2020 | LIBOR | Maximum
Indebtedness and credit agreements
Percentage points added to the reference rate										2.00%
Senior secured revolving credit facility due January 2020 | Alternate base rate | Minimum
Indebtedness and credit agreements
Percentage points added to the reference rate										0.50%
Senior secured revolving credit facility due January 2020 | Alternate base rate | Maximum
Indebtedness and credit agreements
Percentage points added to the reference rate										1.00%
Tranche 1 Term Loan (second lien) due August 2020
Indebtedness and credit agreements
Principal amount of debt													470,000
Tranche 2 Term Loan (second lien) due June 2021
Indebtedness and credit agreements
Principal amount of debt													$ 500,000
Other secured
Indebtedness and credit agreements
Long-term debt									90			90
Guaranteed Unsecured Debt
Indebtedness and credit agreements
Long-term debt									$ 2,534,071			3,481,891
9.25% senior notes due March 2020
Indebtedness and credit agreements
Long-term debt												898,476
Debt instrument, stated interest rate (as a percent)									9.25%	9.25%				9.25%
Principal amount of debt						$ 3,454			$ 0			902,000
Unamortized debt issuance costs									0			4,924
Unamortized premium									0			1,400
Loss on debt retirements, net					$ 3,422
Offer to purchase of outstanding amount							$ 900,000
Percentage of outstanding principal amount redeemed					100.00%	0.38%
6.75% senior notes due June 2021
Indebtedness and credit agreements
Long-term debt									$ 800,687			805,123
Debt instrument, stated interest rate (as a percent)									6.75%	6.75%				6.75%
Principal amount of debt									$ 805,169			810,000
Unamortized debt issuance costs									4,482			4,877
Loss on debt retirements, net	$ 18,075	$ 8
Principal amount of debt redeemed		1,360				$ 3,471
Percentage of outstanding principal amount redeemed	100.00%					0.43%
6.125% senior notes due April 2023
Indebtedness and credit agreements
Long-term debt									$ 1,733,384			$ 1,778,292
Debt instrument, stated interest rate (as a percent)									6.125%			6.125%
Principal amount of debt									$ 1,753,490			$ 1,800,000
Unamortized debt issuance costs									20,106			21,708
Loss on debt retirements, net		56				$ 49			498
Principal amount of debt redeemed		$ 4,759				$ 41,751
Percentage of outstanding principal amount redeemed						2.32%
6.75% and 6.125% senior notes
Indebtedness and credit agreements
Offer to purchase of outstanding amount				$ 700,000
Unguaranteed Unsecured Debt
Indebtedness and credit agreements
Long-term debt									420,891			420,833
7.7% notes due February 2027
Indebtedness and credit agreements
Long-term debt									$ 293,582			$ 293,540
Debt instrument, stated interest rate (as a percent)									7.70%			7.70%
Principal amount of debt									$ 295,000			$ 295,000
Unamortized debt issuance costs									1,418			1,460
6.875% fixed-rate senior notes due December 2028
Indebtedness and credit agreements
Long-term debt									$ 127,309			$ 127,293
Debt instrument, stated interest rate (as a percent)									6.875%			6.875%
Principal amount of debt									$ 128,000			$ 128,000
Unamortized debt issuance costs									$ 691			$ 707

XML

Indebtedness and Credit Agreements - Continuing operations and discontinued operations (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Jun. 02, 2018	Jun. 03, 2017	Mar. 03, 2018	Mar. 04, 2017	Dec. 02, 2017
Indebtedness and Credit Agreements
Long-term Debt, Total			$ 3,889,738
Capital Lease Obligations, Total	$ 47,809		52,554
Total Debt	3,182,603		3,942,292
Amounts reclassified as current liabilities held for sale in connection with the Sale, Debt	(549,549)
Amounts reclassified as current liabilities held for sale in connection with the Sale, Lease Financing Obligations	(1,108)
Amounts reclassified as current liabilities held for sale in connection with the Sale, Total Debt and Lease Financing Obligations	(550,657)
Total debt and lease financing obligations, debt	3,340,189
Total debt and lease financing obligations, lease financing obligations	51,446
Total debt and lease financing obligations	3,391,635
Current maturities of long-term debt - continuing operations	(90)
Lease financing obligations - continuing operations	(20,671)
Current maturities of long-term debt and lease financing obligations - continuing operations	(20,761)
Long-term debt, less current maturities - continuing operations	3,340,099
Lease financing obligations, less current maturities - continuing operations	30,775
Long-term debt and lease financing obligations, less current maturities - continuing operations	3,370,874
Excess cash proceeds from sale of debt				$ 4,027,400
Use of cash for financing purposes	(525,031)	$ (764)
Estimated excess cash proceeds from sale of debt	0		$ 549,549
Estimated excess cash proceeds decrease from sale of debt	$ 24,500
Credit facility
Ownership interest (as a percent)	100.00%				100.00%

XML

Indebtedness and Credit Agreement - Credit Facility (Details) $ in Thousands	9 Months Ended
	Dec. 02, 2017 USD ($)	Jun. 02, 2018 USD ($)	Apr. 29, 2018 USD ($)	Apr. 28, 2018 USD ($)	Mar. 29, 2018 USD ($)	Mar. 03, 2018 USD ($)	Feb. 28, 2018 USD ($)	Jan. 31, 2018 USD ($)	Mar. 04, 2017	Nov. 26, 2016 USD ($)	Jan. 15, 2015 USD ($)
Indebtedness and credit agreements
Long-term debt						$ 3,889,738
Lease financing obligations		$ 47,809				52,554
Total Debt		3,182,603				3,942,292
Current maturities of long-term debt and lease financing obligations		(19,025)				(20,761)
Long-term debt and lease financing obligations, less current maturities		$ 3,163,578				3,921,261
Credit facility
Ownership interest (as a percent)	100.00%	100.00%
Maturities
2019	$ 90
2020	190,000
2021	0
2022	805,169
2023	0
thereafter	2,176,490
Secured Debt
Indebtedness and credit agreements
Long-term debt						(12,986)
Long-term debt		$ 179,832
Senior secured revolving credit facility due January 2020
Indebtedness and credit agreements
Long-term debt						(13,076)
Long-term debt		179,742
Principal amount of debt		190,000				0
Unamortized debt issuance costs		10,258				13,076
Credit facility
Maximum borrowing capacity			$ 2,700,000	$ 3,000,000			$ 3,000,000	$ 3,700,000			$ 2,700,000
Outstanding borrowings	190,000
Letters of credit outstanding	55,790
Additional borrowing capacity	2,454,210
Amount of debt allowed to be outstanding	1,500,000
Threshold amount of debt	$ 750,000
Number of days relating to debt threshold	90 days
Period allowed for extensions on customary terms	90 days
Availability under revolving credit facility	$ 2,454,210
Senior secured revolving credit facility due January 2020 | Minimum
Credit facility
Percentage of fee payable on daily unused revolver availability	0.25%
Additional borrowing capacity	$ 365,000									$ 365,000
Threshold availability on the thirtieth consecutive calendar day	$ 250,000
Fixed charge coverage ratio	1.00
Senior secured revolving credit facility due January 2020 | Maximum
Credit facility
Percentage of fee payable on daily unused revolver availability	0.375%
Threshold availability on revolving credit facility to trigger fixed charge coverage requirements	$ 200,000
Threshold availability on the third consecutive business day	$ 250,000
Senior secured revolving credit facility due January 2020 | LIBOR | Minimum
Credit facility
Percentage points added to the reference rate	1.50%
Senior secured revolving credit facility due January 2020 | LIBOR | Maximum
Credit facility
Percentage points added to the reference rate	2.00%
Senior secured revolving credit facility due January 2020 | Alternate base rate | Minimum
Credit facility
Percentage points added to the reference rate	0.50%
Senior secured revolving credit facility due January 2020 | Alternate base rate | Maximum
Credit facility
Percentage points added to the reference rate	1.00%
Tranche 1 Term Loan (second lien) due August 2020
Indebtedness and credit agreements
Principal amount of debt								470,000
Tranche 2 Term Loan (second lien) due June 2021
Indebtedness and credit agreements
Principal amount of debt								$ 500,000
Other secured
Indebtedness and credit agreements
Long-term debt		90				90
Guaranteed Unsecured Debt
Indebtedness and credit agreements
Long-term debt		$ 2,534,071				3,481,891
9.25% senior notes due March 2020
Indebtedness and credit agreements
Long-term debt						898,476
Debt instrument, stated interest rate (as a percent)	9.25%	9.25%							9.25%
Principal amount of debt		$ 0			$ 3,454	902,000
Unamortized debt issuance costs		0				4,924
Unamortized premium		0				1,400
6.75% senior notes due June 2021
Indebtedness and credit agreements
Long-term debt		$ 800,687				805,123
Debt instrument, stated interest rate (as a percent)	6.75%	6.75%							6.75%
Principal amount of debt		$ 805,169				810,000
Unamortized debt issuance costs		4,482				4,877
6.125% senior notes due April 2023
Indebtedness and credit agreements
Long-term debt		$ 1,733,384				$ 1,778,292
Debt instrument, stated interest rate (as a percent)		6.125%				6.125%
Principal amount of debt		$ 1,753,490				$ 1,800,000
Unamortized debt issuance costs		20,106				21,708
Unguaranteed Unsecured Debt
Indebtedness and credit agreements
Long-term debt		420,891				420,833
7.7% notes due February 2027
Indebtedness and credit agreements
Long-term debt		$ 293,582				$ 293,540
Debt instrument, stated interest rate (as a percent)		7.70%				7.70%
Principal amount of debt		$ 295,000				$ 295,000
Unamortized debt issuance costs		1,418				1,460
6.875% fixed-rate senior notes due December 2028
Indebtedness and credit agreements
Long-term debt		$ 127,309				$ 127,293
Debt instrument, stated interest rate (as a percent)		6.875%				6.875%
Principal amount of debt		$ 128,000				$ 128,000
Unamortized debt issuance costs		$ 691				$ 707

XML

Retirement Plans (Details) - Defined Benefit Pension Plan - USD ($) $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017
Net periodic pension expense
Service cost	$ 312	$ 346
Interest cost	1,578	1,603
Expected return on plan assets	(1,434)	(1,147)
Amortization of unrecognized net loss	507	856
Net periodic pension expense	963	$ 1,658
Employer contributions	813
Expected employer contribution during the remainder of fiscal year	$ 3,800

XML

Segment Reporting (Details) $ in Thousands	3 Months Ended
	Jun. 02, 2018 USD ($) segment	Jun. 03, 2017 USD ($)
Segment Reporting
Number of reportable segments | segment	2
Revenues	$ 5,388,490	$ 5,436,523
Gross Profit	1,168,749	1,161,943
Adjusted EBITDA	147,332	135,964
Retail Pharmacy
Segment Reporting
Revenues	3,897,765
Pharmacy Services
Segment Reporting
Revenues	1,542,762
Operating segments | Retail Pharmacy
Segment Reporting
Revenues	3,897,765	3,972,351
Gross Profit	1,069,457	1,056,971
Adjusted EBITDA	113,469	87,365
Operating segments | Pharmacy Services
Segment Reporting
Revenues	1,542,762	1,513,241
Gross Profit	99,292	104,972
Adjusted EBITDA	33,863	48,599
Intersegment elimination
Segment Reporting
Revenues	$ (52,037)	$ (49,069)

XML

Segment Reporting - Balance Sheet information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 02, 2018	Mar. 03, 2018	Mar. 04, 2018
Segment Reporting
Total assets	$ 8,329,453	$ 8,989,327	$ 8,980,779
Goodwill	1,421,120	1,421,120
Additions to property and equipment and intangible assets	61,626	214,764
Accounts receivable	1,908,955	1,869,100	$ 1,811,203
Operating segments | Retail Pharmacy
Segment Reporting
Total assets	5,434,447	6,089,343
Goodwill	43,493	43,492
Additions to property and equipment and intangible assets	58,067	199,437
Operating segments | Pharmacy Services
Segment Reporting
Total assets	2,950,099	2,954,953
Goodwill	1,377,627	1,377,628
Additions to property and equipment and intangible assets	3,559	15,327
Intersegment elimination
Segment Reporting
Total assets	(55,093)	(54,969)
Long-term deferred tax liability	(40,319)	(38,713)
Accounts receivable	$ (14,774)	$ (16,256)

XML

Segment Reporting - Adjusted EBITDA for continuing operations (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Feb. 28, 2018	Jun. 02, 2018	Jun. 03, 2017
Segment Reporting
Net loss from continuing operations		$ (41,727)	$ (36,037)
Interest expense		62,792	51,000
Income tax benefit		(9,497)	(12,121)
Depreciation and amortization expense		94,529	101,029
LIFO charge		9,966	10,173
Lease termination and impairment charges		9,859	4,038
Loss on debt retirements	$ 8,180	554
Other		20,856	17,882
Adjusted EBITDA from continuing operations		$ 147,332	$ 135,964

XML

Commitments and Contingencies (Details)	3 Months Ended
	Jun. 02, 2018 case	Jan. 19, 2017 state
Commitments and Contingencies
Number of states failed to report Rx savings prices | state		18
Hall
Commitments and Contingencies
Number of similar cases | case	2

XML

Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Balance Sheet (Details) - USD ($) $ in Thousands	Jun. 02, 2018	Mar. 04, 2018	Mar. 03, 2018	Dec. 02, 2017	Jun. 03, 2017	Mar. 04, 2017	Feb. 27, 2016
Condensed consolidating balance sheet
Ownership interest (as a percent)	100.00%			100.00%
Current assets:
Cash and cash equivalents	$ 147,092		$ 447,334		$ 214,449	$ 245,410	$ 245,410
Accounts receivable, net	1,908,955	$ 1,811,203	1,869,100
Inventories, net	1,809,595	1,850,660	1,799,539
Prepaid expenses and other current assets	151,059		181,181
Current assets held for sale	179,442		438,137
Total current assets	4,196,143		4,735,291
Property, plant and equipment, net	1,401,924		1,431,246
Goodwill	1,421,120		1,421,120
Other intangibles, net	568,920		590,443
Deferred tax assets	522,674	592,247	594,019
Other assets	218,672		217,208
Total assets	8,329,453	8,980,779	8,989,327
Current liabilities:
Current maturities of long-term debt and lease financing obligations	19,025		20,761
Accounts payable	1,767,777		1,651,363
Accrued salaries, wages and other current liabilities	1,030,292		1,231,736
Current liabilities held for sales			560,205
Total current liabilities	2,817,094		3,464,065
Long-term debt, less current maturities	3,134,704		3,340,099
Lease financing obligations, less current maturities	28,874		30,775
Other noncurrent liabilities	536,470		553,378
Total liabilities	6,517,142		7,388,317
Commitments and contingencies
Total stockholders' equity	1,812,311	$ 1,592,462	1,601,010
Total liabilities and stockholders' equity	8,329,453		8,989,327
Inventories, LIFO reserve (in dollars)	591,056		581,090
Reportable legal entity | Rite Aid Corporation (Parent Company Only)
Current assets:
Investment in subsidiaries	8,971,553		8,745,390
Total assets	8,971,553		8,745,390
Current liabilities:
Current maturities of long-term debt and lease financing obligations	90		90
Accrued salaries, wages and other current liabilities	74,552		65,223
Current liabilities held for sales			549,549
Total current liabilities	74,642		614,862
Long-term debt, less current maturities	3,134,704		3,340,099
Intercompany payable	3,949,896		3,189,419
Total liabilities	7,159,242		7,144,380
Commitments and contingencies
Total stockholders' equity	1,812,311		1,601,010
Total liabilities and stockholders' equity	8,971,553		8,745,390
Inventories, LIFO reserve (in dollars)	0		0
Reportable legal entity | Subsidiary Guarantors
Current assets:
Cash and cash equivalents	138,400		441,244		181,648	441,244	213,104
Accounts receivable, net	1,390,296		1,502,507
Intercompany receivable	337,627		223,413
Inventories, net	1,809,595		1,799,539
Prepaid expenses and other current assets	147,760		176,678
Current assets held for sale	179,442		438,137
Total current assets	4,003,120		4,581,518
Property, plant and equipment, net	1,401,924		1,431,246
Goodwill	1,421,120		1,421,120
Other intangibles, net	518,167		539,115
Deferred tax assets	522,674		594,019
Investment in subsidiaries	52,591		54,076
Intercompany receivable	3,949,896		3,189,419
Other assets	211,415		209,926
Total assets	12,080,907		12,020,439
Current liabilities:
Current maturities of long-term debt and lease financing obligations	18,935		20,671
Accounts payable	1,762,078		1,641,676
Accrued salaries, wages and other current liabilities	781,315		1,031,379
Current liabilities held for sales			10,656
Total current liabilities	2,562,328		2,704,382
Lease financing obligations, less current maturities	28,874		30,775
Other noncurrent liabilities	518,152		539,892
Total liabilities	3,109,354		3,275,049
Commitments and contingencies
Total stockholders' equity	8,971,553		8,745,390
Total liabilities and stockholders' equity	12,080,907		12,020,439
Inventories, LIFO reserve (in dollars)	591,056		581,090
Reportable legal entity | Non-Guarantor Subsidiaries
Current assets:
Cash and cash equivalents	8,692		6,090		$ 32,801	$ 6,090	$ 32,306
Accounts receivable, net	518,659		366,593
Prepaid expenses and other current assets	3,299		4,503
Total current assets	530,650		377,186
Other intangibles, net	50,753		51,328
Other assets	7,257		7,282
Total assets	588,660		435,796
Current liabilities:
Accounts payable	5,699		9,687
Intercompany payable	337,627		223,413
Accrued salaries, wages and other current liabilities	174,425		135,134
Total current liabilities	517,751		368,234
Other noncurrent liabilities	18,318		13,486
Total liabilities	536,069		381,720
Commitments and contingencies
Total stockholders' equity	52,591		54,076
Total liabilities and stockholders' equity	588,660		435,796
Inventories, LIFO reserve (in dollars)	0		0
Eliminations
Current assets:
Intercompany receivable	(337,627)		(223,413)
Total current assets	(337,627)		(223,413)
Investment in subsidiaries	(9,024,144)		(8,799,466)
Intercompany receivable	(3,949,896)		(3,189,419)
Total assets	(13,311,667)		(12,212,298)
Current liabilities:
Intercompany payable	(337,627)		(223,413)
Total current liabilities	(337,627)		(223,413)
Intercompany payable	(3,949,896)		(3,189,419)
Total liabilities	(4,287,523)		(3,412,832)
Commitments and contingencies
Total stockholders' equity	(9,024,144)		(8,799,466)
Total liabilities and stockholders' equity	(13,311,667)		(12,212,298)
Inventories, LIFO reserve (in dollars)	$ 0		$ 0

XML

Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Statement of Operations (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Feb. 28, 2018	Jun. 02, 2018	Jun. 03, 2017
Condensed consolidating statement of operations
Revenues		$ 5,388,490	$ 5,436,523
Costs and expenses:
Cost of revenues		4,219,741	4,274,580
Selling, general and administrative expenses		1,152,627	1,160,940
Lease termination and impairment expenses		9,859	4,038
Interest expense		62,792	51,000
Loss on debt retirements	$ 8,180	554
Gain on sale of assets, net		(5,859)	(5,877)
Total costs and expenses		5,439,714	5,484,681
Income (loss) from continuing operations before income taxes		(51,224)	(48,158)
Income tax expense (benefit)		(9,497)	(12,121)
Net loss from continuing operations		(41,727)	(36,037)
Net income (loss) from discontinued operations		256,143	(39,312)
Net income (loss)		214,416	(75,349)
Total other comprehensive income (loss)		364	514
Comprehensive income (loss)		214,780	(74,835)
Reportable legal entity | Rite Aid Corporation (Parent Company Only)
Costs and expenses:
Interest expense		59,939	46,447
Equity in earnings of subsidiaries, net of tax		(278,970)	(30,035)
Total costs and expenses		(219,031)	16,412
Income (loss) from continuing operations before income taxes		219,031	(16,412)
Net loss from continuing operations		219,031	(16,412)
Net income (loss) from discontinued operations		(4,615)	(58,937)
Net income (loss)		214,416	(75,349)
Total other comprehensive income (loss)		364	514
Comprehensive income (loss)		214,780	(74,835)
Reportable legal entity | Subsidiary Guarantors
Condensed consolidating statement of operations
Revenues		5,321,025	5,415,128
Costs and expenses:
Cost of revenues		4,158,627	4,255,202
Selling, general and administrative expenses		1,144,832	1,157,270
Lease termination and impairment expenses		9,859	4,038
Interest expense		2,946	4,515
Loss on debt retirements		554
Gain on sale of assets, net		(5,859)	(5,877)
Equity in earnings of subsidiaries, net of tax		1,485	1,312
Total costs and expenses		5,312,444	5,416,460
Income (loss) from continuing operations before income taxes		8,581	(1,332)
Income tax expense (benefit)		(9,631)	(11,742)
Net loss from continuing operations		18,212	10,410
Net income (loss) from discontinued operations		260,758	19,625
Net income (loss)		278,970	30,035
Total other comprehensive income (loss)		364	514
Comprehensive income (loss)		279,334	30,549
Reportable legal entity | Non-Guarantor Subsidiaries
Condensed consolidating statement of operations
Revenues		95,584	39,450
Costs and expenses:
Cost of revenues		89,032	37,902
Selling, general and administrative expenses		7,996	3,201
Interest expense		(93)	38
Total costs and expenses		96,935	41,141
Income (loss) from continuing operations before income taxes		(1,351)	(1,691)
Income tax expense (benefit)		134	(379)
Net loss from continuing operations		(1,485)	(1,312)
Net income (loss)		(1,485)	(1,312)
Comprehensive income (loss)		(1,485)	(1,312)
Eliminations
Condensed consolidating statement of operations
Revenues		(28,119)	(18,055)
Costs and expenses:
Cost of revenues		(27,918)	(18,524)
Selling, general and administrative expenses		(201)	469
Equity in earnings of subsidiaries, net of tax		277,485	28,723
Total costs and expenses		249,366	10,668
Income (loss) from continuing operations before income taxes		(277,485)	(28,723)
Net loss from continuing operations		(277,485)	(28,723)
Net income (loss)		(277,485)	(28,723)
Total other comprehensive income (loss)		(364)	(514)
Comprehensive income (loss)		$ (277,849)	$ (29,237)

XML

Guarantor and Non-Guarantor Condensed Consolidating Financial Information - Statement of Cash Flow (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017
Operating activities:
Net cash (used in) provided by operating activities	$ (16,314)	$ 47,769
Investing activities:
Payments for property, plant and equipment	(47,971)	(38,325)
Intangible assets acquired	(13,655)	(5,521)
Proceeds from insured loss		8,639
Proceeds from dispositions of assets and investments	9,916	2,137
Proceeds from sale-leaseback transactions	2,587
Net cash used in investing activities of continuing operations	(49,123)	(33,070)
Financing activities:
Net proceeds from (payments to) revolver	190,000	(90,000)
Principal payments on long-term debt	(431,106)	(3,503)
Change in zero balance cash accounts	1,083	28,768
Net proceeds from issuance of common stock	910	147
Financing fees paid for early debt redemption	(13)
Payments for taxes related to net share settlement of equity awards		(147)
Net cash used in financing activities of continuing operations	(239,126)	(64,735)
Cash flows of discontinued operations:
Operating activities of discontinued operations	(74,050)	44,965
Investing activities of discontinued operations	603,402	(25,126)
Financing activities of discontinued operations	(525,031)	(764)
Net cash provided by discontinued operations	4,321	19,075
Decrease in cash and cash equivalents	(300,242)	(30,961)
Cash and cash equivalents, beginning of period	447,334	245,410
Cash and cash equivalents, end of period	147,092	214,449
Reportable legal entity | Rite Aid Corporation (Parent Company Only)
Operating activities:
Net cash (used in) provided by operating activities	(48,608)	(13,020)
Financing activities:
Net proceeds from (payments to) revolver	190,000	(90,000)
Principal payments on long-term debt	(426,361)
Net proceeds from issuance of common stock	910	147
Intercompany activity	813,705	161,810
Net cash used in financing activities of continuing operations	578,254	71,957
Cash flows of discontinued operations:
Operating activities of discontinued operations	(4,615)	(58,937)
Financing activities of discontinued operations	(525,031)
Net cash provided by discontinued operations	(529,646)	(58,937)
Reportable legal entity | Subsidiary Guarantors
Operating activities:
Net cash (used in) provided by operating activities	29,692	60,294
Investing activities:
Payments for property, plant and equipment	(47,971)	(38,325)
Intangible assets acquired	(13,655)	(5,521)
Intercompany activity	(813,705)	(161,810)
Proceeds from insured loss		8,639
Proceeds from dispositions of assets and investments	9,916	2,137
Proceeds from sale-leaseback transactions	2,587
Net cash used in investing activities of continuing operations	(862,828)	(194,880)
Financing activities:
Principal payments on long-term debt	(4,745)	(3,503)
Change in zero balance cash accounts	1,083	28,768
Financing fees paid for early debt redemption	(13)
Payments for taxes related to net share settlement of equity awards		(147)
Net cash used in financing activities of continuing operations	(3,675)	25,118
Cash flows of discontinued operations:
Operating activities of discontinued operations	(69,435)	103,902
Investing activities of discontinued operations	603,402	(25,126)
Financing activities of discontinued operations		(764)
Net cash provided by discontinued operations	533,967	78,012
Decrease in cash and cash equivalents	(302,844)	(31,456)
Cash and cash equivalents, beginning of period	441,244	441,244
Cash and cash equivalents, end of period	138,400	181,648
Reportable legal entity | Non-Guarantor Subsidiaries
Operating activities:
Net cash (used in) provided by operating activities	2,602	495
Cash flows of discontinued operations:
Decrease in cash and cash equivalents	2,602	495
Cash and cash equivalents, beginning of period	6,090	6,090
Cash and cash equivalents, end of period	8,692	32,801
Eliminations
Investing activities:
Intercompany activity	813,705	161,810
Net cash used in investing activities of continuing operations	813,705	161,810
Financing activities:
Intercompany activity	(813,705)	(161,810)
Net cash used in financing activities of continuing operations	$ (813,705)	$ (161,810)

XML

Supplementary Cash Flow Data (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 02, 2018	Jun. 03, 2017
Supplementary Cash Flow Data
Cash paid for interest	$ 53,553	$ 75,535
Cash payments for income taxes, net	591	1,461
Equipment financed under capital leases	1,963	3,857
Equipment received for noncash consideration		1,295
Reduction in lease financing obligation		2,416
Gross borrowings from revolver	444,000	579,000
Gross repayments to revolver	$ 254,000	$ 669,000